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Abstract
The avid hybridization of peptide nucleic acid (PNA) to DNA and RNA along with the
molecule’s biological stability has led it to be used in both antisense and antigene capacities.
PNA acts against translation via a steric blockade mechanism. It is therefore reasonable to
assume that increased heteroduplex stability could lead to increased potency. Two ways of
doing this were explored. I) N-Terminal attachment of a platinous chloride chelating moiety
to PNA complementary to Xenopus noggin was synthesized with the objective of selective,
covalent platination of the target transcript in vivo. Phenotypes consistent with knockdown of
the selected gene product were observed; however, it remains unclear whether this is solely
due to site-specific platination. II) The use of the modified cytosine nucleobase [bis-o(aminoethoxy)phenyl]pyrrolocytosine (boPhpC) was previously shown to increase
heteroduplex stability, putatively by interaction with guanine at both the Watson-Crick and
Hoogsteen faces. PNAs containing this base were synthesized to target mutant huntingtin
mRNA - of which the product is the causative agent of Huntington’s disease – and tested in
patient derived fibroblasts where selective inhibition of mutant huntintin was observed with
concomitant fluorescence imaging.
Modified nucleobases find use in fields ranging from materials science to cytogenetics and
has been an area of much endeavour over the past years. Modifications at the 5-position of
uracil abound but examples of similarly modified cytosine are lacking. Rapidly developing
the inventory of cytosine analogues is a primary goal of ours. We aim to synthesize
compounds that may be used as base discriminating fluorophores, created pre- or postsynthetically. Through the reaction of 5-ethynyldeoxycytidine with 1,3-dipoles such as
nitrile oxides or azides a series of heterocycle-appended cytosine analogues have been
prepared and their fluorescence properties studied. They exhibit moderate to good quantum
yields with high sensitivity to their environment and are considered good candidates for
further use as base-discriminating fluorophores. Based on the known pyrrolocytosine
scaffold, Indole-3-acetamide substituted deoxypyrrolocytidine (IAMpC) has shown the
highest degree of solvatochromism for any pyrrolocytosine analogue known to date. The
synthesis of oligodeoxynucleotides containing this base was carried out; however, final
deprotection of the base does not proceed smoothly and the modification was found to be
iii

slightly destabilizing towards duplex formation.

Keywords
DNA, PNA, mRNA, Platinum (II), Cisplatin, PAGE, Base-discriminating Fluorophore,
Copper-catalyzed Azide/Alkyne Cycloaddition, Antisense, Huntington’s Disease, Nucleoside
Analogue, Hydrogelator.
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Preface
During my undergraduate degree, the sequence of the human genome, consisting of
approximately three billion base pairs, was published simultaneously by two groups. This
occasion fell close to the 50th anniversary of Watson and Crick’s discovery of the double
helix. Now, as I come to the end of my Ph.D., we celebrate the 50th anniversary of the
beginning of the determination of the genetic code. In approximately a decade the world
went from not knowing the structure of DNA to knowing the gist of the language it spoke.
The astounding pace of DNA related research continues unabated. DNA is the most
fundamental of biological macromolecules and consequently, the most fascinating. Because
of this, DNA attracts biologists, physicists, and chemists alike. However, chemists are
perhaps the luckiest of these three categories of people: we can grasp the biology with some
determined reading and (although I personally don’t care to do so) many of us can approach
the physics. Moreover, it is only chemists that can see the true beauty and evolutionary
genius of the molecule in its organic chemistry. It is also only us that can rationally modify
the molecule to make it do weirder and more wonderful things. We can change the base, the
phosphate, or the sugar; tagging almost whatever we want to it, mixing it up with different
monomers, activating it with light, forming scaffolds and, make it glow. I count myself lucky
to have been introduced to nucleic acids, and having met them, I forsee spending the rest of
my life in their intimate company.
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Chapter 1
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Introduction to selected aspects of nucleic acid
chemistry

Over half a century since the elucidation of DNA’s molecular architecture and a decade
since the completion of the human genome project, nucleic acids still hold many
questions.

The deliberate application of synthetic organic chemistries towards

nucleosides, DNA and their analogues has a rich history. The development of highyielding oligomerization chemistries opened many doors for the study of nucleobase and
backbone modifications, of which there is a seemingly endless array. These modifications
can skew the basic properties of DNA to tune hybridization efficiency, enzymatic
stability/biological recognition and photophysical properties. In this chapter selected
historical and recent literature on the chemical aspects of nucleic acids and peptides will
be discussed in order to put the reader ‘in frame’ for the present work. Excerpts of this
chapter have been taken from Dodd, D.W.; Hudson, R.H.E. Mini-Rev. Org. Chem., 2009,
6, 378-391.

1.1 Intrinsically fluorescent base discriminating nucleoside
analogues
Modified nucleosides possessing intrinsically fluorescent heterocycles as base surrogates
that are capable of canonical base-pairing are becoming important biomolecular tools.
These “base-discriminating fluorophores” (BDFs) find use in hybridization-based
mismatch detection, elucidation of DNA damage and the study of localized structural
phenomena as exemplified in the study of ribozymes and nucleic acid/ligand interactions.
Classically, the central dogma of biology purports that the characteristics which make us
unique are peculiar to the heritable material within almost every cell of our body: our
DNA. It is therefore of no surprise that many disease states, both acquired and heritable,
are derived from permutations within the genome. Mutations can make one more
susceptible to heart disease, various carcinoma and are also the cause of diseases such as
phenylketonurea, autism and cystic fibrosis, to name only a few. Diagnosis of mutations
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that make one, or one’s progeny, susceptible to disease is a very desirable advancement
of modern medicine and many research groups are currently working on making this
process more rapid and economical. A few existing techniques for sequence analysis are
outlined in the following paragraphs.
One of the most frequently used methods for the detection of permutations within a
polynucleotide sequence employs molecular beacons based on fluorescent resonant
energy transfer (FRET).1 The quintessential morphology of a molecular beacon consists
of an oligonucleotide labeled at opposing termini with a fluorophore and a quenching
moiety. Complementary sequences are placed at each terminus such that a hairpin
structure is formed and the loop region is chosen to be complementary to the target
oligonucleotide sequence to be analyzed. Upon hybridization of the interrogated
sequence to the loop region, the stem opens and the fluorophore is no longer quenched as
this quenching is distance dependent (Fig. 1-1). This basic technique can be applied in a
variety of different ways, the fluorophore and quencher may be appended to different
sequences and FRET can be used to obtain emission at differing wavelengths.2

Figure 1-1: Illustration of the underlying mechanism of molecular beacon operation
based on FRET.
Detection of single nucleotide polymorphisms (SNPs) can oftentimes be difficult due to
the sheer size of the genome. A point mutation may occur only in low abundance creating
the problem of interference from the wild-type gene. In order to increase sensitivity,
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sequences can be examined and amplified through PCR-clamping using oligonucleotide
analogues that will suppress the association of a primer to the template by steric
hindrance. PCR clamping is most often peptide nucleic acid (PNA) mediated. Due to the
unnatural N-(2-aminoethyl)glycine derived backbone, PNA is not recognized
enzymatically and therefore does not act as a primer for DNA polymerase.3 When a
sequence of PNA is complementary to a PCR primer site it will virtually eliminate the
formation of PCR product. PNA can be used in this manner to selectively silence or
amplify genes differing by only one base. This technique, in conjunction with
hybridization probes, has been used by several groups to great effect. The detection of
point mutations using a wild-type-specific PNA and a mutant-specific PCR primer has
been carried out for oncogenes4,5 and even on mitochondrial DNA.6
Full sequencing of a PCR amplified gene is the archetypal method of SNP analysis; this
technique is currently undesirable as it is costly and time consuming despite the
significant advances that continue to be made in this area.
Electrochemical means may also be used for SNP detection. Many different approaches
have been used, although most involve oligonucleotide modified electrodes that result in
differing charge transfer rates upon complementary sequence binding. As an example of
this, a recent paper has illustrated that a mismatch can be discriminated through labeling
of an oligonucleotide immobilized on a gold surface with anthraquinone at the 2’position, as the anthraquinone moiety intercalates the charge transfer rate decreases
allowing for mismatch detection.7 Electrochemical mismatch detection offers the
advantages of simple readout and amenability to digitization. Microarray analysis of
SNPs by electrochemical means remains limited as a mechanical connection is required
to each electrode pad. This would make the manufacture of larger arrays, required for full
sequence-screening, a difficult challenge.8
The aforementioned techniques, molecular beacons in particular, are limited as they rely
in differences in hybridization efficiency. These differences vary greatly with sequence
context and with the ionic strength of the medium and strict hybridization conditions
must be met.9 In the context of oligonucleotide arrays, variations in packing density can
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affect hybridization efficiency therefore making the manufacture of high-throughput
screening devices technically challenging.10
Fluorescent base-pairing nucleoside analogues which may fluorometrically respond to
hybridization when placed within an oligonucleotide sequence are of high interest as they
overcome the reliance on hybridization efficiency and offer a conveniently measured
parameter in the wavelength or intensity of light emission (Fig. 1-2). These basediscriminating fluorophores (BDFs) may be used for a wide range of sensing applications
including the detection of SNPs which may be used for the diagnosis of heritable diseases
in a less costly and more expedient manner than full sequencing.

Figure 1-2: Illustration of the principle of sequence readout by a base discriminating
fluorophore (BDF) containing probe. The interaction of a BDF-containing probe
with a complementary sequence leads to an observable property.
The use of BDFs allows for the elucidation of localized events as opposed to other
methodologies which monitor global structural phenomena (UV-Vis, CD spectroscopy).
Other methods for detecting localized structural events do exist, such as NMR
spectroscopy and gel electrophoresis of kinetically trapped radiolabeled products;
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however, these techniques are time consuming and limited with respect to reaction time
scale.
As the natural nucleobases are essentially non-emissive,11 much work has been put
towards the synthesis of base analogues which are luminescent. In the design of novel
base-discriminating fluorophores several basic criteria should be met. The fluorophores
should maintain a high degree of structural similarity with the natural nucleobases so as
not to affect the hybridization efficiency, the compounds must obviously be fluorescent,
their excitation wavelengths should not be within the absorption range of biological
macromolecules, and the fluorescence should be sensitive to microenvironmental
conditions. The fluorescence response may be a change in emission wavelength, an
increase or decrease in quantum efficiency or length of the excited state lifetime;
however, dramatic changes in emission wavelength or intensity are the most conveniently
measured parameters.

Figure 1-3: Representative molecules of the different classes of BDF as defined by
Tor.12
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Tor has divided fluorescent base analogues into five basic categories: isomorphic base
analogues, pteridines as purine analogues, extended nucleobases, conjugated base
analogues, and aromatic hydrocarbon and chromophoric base analogues (Fig. 1-3).12
Fluorescent base analogues may be more selectively divided into two categories which
are capable of canonical base pairing: those possessing pendant fluorophores and
intrinsically fluorescent nucleoside analogues. Below are pictured representative
molecules of these classes (Fig. 1-4).13,14 Both of these molecules are able to hydrogen
bond with natural bases and respond fluorometrically to hybridization. The former class
often has an advantage in that higher overall brightness (brightness is defined by the
quantum yield multiplied by the extinction coefficient at the excitation maximum) and
greater quantum yields are often achieved through the attachment of a traditional
chromophore. However, fluorescence spectroscopy is a fantastically sensitive technique
and oftentimes highly luminescent molecules are not required to be a practical and useful
reporter group.

Figure 1-4: Representative molecules of the two basic fluorescent nucleobase
analogue designs: those containing a pendant fluorophore, and the intrinsically
fluorescent 6-phenylpyrrolocytosine.13,14
The use of conventional fluorescent moieties, attached to the base via a flexible
linker, can allow independent movement of the fluorophore, this can make
interpretation of results complicated as the fluorescence response is not necessarily
originating from the area of interest. The intrinsically fluorescent BDF category has
become attractive as it is the nucleobase itself whose environment is being monitored,
they are synthetically accessible and also have potential for biological incorporation.
Such intrinsically fluorescent, complementary base-discriminating/pairing nucleobase
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analogues are the subject of this sub-chapter. Whenever possible the photophysical
parameters characterizing the BDFs ablility to act as a reporter group are given;
however, for some analogues this information is not yet available.
Intrinsically Fluorescent Purine Nucleobase Analogues:

Complementarity and

Response to Pyrimidines
Isomorphic bases: 2-aminopurine and 8-azaguanine
The base analogues 2-aminopurine (2-AP) and 8-azaguanine (8-azaG) are historically
two of the most often used isomorphic, fluorescent nucleobases. Their overall size
matches that of the natural bases and they are able to form isostructural Watson-Crick
base pairs (Fig. 1-5). 2-AP, a constitutional isomer of adenine, has been used for almost
40 years.15 Owing to its high quantum yield as the free nucleoside in aqueous solution (Φ
= 0.68) and extreme sensitivity to microenvironmental changes with drastically lower
emission observed in single-stranded (ss) and double stranded (ds) oligonucleotides (as
much as 100 fold decrease in emission in dsDNA),16 2-AP has been employed in many
studies of nucleic acid structure and dynamics and in a wide array of biochemical assays.
Examples

include:

real-time

monitoring

of

hammerhead

ribozyme

folding,

oligonucleotide cleavage and inhibition and nucleic acid/protein and nucleic acid/drug
interactions.17 2-AP can form Watson-Crick type base pairs with thymine, uracil or
cytosine, this can either be a benefit or a drawback, depending on the application. It also
has a red shifted absorption spectrum which allows differential excitation in the presence
of biological macromolecules.
8-azaG is another isomorphic purine analogue which can be enzymatically incorporated
into oligonucleotides.

It is relatively emissive, exhibits a high degree of

solvatofluorochromism and is quenched by adjacent nucleobases (Fig. 1-5). 8azaguan(os)ine has a high quantum yield when N1 is deprotonated at high pH (Φ = 0.55)
but much lower fluorescence when the natural Watson-Crick base-pairing face is
presented. One of the more interesting and recent advances made with this BDF has been
the development of a highly efficient enzymatic synthesis of the triphosphate from 8azaguanine and the establishment of pH dependent fluorescence within a structured
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oligoribonucleotide (with implications towards ribozyme mechanism elucidation).18

Figure 1-5: The isosteric base analogues 2-aminopurine and 8-azaguanine in
hybridization with their natural base complements uracil and cytosine,
respectively.
Purines modified at the 8-position
The 8-position of purines lends itself well to derivatization; 8-bromoadenosine is
remarkably easy to prepare in high yield and can be used in a variety of transition metalcatalyzed cross-couplings. Deoxyadenosine and guanine derivatives with phenol directly
attached at the 8-position can be accessed through the coupling of hydroxyphenylboronic
acid with the appropriate 8-bromonucleoside in the palladium catalyzed Suzuki-Miyaura
reaction.19 These compounds are of interest for several reasons: the compounds are
biomarkers for phenol exposure and are therefore of use for the study of mechanisms of
carcinogenicity, the compounds exhibit pH dependent fluorescence 20 and the phenolate,
anionic form of the modified base can act as a quencher through photoinduced electron
transfer (PET).21

Although these nucleosides have not yet been incorporated into

oligonucleotides, their high quantum yields at neutral pH (Φ = 0.25–0.56) could make
them quite useful as BDFs.
Various other moieties have been attached to purines in the same manner including

Figure 1-6: Purine nucleosides derivatized at C-8 (R = H, bpy).
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bipyridine and phenanthroline for use as metal chelators (demonstrated for RuII) and
various aryl substituents to tune fluorescence properties (Fig. 6).22
Triazolyl adenosines have been made and characterized through a collaborative effort and
have been found to be highly fluorescent (Fig. 1-7 left). The first report by Dyrager et al.
showed that quantum yields as high as 0.62 are achieved.23 A follow up study also
showed that the base (when incorporated into oligomers) was sensitive to its
microenvironment, caused only mild structural perturbations to B-form DNA and formed
base pairs with thymine and also, more surprisingly, adenine.24 The high fluorescence
observed was surprising to us as we had synthesized geometric isomers of the compounds
reported (Fig. 1-7, right) and found quantum yields to be very low (ΦF ~ 0.02)
(unpublished results).

Figure 1-7: Geometric isomers of 8-triazolyldeoxyadenosines for use as BDFs,
R=Alkyl.
Both syntheses started from 8-bromoadenosine, the former work then used a
Sonogoashira coupling to introduce the alkyne while we took the opposite approach of
introducing an azide via a simple SNAr with sodium azide. We found that 8azidoadenosine was very unreactive towards cycloaddition with alkynes and were only
able to produce two compounds in low yield (R = Ph, R = EtOMe).
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Purines modified at the 6-position: 2-Amino-6-(2-thienyl)purine and 2-amino-6-(2thiazolyl)purine
The compounds shown in figure 1-8 have been known for some time and applications for
the highly emissive base analogues continue to be found.25-27 The unnatural base pairs of
2-amino-6-(2-thienyl)purine with 2-oxopyridine and 2-amino-6-(2-thiazolyl)purine with
imidazolin-2-one remarkably function in transcription with good fidelity and hence may
be placed specifically within an RNA transcript with ease. Both the thienyl and
thiazolylpurines have quantum yields from 0.41-0.46 as the free 5’-monophosphates.
These quantum yields are roughly halved upon incorporation into a ss oligonucleotide
and halved again when in ds DNA/RNA. Used alone or in FRET experiments, with
fluorescein derivatives (FAM) as an acceptor moiety, accurate descriptions of
hybridization events have been obtained. When placed adjacent to one another, the
modified bases exhibit self-quenching behaviour but may still allow for the excitation of
a nearby FAM moiety. The authors suggest that this may be desirable as it would enable
the use of excess probe to test sequence in biological assays.27

Figure 1-8: 2-amino-6-(2-thienyl)purine and 2-amino-6-(2-thiazolyl)purine used as
guanosine mimics despite not presenting an isostructural Watson-Crick face.
Pteridine nucleoside analogues
Pteridines are naturally occurring compounds, originally isolated from the wings of pierid
butterflies by the pioneering biochemist F.G. Hopkins in 1895.28 Hopkins would later
receive a Nobel prize for his discovery of vitamins (not that this is of any particular
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relevance to us here). Pteridine derivatives have had many pharmaceutical applications,
particularly as anti-cancer drugs. Pteridines have more recently been utilized as
nucleoside analogues; they are highly fluorescent and are synthetically accessible through
the condensation of the appropriate triaminopyrimidine with the desired pyruvate
derivative (Fig. 1-9).29

Figure 1-9: Pteridine purine analogues.
Once the base analogue has been synthesized, N-glycosylation can be carried out to yield
the desired nucleoside, this in turn can be converted to the corresponding
phosphoramidite by well established methods.
The pteridines described by the Hawkins group are structurally similar to the natural
purine bases, containing the appropriate hydrogen bond donor and acceptor components,
with one exception (vide infra). The compounds 3-methylisoxanthopterin (3MI) and 6methylisoxanthopterin (6MI) have been employed as guanosine analogues while 4amino-6-methyl-8-(2’-deoxyribofuranosyl)-7(8H)-pteridone (6MAP) and 4-amino-2,6dimethyl-(2’-deoxyribofuranosyl)-7(8H)-pteridone (with the unforntunate acronym
DMAP) have been used as adenosine mimics.30 While other derivatives have been
synthesized, it is the aforementioned compounds that have found the greatest success in
the elucidation of DNA structural events.
The applications of the pteridines as BDFs are diverse as the compounds are highly
fluorescent (Φ = 0.77-0.88 for the adenosine analogues and 0.39-0.48 for the guanosine)
and highly sensitive to microenvironmental conditions. All compounds are well tolerated
within the duplex excepting 3MI due to the methyl group at the 3-position interfering
with hydrogen bonding. This methylation destabilizes the duplex to a similar extent as
would a single canonical mismatch.
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Pteridines have been used in the following applications: HIV-1 integrase activity assays,
alkyl transferase coupled assays, use as hydridization probes, HU protein binding
detection, ‘A-tract’ structure detection, RNA polymerase activity and intracellular
oligonucleotide transport analysis.30
Intrinscially Fluorescent Pyrimidine Nucleobase Analogues: Complementarity and
Response to Purines
5-Ethynyluridine
Variously substituted 5-ethynyluridine derivatives have been exploited in our laboratory
for mismatch detection. These structurally simple and compact fluorophores are able to
report hybridization events by “turning on” in the presence of a match sequence when
placed internally within the modified strand. The greatest fluorescence response, out of a
small selection of compounds, was observed for a p-methoxyphenylethynyluracil
containing probe (Fig. 1-10) giving a six-fold increase in fluorescence upon encountering
a match sequence.31

Figure 1-10: 5-(p-methoxyphenylethynyl)uracil containing oligonucleotide in the
presence of a match sequence (black) as compared to ss (grey).31
The mismatch duplexes offer surprising results: when the mismatch is guanine the
fluorophore is quenched considerably; when it is thymine, the chromophore suffers an
intermediate degree of quenching and; when it is cytosine, mismatch duplexes are not
quenched significantly. These data imply that the fluorophores are exquisitely responsive
to their local environment and may therefore find further use in determining DNA
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structural characteristics and ligand/DNA interactions.
Related alkynyluracils have been exploited for mismatch detection by Brown and coworkers. Again using Sonogashira cross-couplings, anthracenyl-ethynyl (Ae) and
naphthalenyl-ethynyl (Ne) moieties have been appended to deoxyuridine at the 5-position

Figure 1-12: Phenyl, naphthalenyl and anthracenyl-alkyne derivatized
deoxyuridines used for mismatch detection (R = H, OMe).31,33
(Fig. 1-11).32,33 The corresponding anthracenyl -diyne (Aee) was also synthesized and
these compounds were found to be only marginally destabilizing towards duplex
formation. As is typically the case with fluorophores appended to pyrimidines at the 5position, an increase in fluorescence was observed on duplex formation due to a change
in the polarity of the microenvironment when the chromophore is projected into the
aquated major groove of dsDNA versus its position in ss form.32,33

Figure 1-11: Anthracenyl-ethynyl (Ae) derivatized riboguanosine (G) and
ribocytidine (C) and dimethylaniline-(DMA) modified bases.34
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Alkynylnaphthalene analogue of deoxthymidine (AeT) containing oligomers showed the
greatest increase in emission upon binding to a match sequence; however, when
presented with a C mismatch the fluorescence was also much increased (quantum yields
not reported). The results were very similar with the anthracene containing oligomer only
with overall lower fluorescence. The diyne compound gave surprising results, the
fluorescence increased greatest in the case of a C or T mismatch, the T mismatch increase
in emission intensity was also accompanied by a bathochromic shift of 12 nm. It can be
said that all three of the compounds tested could potentially be used to effect in A/G SNP
typing.33 A similar modification, but for cytidine, was reported earlier by Sessler and
coworkers.34 They prepared a pair of base-modified ribonucleosides to examine
photoinduced electron transfer in a hydrogen bonded ensemble. They chose to prepare a
C8-modified guanosine and a C5-modified cytidine (Fig. 1-12).
Although the purpose of the study was not base-discrimination, the fluorescence spectra
of AeC and AeG were reported.

The fluorescence was mostly characteristic of

anthracene, yet each modified base had slightly different photophysical properties. Given
the conjugated nature of the linkage of the luminophore to the nucleobase, it is reasonable
to suspect that they may be responsive to base pairing in the context of an
oligonucleotide.

Likwise, the dimethylaniline-modified bases, especially DMAG, is

structurally related to modified purines already presented (Fig. 1-6).

A detailed

characterization of DMAG and DMAC were not reported in this work.
A fluorene derivatized deoxyuridine35 nucleoside and the analogous PNA monomer
(Fig.1-13) have both been synthesized and were found to be moderately fluorescent (Φ =
0.14 for the free nucleoside).36 Oligonucleotides containing the nucleoside analogue were
amenable to SNP typing, selectively fluorescing in the presence of a match sequence in a
quencher-free molecular beacon construct.35
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Although the fluorescence of the PNA monomer was found to be ca. 50 times greater
derivative,36 (Fig. 1-14) the

than the structurally similar 5-phenylethynyluracil

fluorescence response on duplex formation was very modest.

This highlights the

principle of making only minor structural changes to the nucleobases to maintain
sensitivity to the microenvironment. It also highlights the differences in the structures on
ssPNA

versus

ssDNA

and

the

challenges

associated

modifications/technologies to oligonucleotide analogues.

with

portability

of
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fluorophore undergoing charge redistribution dependent on the polarity of the
environment. DAN has been appended to guanosine and cytidine via the exocyclic amino
group in order to monitor the polarity of the minor and major grooves of DNA (in both B
and Z-form) respectively.38,39 This same fluorophore has recently been appended to 2’deoxyuridine by Saito’s group in different ways as shown in figure 1-15.40
The fluorescence of these nucleoside analogues was measured with respect to solvent
polarity. The fully conjugated system (Fig. 1-15) was accessed from a Suzuki-Miyaura
coupling of the DAN borate ester with 5’-O-DMT-5-iodouridine and showed the greatest

Figure 1-15: DAN appended nucleosides differing by linkage strategy: directly
attached, propanoyl, and carboxamide linkages.37
degree of solvatofluorochromicity. Surprisingly, the pendant chromophore (electronically
separated from the base) and cross-conjugated compounds (Fig. 1-15) showed very
different fluorescence properties with the being the least fluorescent of the three and the
propynoyl linked compound being the most, the highest quantum yield being 0.26. The
high degree of solvatofluorochromicity displayed by these compounds implies that there
is strong charge transfer character to the relevant excited state.40
C5-Furan substituted uridine
Purines, typically modified at C8, and pyrimidines modified at C5 are prominent in the
literature due to a minimal thermodynamic penalty upon hybridization and ease of
synthesis. A particularly rewarding modification at C5 of uridine was the appending of a
furan ring via the 2-position of furan. This was done by the Stille coupling of 2(tributylstannyl)furan with 5-iodouracil and was first reported in 1991.12,41 The
furanyluracil was found to have a relatively low quantum yield (Φ=0.03 in H2O) but
demonstrated interesting bathochromic and hyperchromic shifts upon increase in solvent
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polarity

(ether→water).

Despite

the

low

luminescence,

the

sensitivity

to

microenvironment implies that the compound may be useful in mismatch detection;
indeed, the compound has been used for the successful detection of abasic sites in
DNA.32 In the same paper, nucleosides modified with oxazole, thiazole and thiophene
showed less favourable photophysical properties. In addition to the favourable
photophysical properties displayed by 5-furanyluridine it was also later found that the 5’triphosphate was able to be incorporated by T7 RNA polymerase in the place of
thymidine with good fidelity.42 The fluorescence of the monomer has been shown to be
dependent on microscopic polarity; a well definined linear plot of fluorescence intensity
versus experimentally determined ET(30) values

43

has been obtained. The use of

microscopic polarity scales, such as ET(30) values, has often been a more accurate
parameter for such research than the use of dielectric constants.44 The furan modified
nucleobase has been incorporated into the potential pharmaceutical target: the bacterial
decoding site known as the A-site and was used to screen aminoglycoside antibiotics.
Although the fluorescent response on binding of the aminoglycoside was less than that
exhibited by 2-aminopurine, when used in conjunction with 2-aminopurine an effective
assay was developed. The need for new RNA structural probes still exists as potent
inhibitors of this site do not induce a proportional change in fluorescence when using the
currently available fluorophores. This fluorophore has also been used to examine the
polarity of the major grooves of A and B-form nucleic acids due to its strong
solvatochromic behaviour.45

The C5-furan modified deoxycytidine has also been

prepared, but it is approximately 3-fold less emissive than furanyl-U (Fig. 1-16). Despite
this lower emission the base has been employed in the successful discrimination between
8-Oxoguanosine, G and T. 8-oxoguanosine is a biomarker for oxidative stress and has
been found to cause transversion mutations during DNA replication; therefore, its
detection/quantification within the genome is desirable.46

Figure 1-16: Furan-decorated nucleosides.
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Due to the success found with furan-modified uridine, Tor and co-workers prepared the
C8-furan modified adenosine and guanosine. Even though the nucleosides were highly
emissive with quantum yields of 0.57 and 0.69, respectively, they possessed maximal
emission in the near UV (375 nm) which displayed little solvent polarity dependence.
Likely because of these suboptimal properties, investigation of their use as BDFs in
oligonucleotides has not yet appeared.12
Triazole appended nucleosides
Although there are many examples utilizing the Huisgen 3+2 azide/alkyne
cycloaddition47 for the modification of pre- and post-oligomerized nucleic acids, little
attention has been paid towards the fluorescent properties of the resultant molecules. The
most popular substrate for this copper(I) catalyzed “click” reaction has been 5alkynyluracil as it can be accessed readily from the Sonogashira cross-coupling of 5iodouridine with trimethylsilylacetylene, followed by desilylation. Various azides have
been used and it has recently been found that stacking between adjacent triazole modified
bases can be stabilizing towards the duplex.48 A full set of fluorescent nucleobase
analogues have also been developed through the “clicking” of azidocoumarin with 7deaza-7-alkynyldeoxyguanosine,

7-deaza-7-alkynyldeoxyadenosine,

5-alkynyl-

deoxyuridine and 5-alkynyldeoxycytidine to form 1,4-disubstituted triazoles.49 These
compounds are not “inherently fluorescent” as categorized by the present review as they
possess an independently fluorescent moiety attached to the nucleoside. Carell and coworkers have also used this reaction as a means of modifying DNA post-synthetically;
the applications of this strategy abound.50
Benzyltriazolyluridines have also been synthesized for use as small molecule
hydrogelators

51,52

and our group has synthesized the corresponding cytidine analogues

that were found to be moderately fluorescent (Fig. 1-17).53 A variety of azides have been
utilized including benzyl, phenyl, ethylphenyl, thiophenyl (connected via the 3-position
of thiophene) and bithiophenyl azide. These monomers have been studied as potential
base-discriminating fluorophores and are described in greater detail in chapter 5.
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Figure 1-17: 1,4-disubstituted triazolylcytidines synthesized for use as potential
BDFs (further described in chapter 5).

Thiophene appended nucleosides
5-(Thiophen-2-yl)uridine was first synthesized in 1994 with the aim of increasing duplex
stability through stacking interactions.54 However, only a modest increase in melting
temperature resulted. The fluorescent properties of this and related molecules have been
since exploited for mismatch detection. Bi- and terthiophene moieties appended to
deoxyuridine with or without an ethynyl spacer (Fig. 1-18) all bestow fluorescent
properties on the nucleosides with varying suitability towards practical application.55

Figure 1-18: : Bi- and terthiophene derivatized uridines synthesized for use as
BDFs.
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It was found that there was only a small thermodynamic penalty associated with duplex
formation; however, high ss emission and complex fluorometric data make the nucleoside
analogues of limited use for mismatch detection.
Fused ring systems: Fluorescent analogues of purines and pyrimidines
Benzo- and Naphtho-pyridopyrimidines
Some base discriminating nucleobases of particular interest have been described by Saito
and co-workers. Benzopyridopyrimidine (BPP) is quenched effectively by G but
fluoresces in the presence of A; however, low overall quantum yield and high ss emission
prompted the researchers to further elaborate on this scaffold thus giving rise to
naphthopyridopyrimidine (NPP) (Fig. 1-19).9 The latter modified base was found to have
a markedly higher quantum yield and less intense ss emission and has therefore found use
in A/G SNP typing. Two other fluorescent bases of importance devised by the same
group are methoxybenzodeazaadenosine (MDA) and methoxybenzodeazainosine (MDI)
(Fig. 1-19).9 Probes containing these bases are quenched in the presence of T and C
complementary oligonucleotides respectively.

Figure 1-19: Expanded-ring-system fluorescent nucleobases developed by Saito
and coworkers.
Size expanded nucleobases
A discussion of fluorescent, modified nucleobases would not be complete without
mention of the pioneering work by Leonard and subsequent elaboration by Kool on size
expanded nucleobases.66,57 Leonard’s lin-benzoadenosine was one of the first examples
of size expanded nucleobases which retain the natural hydrogen-bonding characteristics
of the parent base (Fig. 1-20). Through the insertion of benzene into the purine ring,
desirable photopysical properties may be achieved. Kool then applied this ideology to the
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remaining three natural bases and acquired a full set of benzo-expanded nucleosides and
incorporated them into an oligomer which was coined “xDNA” (Fig.1-20).59

Figure 1-20: The full set of “xDNA” benzo-expanded fluorescent bases which
maintain canonical Watson-Crick hydrogen bonding.56-58
This work has been developed further by the creation of “yDNA”, which differs by the
point of insertion of the benzene into the natural base, and naphtho-expanded
nucleobases, both of which are highly fluorescent.59 Although these fluorophores are not
well tolerated with natural nucleotides in the same strand, full sequences of the modified
bases show interesting fluorescent properties. New emission maxima appear within
certain sequence contexts due to excited state interactions and these may be exploited in
the future for SNP analysis or other sensing applications.
Thieno[3,2d]pyrimidine
A particularly elegant, divergent synthesis of isomorphic fluorescent base analogues was
recently described by Tor which relies on modification of the thieno[3,2d]pyrimidine

Figure 1-21: Alternative glycosylation of the thieno[3,2d] pyrimidine core with a
protected ribofuranoside yields both purine (top) and pyrimidine (bottom)
analogues.
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core. Glycosylation at N-1 provides a pyrimidine analogue, while C glycosylation at the β
position of thiophene yields the purine analogue (Fig. 1-21).60
The functional groups can then be manipulated to yield isosteric nucleobase analogues
that maintain hydrogen bonding with the natural bases.
Of the 4 isosteric base analogues synthesized, the thymine mimic showed the greatest
fluorometric response to changes in solvent polarity. Upon titration with the four natural
5’-monophosphates this analogue showed quenching in the presence of all bases
excepting the complementary nucleotide AMP.60 Such quenching may also occur in ss
form making SNP analysis troublesome; indeed, it is yet to be shown if this fluorescence
response can be replicated in the context of oligomers.
More recently, a constitutional isomer of the aforementioned compound, based on the
thieno[3,4-d]pyrimidine core, has been synthesized. Due to the apparent hypsochromic
effects observed in lower polarity solvents, the triphosphate was incorporated
enzymatically into an RNA transcript. This oligomer was shown to report a C mismatch
by an increase in emission.61 Introduction of this monomer into a specific RNA hairpin
the detection of the heterodimeric protein ricin was possible. Ricin catalyses the depurination of ribosomal RNA at specific sites and therefore causes a halt in translation
and cell death. Upon cleavage of the unnatural nucleobase an increase in fluorescence is
observed. This is a useful contribution to the field as a practical field test for a potential
biological warfare agent can be envisaged in the near future.62
Benzoquinazolines
Benzoquinazoline derivatives have been used as probes for duplex and triplex formation
and can be synthesized either by the condensation of an α-aminocyanonaphthalene or an
α-aminonaphthanoic acid with urea (Fig. 1-22).63,64
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Figure 1-22: Synthesis of benzoquinazolines for use as fluorescent pyrimidine
mimics.63,63
The reaction of α-aminocyanonaphthalene with urea results in a cytosine analogue which
can be converted to the thymine mimic by treatment with conc. HCl in DMF.
Amongst other uses, the benzoquinazolines have been successfully employed as triple
helix probes. Homopurine tracts are requisite for triple-helix formation whereby a third
strand binds in the major groove of the duplex; in parallel triplexes the third strand,
composed of pyrimidines, binds to the purine strand of the duplex in the major groove by
Hoogsteen base-pairing.65,66

Benzoquinazoline thymidine mimics (Fig. 1-22) were

incorporated into an oligopyrimidine sequence, they were found to be stabilizing towards
triple-helix formation (due to more favourable stacking interactions) and, more
relevantly, they were also found to respond fluorometrically to hybridization, particularly
when incorporated into the Hoogsteen strand. Fluorescence maxima were blue-shifted
and decreased in intensity while the excited state lifetime increased upon triple-helix
formation. As the formation of parallel triplexes are pH sensitive (relying in part on
CG*C+ triplets) the fluorescence observed was also subject to pH.64
Etheno(ε)-bridged bases
Although structurally similar to the natural bases, etheno(ε)-bridged bases possess
strikingly different photophysical properties (Fig. 1-23).
These base analogues can be formed in vivo through the action of various carcinogens
such as vinyl chloride and ethyl carbamate on the natural exocyclic amine-containing
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bases.67
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Figure 1-23: Etheno(ε)-bridged bases: ε-adenosine in equilibrium with the cationic
form responsible for its desirable photophysical properties, ε-guanosineand εcytidine.
These analogues are highly fluorescent (quantum yields as high as 0.6) and also very pH
sensitive, in the deprotonated state the compounds are only weakly fluorescent, this pH
sensitivity has been exploited in related derivatives to gauge the acidity of nucleotide
binding sites,68 and with excitation wavelengths of 290-300 nm, their usage in the
presence of absorbing biological macromolecules is permitted.
Described by Leonard in the early 1970s, ε-adenosine has been used in numerous
applications. Its first biologically significant uses were as the bridged ε-adenine
dinucleotide (εNAD+) and ε-adenosine triphosphate (εATP).69,70 The synthetic NAD+
analogue was found to be an active coenzyme in 4 different dehydrogenase-catalyzed
reactions and was also an effective substrate for NADase and phosphodiesterase I.
Although the emission intensity of εNAD+ is only 8% of the parent monophosphate, full
emission is restored upon phosphodiester cleavage allowing the real-time monitoring of
such hydrolyses. εATP was found to be a versatile analogue of ATP, it is an allosteric
effector of several enzymes and a co-substrate of kinases.70
It has been found recently that ε-7-deaza-2’-deoxyadenosine has a higher quantum yield
than the corresponding ε-adenosine and is more stable to extreme pH.71 Despite the
solution of a crystal structure containing a putative ε-A – G base pair

72

evidence for
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similar behaviour in solution is scant as both ε-A and its corresponding deaza-compound
are destabilizing towards duplex formation when placed within an oligonucleotide
sequence. This lack of base-pairing competency obviously limits their potential use as
BDFs.
Tricyclic analogues of cytosine: 3,5-Diaza-4-oxophenothiazine (tC) and 3,5-diaza-4phenoxazine (tCO)
These base analogues have been known for over a decade and were the first example of
tricyclic pyrimidine base analogues capable of complementary base-pairing and
compounds of similar structures continue to be pursued (Fig. 1-24). These tricyclic
cytidine analogues base-pair with guanine effectively and also impart greater stability
towards the duplex, purportedly due to increased stacking interactions; indeed, when two
phenoxazine or phenothiazine tricycles are neighbouring one another the duplex stability
is further increased.73 The compounds are highly fluorescent, tC (X=S) as the free
nucleobase analogue (which can be prepared according to Roth and Schloemer 74) is only
very slightly more emissive than when incorporated into an oligonucleotide. A small
increase in anistropy is found upon hybridization to a complementary strand, brought
about by the increase in effective molecular mass. The long emission wavelength of tC
means it may be used in FRET experiments coupled with chromophores such as
rhodamine as the acceptor moiety.75 Unfortunately, there is little change in the emission
spectrum upon hybridization to a complementary strand and only a small increase in the
fluorescence lifetime.76 The phenoxazine (X=O) (tCO) has very similar properties to the
phenothiazine although it is slightly more emissive and has had the honour of “brightest
DNA-incorporated base analogue” bestowed on it by the authors of a recent puclication,
as judged by its quantum yield in the duplex state.77 This striking luminescence was put
to use in probing the conformational dynamics of DNA polymerase. Using an Alexa-555
labeled cysteine residue as the FRET acceptor, movement of a subdomain was measured
using stopped-flow experiments on nucleotide binding.78
The phenoxazine derivative, first prepared by Matteucci and co-workers, has been used
more recently by Sigurdsson as a structural scaffold for nitroxide spin labeling which is
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useful for EPR studies (Fig.1-24).79 The nitroxide, quite expectedly, quenched the

Figure 1-24: 3,5-diaza-4-oxophenothiazine (tC) (X = S) and 3,5-diaza-4phenoxazine (tCO) (X = O) in hybridization with guanine. Elaboration of the
tC(O) scaffold has yielded a nitroxide spin labeled compound that may be used
for EPR measurements and the “G-clamp” which has increased binding affinity
to

guanine.73-83

fluorophore; however, fluorescence could be re-introduced by reduction of the nitroxide
to the sulphonate ester or the hydroxylamine (the latter of which is fully reversible) while
incorporated within an oligonucleotide. This switchable behaviour has obvious benefits,
fluorescence and EPR measurements may be made within the same vessel. The use of
this compound for SNP typing has been investigated in some simple sequences, it is
possible to distinguish between single stranded, match sequence and various mismatches
based on emission intensity. Matches with G result in a ca. 60% decrease in intensity
from the single stranded form with mismatches being flanked by the two extremes of
emission. When placed opposite A several maxima appear in the emission spectrum for
reasons, as of yet, unclear.80
Another elaboration of the phenoxazine has been the introduction of an ethoxyamino
group to the terminal aromatic ring. The primary ammonium is capable of forming an
additional hydrogen bond to guanine on the Hoogsteen face, further increasing duplex
stability while maintaining desirable photophysical properties 81 this additional hydrogen
bonding inspired the moniker “G-clamp”. The G-clamp has been introduced into both
DNA and PNA and shows a high degree of sequence dependence with regards to binding
affinity.82,83 The increased binding affinity of the G-clamp has been exploited to sterically
inhibit HIV-1 Tat-dependent trans-activation in vivo when incorporated into a 2’-O-Me
oligoribonucleotide.83 Replacing the primary amine of the “G-clamp” with a guanidine
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functionality further stabilizes the duplex through an additional hydrogen bond with the
N7 of guanine. These modified bases have been incorporated into PNA, 2’-O-Me
oligoribonucleotides, 2’-O-methoxyethyl phosphorothioate oligoribonucleotides and
DNA primarily for stability purposes and the fluorescence response data have not been
hitherto reported.84-86
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Figure 1-25: Purported hydrogen-bonding motif between Cbz-protected “Gclamp” and 8-oxoguanosine (R=2’-deoxyribose).
G-clamp derivatives have been used for the fluorometric detection of 8-oxoguanosine.87
Protection of the pendant amino functionality of the “G-clamp” with a Cbz group allowed
for selective quenching in the presence of 8-oxoguanosine. This is purportedly due a
hydrogen bonding interaction of the carbonyl oxygen of the Cbz group with the N7
hydrogen of 8-oxoguanosine (Fig. 1-25).
Quenching was found to occur only on titration of 8-oxoguanosine, the natural
nucleosides, A, C and T, did not affect fluorescence appreciably.
CONCLUSIONS
Although much progress has been made, the repertoire of useful fluorescent nucleotides
must continue to be expanded as no universal system exists. SNP analysis remains one of
the primary goals in this field; however, new applications continue to be found. The
ability to monitor gene regulation, transcription and protein/nucleic acid interactions in
general is becoming increasingly accessible.

Combinations of a BDF with an

oligonucleotide analogue which provides high affinity and discriminating binding, such
as LNA, PNA or morpholinos has yet to be fully explored.
Certain examples were highlighted in order to give a broad overview of the field. For a
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more complete overview of the literature the reader is directed to several excellent
reviews.9,42,88-93

1.2

‘Chemical’ synthesis of peptides and nucleic acids

DNA: An Historical Perspective 1871-1953.
As the story goes, on the 28th of February, 1953 James Watson and Francis Crick walked
into the Eagle pub in Cambridge proudly declaring “We have found the secret of life.”
Worn-out controversies surrounding X-ray diffraction data aside, Watson and Crick were
standing on tall shoulders indeed when they proposed the structure of the double helix.94
The story of the elucidation of DNA’s molecular architecture begins much earlier and
what follows is a very brief tour of the early science which led Watson and Crick to the
pub that day for a celebratory pint.
He did not know the gravity of his findings at the time but the Swiss scientist Friedrich
Miescher discovered DNA in 1871, a substance he termed nuclein.95 It was isolated from
puss-soaked bandages he obtained from a nearby hospital and was not totally free of
protein contaminants. Many at the time discredited his discovery thinking that it was
simply phosphorus contaminated protein, but Meisher continued to work and found that
nuclein could be isolated from other sources and had a high molecular weight (inferred
from the viscosity of his preparations in solution). He was also able to conduct elemental
analysis and found that it had a unique P/N ratio. In 1880 Kossel, embarked on the first
real structural determination of DNA and found that a hydrolysate of nuclein contained
four bases; adenine, cytosine, guanine and thymine.96 Later, Altmann obtained proteinfree nuclein and also found it to contain phosphorus and that it was acidic in character.
He then introduced the term nucleic acid. It was now little doubted that nucleic acids
contained bases and phosphorus but another component was missing. Phoebus Levene
discovered that nucleic acids from isolated from some sources contained D-ribose while
from other sources the hitherto unreported sugar 2-deoxyribose predominated.97
At this stage the components of DNA were known and now it was a matter of fitting
them together. At the time, there was no reason to believe that DNA was a
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macromolecule. People still held that proteins were the hereditary material accounting for
Mendel’s pea’s behaviours. Nothing that has only four distinct units could ever be the
basis for the astounding complexity of life on earth (sic). It was also thought that the
bases were present in equal proportions. Due to these preconceptions and compounded by
the lack of sufficient analytical techniques, a tetranucleotide hypothesis for the structure
was put forward by both Levene and Takahashi. Levene proposed a linear tetranucleotide
and Takahashi, a circular. Having correctly determined the ring structure of thymidine,
Levene and Tipson were remarkably close with their second proposal98 knowing that the
phosphate must link 5’ and 3’ positions. However, over the next two decades, two major
developments would reveal the inadequacies of Levene’s tetrameric idea.
Remarkable work, first by Griffith,99 then Avery, McCleod and McCarty,100 culminating
in the Hershey-Chase101 experiments showed that DNA was the hereditary material.
Hershey and Chase showed through radiolabeling that bacteria transformed by a T2
phage did not retain the tranfected protein and DNA was the molecule responsible.101
Edwin Chargaff found that the proportions of nucleobases varied between samples but
the molar ratios of A to T and G to C remained constant, regardless of the source of the
DNA.102,103
The lack of analytical techniques in the past is really what spurred on natural productdriven chemistry. There was a time, and it is even so today (albeit to a lesser extent),
where to prove the identity of a molecule it must be pepared at the bench and compared
to the natural substance. Although we do not often think of it in these terms, DNA is a
natural product and it was chemical synthesis of oligodeoxynucleotides that originally
determined and confirmed its primary structure. Emil Fischer had used this method to
unambiguously determine the structure of the purines around the turn of the century. He
recognized that guanine, adenine, xanthine, uric acid, and caffeine were all derivatives of
a parent bicyclic compound he named purine. Having synthesized purine in 1898 he then
found the differences between the naturally occurring compounds were differential
hydroxyl and amino substitutions. Lord Alexander Todd, just in time for Watson and
Crick, unambiguously determined the β-anomeric configuration in nucleotides104,105 and
then set about to make a dinucleoside phosphate with the natural 3’→5’ linkage.106 In
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doing so, he would lay the basis for further oligomerization chemistries.
Before the synthesis of the dinucleoside phosphate, as was suggested, Watson and Crick
made their leap of thought to correctly guess the structure of DNA. Crystal data supplied
by Maurice Wilkins and (perhaps unwillingly supplied by) Rosalind Franklin told them
the structure was helical in nature and highly hydrated. In talking with chemists in
neighbouring laboratories they were told the proper tautomeric forms of the bases. With
Chargaff’s rules in hand, the leap doesn’t seem so far today. Their model correctly
contradicted that of Linus Pauling.107 Pauling had proposed a three stranded structure
with many inherent problems. They proposed that there was hydrogen bonding between
hydrogen phosphates that would be deprotonated at physiological pH and they placed the
hydrophobic bases on the outside of the helix. There was no plausible mechanism for self
directed replication. Watson and Crick’s model accounted for self replication, a helical
structure that seemed chemically sound. We will now focus back to chemistry directed
towards the synthesis of oligomeric DNA.
DNA Synthesis.
Todd’s contributions were significant as they created both the H-phosphonate and
phosphotriester approaches (Fig. 1-26). The first step shown below is an H-phosphonate
coupling giving the H-phosphonate diester that may be activated using an electrophilic
chlorine source (in this case N-chlorosuccinimide), which then undergoes a
phosphotriester coupling to give the desired linkage (Fig 1-26).106 Deprotection thusly
yielded the first synthetic dinucleoside phosphate. There were inherent drawbacks to this
method. Most seriously there was no clear way to extend this method to trimers and
beyond. Although it would later prove necessary to protect the phosphate, the protecting
group choice of benzyl was not ideal as it was somewhat base-labile. Todd’s approach
was abandoned for a period as a new method was introduced by Khorana.
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Figure 1-26: Lord Todd's synthesis of a dinucleoside phosphate using the
phosphotriester approach.
Khorana’s synthesis came later to be known as the phosphodiester method,108-110 and is
important for several reasons. The synthetic scheme is outlined in figure 1-27. It is
perhaps the most simple of approaches; a condensation of a phosphate with an alcohol.
At first, dicyclohexylcarbodiimide was used as a coupling reagent but was later replaced
by arenesulfonyl chlorides (Fig.1-27).111
Perhaps the most important part of this synthesis is the choice of 5’-protection. 4,4’dimethoxytrityl (DMT) is able to be introduced selectively to the 5’-OH due to its steric
bulk and is labile under very mildly acidic conditions. The glycosidic bond of purine 2’deoxynucleosides is susceptible to acid hydrolysis; however, not under conditions
required for DMT removal. This choice is orthogonal to base protecting groups
commonly used to date (vide infra) and allows for stepwise elongation of the oligomer.
Downfalls of this approach include the long coupling times required (up to 2 days), and
the accumulation of charge on the oligomer. The anionic backbone is able to act as a
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nucleophile in subsequent coupling steps and therefore reduces yield considerably.
Purification was also laborious due to the presence of many side-products.

Figure 1-28: Khorana's phosphodiester approach sees the introduction
of the important 4,4'-dimethoxytrityl protecting group.
In the late 1960s Letsinger began to revisit the phosphotriester approach of nucleotide
synthesis as outlined in figure 1-28. We have already seen chemistry similar to this;
however, here we are introducing a new protecting group. As mentioned earlier,
protection of the phosphate was imperative; it cut down on side reactions and allowed
easier purification. The choice of the base labile β-cyanoethyl group as a permanent
protecting group was an important one. It is cleaved along with base protecting groups
and is completely orthogonal to the DMT group which Letsinger had brought from
Khorana’s work.112,113
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Figure 1-27: Letsinger's phosphotriester approach utilizing the base-labile 2cyanoethyl protecting group.
Again, these coupling reactions were slow and prompted Letsinger to harness the
inherently higher reactivity of P (III) phosphorylating agents thus giving rise to the
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phosphite triester approach shown in figure 1-29.114

Figure 1-29: Letsinger's phosphite triester approach harnessing the
high reactivity of phosphorus III. R = phenoxyacetyl, R’ = Cl3CCH2
The first step of the reaction shown above (Fig. 1-29) is incredibly fast and is carried out
at -78˚C in THF. The intermediate phosphorochloridite is not isolated, as it is extremely
sensitive to water, and is reacted directly with the free 5’-hydroxyl of another nucleoside
to give the phosphite triester which can be oxidized in situ with iodine and water.
Although much faster, there were several disadvantages to this method; the high
reactivity of the phosphodichloridite and its bifunctionality necessitated the use of low
temperature and led to the possibility of 3’→3’, 3’→5’, and 5’→5’ linkages occurring.
Nevertheless, Letsinger was able to carry out the synthesis of a tetramer and laid in place
the last of the important developments to allow the now gold standard phophoramidite
coupling method to emerge.
In 1981 Beaucage and Caruthers developed the phosphoramidite technique which is what
is almost exclusively used today.115 Caruthers’ technique along with the introduction a
few minor modifications116,117 is shown in figure 1-30 and borrows on many of the
chemistries hitherto developed. The power of this technique lays in the caged reactivity
of the monofunctional phosphoramidites used. Only in the presence of a weak acid are
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they activated sufficiently and are stable to ambient conditions to a much larger degree
than the previously used P(III) derivatives.

Figure 1-30: Caruthers' phosphoramidite approach. R = levulinyl.
Using tetrazole as a weak acid, the diisopropylamine moiety becomes protonated and
displaced by tetrazolate which then acts as leaving group for the incoming 5’-OH. After
this addition oxidation can occur in the same manner as previously described by
Letsinger.
The phosphoramidite approach represents the highest yielding and most practical way of
synthesizing oligonucleotides in the laboratory; however, it would be of limited use if it
was not used in conjunction with the solid-supported chemistry that is outlined in the next
segment of this sub-chapter.
Solid-Supported Oligomerization of Nucleic Acids and Peptides.
It is little doubted that few things have changed the face of biological polymer synthesis,
and indeed oligonucleotide synthesis, to the extent that solid-phased chemical approaches
have. There are three main benefits to solid-phase synthesis. 1) Separation of the resin
bound product or intermediate products can be carried out simply by filtration and a few
washing steps; this makes the process amenable to automation. 2) Minimized handling
losses occur as the product remains attached to the resin. 3) Reagents can be used in
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excess in order to drive the reaction to completion resulting in very high stepwise yields.
The three preceeding points also make the technique particularly amenable to the
synthesis of oligomers as repeated chemistries may be applied to lengthen a chain
sequentially. As are all scientific discoveries today, solid-phased peptide synthesis
(SPPS) was only possible due to the extant body of hard won research in related fields;
however, this makes its advent no less significant. Proof-of-principle was illustrated in a
pair of reports from R.B. Merrifield at The Rockefeller Institute in 1963 and 1964,
respectively.118,119 The second of these papers demonstrated a method that, with only
minor modifications, is still in use today. Insoluble chloromethylated polystyrene was
used and to it was attached the C-terminus of an (N-Boc protected) amino acid.
Merrifield synthesized the nonapeptide bradykinin via dicyclohexylcarbodiimide (DCC)
coupling in record yield. Synthesis, purification and characterization was complete in 8
days. Coupling efficiency was shown to be nearly quantitative and the final product
obtained behaved identically, both biologically and chemically, to those prepared
previously. Temporary protection of the terminal amino group was done using tertbutyloxycarbonyl (Boc) resulting in an acid labile carbamate that was readily cleaved
with 1 M HCl in AcOH in iterative cycles while cleavage of the benzyl ester linkage to
the resin could be carried out with HBr in trifluoroacetic acid (TFA). This was later
optimized to give the current Boc chemistry protocol whereby the temporary protection is
removed with TFA while the permanent protecting groups and the linkage to the resin are
cleaved using HF. Because these protecting groups are both acid-labile on each cycle of
Boc deprotection some side chain deprotection and cleavage unavoidably occurs causing
branching and reduced yield. Another downfall of this approach is the use of HF which is
an extremely hazardous reagent requiring special equipment for safe handling. Some
peptides are also not stable under these conditions and side reactions reduce yield. Figure
1-31
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Problems of solvent accessibility to the resin also needed to be overcome, what was
required was a more polar resin that would allow penetration of solvent and reagents.
Sheppard’s laboratory developed more polar resins that allowed for increased yields in
the synthesis of peptides and nucleic acids.120,121 As the resins used became better and
sequences became longer the issue of cleavage from the resin by repeated acid treatment
became the limiting factor for Boc chemistry. What was needed was an orthogonal
approach in peptide synthesis.

Figure 1-31: Contrast of Boc (graded) and Fmoc (orthogonal)
protecting group strategies.
The introduction of the base labile fluorenylmethoxycarbonyl (Fmoc) nitrogen protecting
group by Carpino122 attracted little attention at first. Many existing amino protecting
groups formed volatile or otherwise easily removed by-products and this was not the case
with Fmoc. The dibenzofulvene formed can react further and polymerize making
isolation of the desired product more difficult. A problem for solution phase chemistry
but not so for solid-supported approaches as the by-products can be simply washed away
(Fig. 1-32).
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A schematic representation of modern Fmoc-based peptide synthesis is shown above. In
this case HBTU is used as a coupling reagent. The active ester is formed and coupled to
the amine of the support (in this case NovaSyn® TGR) creating tetramethylurea and Nhydroxybenzotriazole as by-products that can readily be washed away. During this step a
large excess of active ester (ca. 5 fold) is introduced in order to maximize stepwise
coupling yields. A capping step allows for increased yields and easier purification by
preventing the continued synthesis of truncated sequences. Acetylation renders any
remaining amino groups unreactive. Removal of the Fmoc group is typically carried out
with 20% piperidine in DMF. The use of a secondary amine for this purpose is important
as it can further react with the liberated dibenzofulvene to form an adduct thus preventing
its potential reaction with the growing oligomer or its polymerization. At this stage the
progression of coupling can be monitored by the release of the dibenzofulvene either by
conductivity readings or photospectroscopically. The process is then repeated until the
desired length is reached and then cleaved from the resin using TFA. This process also
removes permanent protecting groups; shown here is Boc. Purification of the
trifluoroacetate salt is then carried out by HPLC or less often by electrophoresis and
characterized by mass spectrometry. With the use of this resin a carboxamide Cterminated peptide is obtained; however, more traditional linkers result in the natural
carboxylic acid.
The first report of solid-phase synthesis of nucleic acids123 went largely unnoticed and it
was not until 15 years or so later that its true potential was found. This was due to the
problems with the chemistry at the time and the unsuitability of the resins in use. The
most commonly used support today is the controlled pore glass124 and is usually
functionalized with a long-chain alkylamine. The alkylamine is conjugated to the base via
a linker (often succinoyl) which can be cleaved by base. Original efforts concentrated on
the phosphotriester approach but this and the H-phosphonate approach have now been
overwhelmingly superceded by the phophoramidite approach. Shown in figure 1-33 is a
modern solid-phase strategy using a universal support. Many approaches start with a preloaded support where the first sugar is attached directly to the succinoyl linker using a
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Figure 1-33: Modern solid supported oligonucleotide synthesis
by the phosphoramidite method.
coupling reagent such as DCC yielding, upon cleavage, an oligonucleotide with a free 3’-
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coupling reagent such as DCC yielding, upon cleavage, an oligonucleotide with a free 3’OH. Use of a universal linker allows for the straight phosphoramidite coupling of the first
nucleotide and upon cleavage yields an oligomer with a 3’-terminal OH (Fig 1-33).
Tetrazole is still used by many as an activator; however, other activators are now also in
common use such as dicyanoimidazole and ethylthiotetrazole. Ethylthiotetrazole offers
advantages in that, due to a lowered pKa, it can be used in lower concentration. It also is
more soluble in acetonitrile than tetrazole.125 For these reasons Glen Research has termed
it the “Rambo Activator”. Research by the company found that it performs better in
0.25M concentration than 0.45 M tetrazole, particularly for RNA synthesis. After
coupling, the phosphorus(III) must be oxidized to phosphorus(V) prior to capping and
this is carried out with either I2 or an organic peroxide. Capping then proceeds for the
same reasons as demonstrated in peptide synthesis, followed by mild acidolysis of the
DMT group. The cycle may then be repeated until the desired length oligomer is reached
then cleaved from the resin with concomitant removal of base- and phosphate-protective
groups using concentrated aqueous ammonia. HPLC purification is oftentimes carried out
first with the 5’-terminal DMT group still attached, effectively separating the oligomer
from truncated sequences. This is then removed in solution with 80% acetic acid,
lyophilized and re-purified.

1.3 Oligonucleotides and their analogues as modifiers of
gene expression
Altering gene expression using oligonucleotides, or their analogues, targeted to mRNA is
an attractive proposal for several basic reasons. Up until the late 1980s nucleic acids were
often overlooked as drug targets and still today most therapeutics act at the protein level,
where there may be thousands of targets stemming from one corresponding transcript.
Preventing translation of a single transcript has the potential to affect the production of a
multitude of aberrant proteins or proteins associated with a particular disease state. Easily
predictable design rules, based on Watson-Crick hybridization,94 could simplify the
procedure of identifying a lead compound and, moreover, could be wholly selective of a
specific gene. With the sequence data now available and an increasing understanding of
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molecular processes occurring in the cell; the antisense concept has only become more
seductive.
The first demonstration of the aforementioned principle was carried out in a cell-free
eukaryotic translation system.126 The authors found that the translation of β globin
mRNA was reversibly arrested when hybridized with a complementary DNA sequence.
Shortly thereafter, Zamenick and Stevenson found a therapeutic value in this
phenomenon in 1978127 through the inhibition of replication of the Rous sarcoma virus.
Chick embryo fibroblasts infected with the virus were cultured in the presence of a 13mer DNA complementary to the 5’ and 3’ ends of the viral 35S RNA. The presence of
the oligomer was found to decrease the infectivity and replication of the virus; the authors
proposed a steric block mechanism as a possible therapeutic modality. Many broader
targets have been addressed and will be discussed later in this chapter; but first, some
more background.
Mechanisms of antisense dug action.
There are essentially three ways in which an antisense drug may exert its desired effect
which is the inhibition of protein synthesis. The most conceptually simple of these is
termed the steric block mechanism. In this case, the association of the antisense
oligonucleotide (ASO) to the target mRNA prevents, by its occupancy, the association or
progression of the ribosome across the transcript. This mechanism is most effective when
the 5’-untranslated region (UTR) is targeted as this is where translation initiation occurs.
Certain areas of the transcript are required to be structured for effective splicing or
translation initiation, disturbance of these structured areas can also be of therapeutic
value. The steric block mechanism can also be used for exon skipping and this
therapeutic modality is seeing great progress as treatment for Duchenne and Becker
muscular dystrophies. In this case a protein coding region (exon) within the dystrophin
gene contains a mutation that results in a non-functional, truncated protein. By the
binding of an ASO to the 5’-end of an exon an alternate splice site may be chosen
resulting in expression of a shorter but still functional protein.128,129 For this strategy to be
effective the ASO must obviously not recruit degradative enzymes so only some ASOs
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are available for use.
The second method works by the recruitment of RNaseH enzymes. RNaseH is expressed
ubiquitously and is present both in the nucleus and the cytoplasm,130 its natural function
is to cleave the RNA strand of a DNA/RNA heteroduplex, this is required during the
removal of RNA template strands during lagging strand DNA synthesis and for Okazaki
fragment processing. Because of the importance of these functions knockout of the gene
is embryonic lethal.131 It recognizes A-form duplexes and the silencing is generally more
robust than the previous mechanism as it is catalytic; one ASO can induce the
degradation of multiple transcripts. The enzyme has limited sequence specificity and can
therefore be manipulated easily with synthetic ASOs to cleave target RNA. Many of the
most therapeutically important ASOs operate by this mechanism. This mechanism can
also see the use of analogues that do not directly recruit RNaseH. So called gapmers
consist of a central DNA sequence flanked at its 5’ and 3’ termini with modifications that
impart enzymatic stability, improved binding, and pharmacokinetics.132
Perhaps the most remarkable of gene silencing mechanisms and currently the most
studied is RNAi. Because of its dissimilarity to the previous two mechanisms described it
is often placed in a category of its own. Using small RNAs as a guide, a complementary
sequence is cleaved or its rate of translation is otherwise diminished by a series of
endogenous enzymes that are thought to have evolved as a defense against viruses. The
phenomenon was first discovered in plants133 and then later in Caenorhabditis elegans.134
Shortly thereafter, Fire and Mello discovered that double stranded RNAs were the cause
of the observed silencing for which they would later receive the Nobel Prize.135
Importantly, they noted that only a few molecules were required to give significant
reduction of protein levels. This then ruled out a stoichiometric mechanism and implied
that there was a catalytic or amplification process in operation. It was later found that
larger dsRNAs were converted to shorter sequences and it was these that induced
silencing.136 The exact mechanism of gene silencing will not be described in great detail
here, but, in short, the process begins as small double stranded RNA is loaded onto a
RNA induced silencing complex (RISC). In mammals, this may consist of simply
argonaute protein 2 (Ago2) loaded with a short interfering RNA (siRNA) or a very large
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multiprotein complex. The associating factors enhance or otherwise modulate the
silencing activity.137-139 Using the antisense strand as a guide, RISC finds the cognate
sequence and cleaves it giving a 5’-terminal phosphate and 2’- and 3’-terminal hydroxyl
groups. Although, as we will see, the more traditional, single-stranded ASOs have seen
extensive chemical modification, RNAi is yet to see substantial benefit from this
chemistry.
Oligonucleotide analogues.
Enticing as oligonucleotide therapeutics may seem for the treatment of various diseases,
we are yet to see comensurate translation into the clinic. At its advent, it was thought that
antisense technology was the beginning of the end for many disorders. However, there
are several inherent difficulties with the antisense approach that have brought the organic
chemist to the table. DNA and RNA are readily degraded by enzymes, can invoke
unwanted immune response, and are, for the most part, unable to penetrate cells.
In the following paragraphs, I will describe different oligonucleotide analogues and
highlight the mechanism(s) of antisense action to which they pertain. We can divide the
chemical modifications into distinct categories. The first two are phosphate and sugar
modified respectively. The so-called first generation of modified oligonucleotide
analogues are phosphate modified. Phosphorothioates (PS) were first synthesized in the
late 1960s140 with the aim of stabilizing polyribonucleotides that were used to induce
interferon and are the most widely used backbone-modified ASO for several reasons
(Fig. 1-34). Sulfurization of the phosphite triester can be easily carried out as opposed to
the oxidation step in the phosphoramidite approach of DNA synthesis using Beaucage’s
reagent141 or others such as 3-((dimethylaminomethylidene)amino)-3H-1,2,4-dithiazole3-thione (DDTT).142 This sulfurization results in the formation of a chiral centre which
can complicate the HPLC purification as a large number of diastereomers are created.
However, the benefits of this modification far outweigh this minor problem. They are far
more resistant to nucleolytic degradation and therefore have long half lives in serum and
cells and binding to serum proteins prevents rapid renal clearance.143 This protein-binding
ability adds the benefit of increasing cellular uptake but is also the cause of their
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toxicity.144 These ASOs operate by eliciting RNase H activity; however, their affinity to
target RNA is reduced as compared to DNA. Several uniformly modified PS-ASOs are in
clinical trials and one has FDA approval (Vitravene®, a 21-mer used to treat
cytomegalovirus retinitis in immunocompromized patients) and many more are employed
in gapmers (these will be explained soon). The PS backbone has also been introduced
into siRNA and shown to be an effective and stable substitution although toxic at higher
concentrations.145
The methylphosphonate modification (Fig.1-34) was first pursued to evaluate the effects
of charge on hybridization efficiency of nucleic acids146 and it was thought that the lack
of charge, making the molecule more lipophilic, would allow for better cell penetration.
Like PS ASOs the methyphosphonates are present as a mixture of diastereomers. These
diastereomers vary greatly in their affinity towards target nucleic acids and do not recruit
RNaseH.147

Figure 1-34: First (left) and second (right) generation antisense
oligonucleotides (ASOs).
Two examples of second generation oligonucleotides are shown above (Fig. 1-34, right).
2’-O-Me and 2’-O-methoxyethyl RNAs148,149 were sythesized to hopefully alleviate the
shortcomings of the first generation ASOs. They maintain the 3’-endo conformation of
RNA but the lack of an available proton of the 2’-O confers increased resistance to
nucleases. Unfortunately they do not elecit RNaseH but may still be used in gapmers and
are beginning to find success in RNAi experiments.
More dramatic departures from the natural structure of the sugar phosphate backbone
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may be termed third generation ASOs, of which there are many. A select few of these
structures are shown below in figure 1-35.
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Figure 1-35: Third generation antisense oligonucleotides.
Wengel and Imanishi published simultaneously in 1998 on locked nucleic acid
(LNA).150,151 A methylene linker between 2’-O and 4’-C gives a conformationally stained
nucleoside “locked” in the north or C-3’ endo postion. This locking minimizes the
entropic penalty associated with binding and results in high affinity towards DNA and
RNA. It does not, however, elicit a response from RNaseH in and of itself but again can
be used in gapmers or chimeras.
2’-Deoxy-2’-fluoroarabinonucleic acids (2’-FANAs) were a particularly rewarding
modification for oligonucleotide therapeutics.152 They were first oligomerized in 1993 by
Watanabe’s group.153 Although arabinonucleic acids were found to hybridize poorly with
DNA and RNA,154 likely due to steric reasons, substitution of the C2’-hydroxyl with the
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much smaller fluorine results with an analogue that binds strongly to both DNA and
RNA.155 The duplex formed with RNA is of A-type structure and is able to elicit RNA
cleavage from RNaseH, this was a dramatic discovery at the time as up until that point
only DNA/RNA heteroduplexes had been unequivocally proven as substates of this
enzyme.155 What is more is that the 2’-F modification imparts stability towards
nucleases156 and the electronegative fluorine also make the nucleosides highly resistant to
glycosylases. This modification finds much use in gapmers, altimers and chimeras for
RNaseH supported cleavage and in siRNA.157-159
Peptide nucleic acid (PNA) is a neutral polyamide first synthesized in 1991 by Nielsen
and coworkers.160 Its backbone departs dramatically from natural oligonucleotides; it is
composed of N-(2-aminoethyl)glycine units to which the bases are attached via a
carboxymethyl linkers (Fig.1-35). The molecule was originally designed for triplex
formation but it was found that it can displace the opposing strand of a DNA duplex and
follows Watson-Crick hydrogen bonding rules.160,161 Partly because of its non-ionic
nature, PNA binds to DNA and RNA with greater affinity than either do with themselves
and has therefore been studied in great detail as an ASO operating by a steric block
mechanism. PNA may bind to its targets in different ways depending on concentration
and sequence identity (Fig. 1-36).

1-36: PNA binding modes withe PNA shown in bold.
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PNA binds to DNA and RNA in an antiparallel fashion if one considers the N-terminus
of the peptide to be pseudo-5’. This is not to say that parallel duplex formation is
impossible, only that is a markedly less stable configuration.161 Homopyrimidine PNA
oligomers form highly stable triplex invasion complexes with target DNA while other
sequences may form duplex invasion complexes as observed in Nielsen’s initial
publication. With the aid of the modified bases 2,6-diaminopurine and 2-thiouracil it is
possible to form double duplex invasion species that prevent transcription and can also be
used effectively as artificial restriction endonucleases.162,163 These attributes make PNAs
suitable for targeting DNA in anti-gene therapies as they have been shown to suppress
transcription and,164 curiously enough, activate it also.165 When targeted to mRNA PNA
can prevent translation if targeted to the 5’-UTR of the transcript and occasionally when
targeted to the coding region. Due to its structural dissimilarity to any natural
oligonucleotide or peptide it operates only by a steric block method as it is not recognized
by RNaseH.166 Although, as with other analogues, it can still be used in chimeras with
analogues that do recruit RNaseH.167 PNA and its applications will be discussed further in
chapters 3, 4 and 7.
In short, the objectives of the work contained in the following chapters are twofold. We
wish to increase the scope of cytosine analogues to be used as base-discriminating
fluorophores. This will be approached in two ways. Firstly, using the Huisgen
cycloaddition, we will generate a range of analogues in a modular fashion. In addition to
this, we will modify the pyrrolocytosine scaffold to give a range of useful fluorophores
for use in mismatch detection. The second objective is to design oligomers with highaffinity towards DNA and RNA, either by the attachement of a platinum centre or
through the incorporation of a modified nucleobase to PNA, for use as tools for the
modulation of gene expression.
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Chapter 2

2

Synthesis and evaluation of the in vitro DNA binding
properties of chiral cisdichloro(pyridyloxazoline)platinum(II) complexes

A series

of chiral

cis-dichloro(pyridyloxazoline)platinum(II)

and

palladium(II)

complexes were synthesized and their reactivity towards a defined sequence of singlestranded- and double-stranded DNA was investigated in comparison to cisplatin. The
compounds differed in the nature and absolute configuration of the substituent at the C4
position of the oxazoline ring. The DNA binding ability of these compounds was
evaluated by HPLC analysis, post metal exposure, of enzymatic digests of an undecamer
duplex containing one putative metallation site. Polyacrylamide gel electrophoresis
(PAGE) and thermal denaturation confirmed the results of the HPLC analysis which
showed that the stereochemistry and character of the substituent at the C4 position of the
oxazoline ring had little effect on DNA binding, possibly due to the formation of
monofunctional adducts. Excerpts of this chapter have been taken from Dodd, D.W.;
Toews, H.E.; Trevail, M.J.; Jennings, M.C.; Hudson, R.H.E.; Jones, N.D.. Can. J. Chem.
2009, 87, 321-327.

2.1 Introduction
The serendipitous discovery of the antiproliferative properties of cis-dichlorodiammineplatinum(II) (cisplatin) over 30 years ago led to its eventual use as a chemotherapeutic
agent.1 Today, cisplatin remains one of the most widely used drugs for the treatment of
solid cell tumours.2 Motivated by cisplatin’s effectiveness, similar treatments have been
pursued; however, despite vigorous research towards this end, only a handful of
successful analogues have been developed.3 While complexes of other metals such as
titanium, rhenium, ruthenium and gallium have shown promise as potential antineoplastic
agents, the literature of metal anticancer theraputics is dominated by platinum
complexes.4 The efficacy of cisplatin in the treatment of carcinomata is almost
universally thought to be due to its ability to form intrastrand adducts between adjacent
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purines in DNA.2-5 The design principles of cisplatin analogues were described two years
after the first clinical trials: the complexes should be neutral and four coordinate with two
coordination sites occupied by labile leaving ligands and two occupied by inert am(m)ine
ligand(s) in a cis geometry.6
Once cisplatin enters the cell, the lower intracellular chloride concentration permits
dissociation of the halides resulting in the formation of an aquated platinum centre. This
cationic species reacts predominantly with the N7 of guanine or adenine nucleobases.5
The guanine adduct is thought to be stabilized through hydrogen bonding of an ammine
proton with the carbonyl oxygen of C6 making deoxyguanosine dinucleotide (-dGpdG-)
the preferred target sequence.7 Binding to DNA in this fashion causes a kinking of the
double helix and a widening of the minor groove; this can inhibit transcription and lead to
apoptosis by inducing the binding of high mobility group (HMG) box proteins (5).
Although cisplatin is indeed an effective drug, there are problems associated with
prolonged dosages such as toxicity and acquired resistance. Therefore the search
continues for improved platinum based therapies.
While several thousand cisplatin analogues have been synthesized and tested for
biological activity,8 only a select few have been entered into clinical trials. This has led
many in the scientific community to believe that the search for Pt(II) chemotherapeutics
is futile. Discovery of a drug suitable for clinical trials is a rare occurrence in every field,
yet failure in cisplatin analogue discovery draws inordinate attention. Perhaps the reason
for the reluctance to continue in this area is due to the remarkable simplicity of cisplatin
itself: even minor substitutions cause drastic changes in efficacy. Although the structure
of cisplatin is simple, the mode of action certainly is not, and many questions remain
unanswered.5
Although it is unlikely that a simple substitution of the ammine ligands will yield a
complex with activity surpassing that of cisplatin, more elaborate changes, such as
variation in the σ-donation character of the ligand and the introduction of chirality could
yield complexes with novel reactivities in vitro and corresponding cytostatic effects in
vivo.
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As DNA is a chiral molecule, binding of chiral platinum complexes results in
diastereomeric adducts. Different binding affinities for enantiomeric complexes have
been reported and (of no lesser importance) it has also been found that the diastereomeric
adducts may be dealt with by cellular machinery in vastly different ways.9 For example,
the S,S enantiomer of (1,2-diaminocyclohexane)oxalatoplatinum(II) (S,S-I, Fig. 2-1) is
significantly more mutagenic than the R,R enantiomer and consequently only the latter
was pursued in clinical trials.9,10 Other examples of chiral DNA-binding Pt complexes
that

have

been

studied

in

detail

include

dichloro(N-methyl-2-

aminomethylpyrrolidine)platinum(II) (II, Fig. 2-1)10 and complexes involving 1,2bis(aminomethyl)carbobicyclic ligands (III, Fig. 2-1).11 Differences in reactivities of
enantiomeric complexes towards DNA are rare.12
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Figure 2-1: Chiral platinum complexes I-III studied as cisplatin analogues.9-11
Chiral centres are denoted by asterisks.
Although hydrogen bonding involving coordinated NH groups have been considered
necessary for cytostatic activity,13 there are examples of compounds lacking an NH
proton that display significant antitumour effects.14,15
Pyridyloxazolines, derived from the condensation of a chiral β-amino alcohol with 2cyanopyridine, are planar, bidentate ligands for platinum(II) and are necessarily bound
cis (Fig. 2-2). The substituent at the α-position of the amino alcohol, C4 in the resultant
O
R
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N

N

R

N

M
Cl
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M

Cl

R-1 R = iPr, M = Pt
R-2 R = Bn, M = Pt
R-3 R = Ph, M = Pt
R-4 R = iPr, M = Pd

Cl

Cl

S-1 R = iPr, M = Pt
S-2 R = Bn, M = Pt
S-3 R = Ph, M = Pt
S-4 R = iPr, M = Pd
S-5 R = sBu, M = Pt
6 R = H, M = Pt

Figure 2-2: Pyridyloxazoline platinum and palladium dichlorides employed in this
study. The chiral centre is derived from the enantiomerically pure amino acid.
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oxazoline ring, can be varied greatly and inexpensively as the alcohols are obtained by
the reduction of the corresponding enantiopure amino acids.16,17
Pyridyloxazoline Pt(II) complexes have found use in enantioselective enyne
cyclizations18 and the unsubstituted complex 6 has shown some promise as an anticancer
therapeutic, displaying significant toxicity towards rat brain tumour cell lines in vitro.19
The palladium analogues have not been used in DNA binding studies, but have been
investigated as asymmetric catalysts for the intermolecular asymmetric Heck reaction.16
In this work, binding of these complexes to a defined sequence of oligomeric double
stranded (ds) DNA containing one putative metallation site was investigated by HPLC
analysis of enzymatic digests. The duplexes that were exposed to the metal complexes
were also analyzed by thermal denaturation and polyacrylamide gel electrophoresis
(PAGE).
Difference in binding abilities between enantiomers and sidechain identity was
investigated, the objective being to gain a better understanding of the SAR of chiral
platinum antineoplastic agents.

2.2 Results and discussion
The modular nature of the pyridyloxazoline ligand scaffold, combined with its brief
synthesis from readily-available enantiopure starting materials and facile metal
coordination, permitted the rapid development of small libraries of enantiomeric Pt(II)
and Pd(II) complexes. The known pyridyloxazoline ligands required for the syntheses of
complexes 1(4)–6 were made by the ZnCl2-catalyzed coupling of 2-cyanopyridine with
the β-amino alcohols, valinol, phenylalaninol, phenylglycinol, isoleucinol, and

Figure 2-3: Synthesis of dichloro(pyridyloxazoline)metal(II) complexes.
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ethanolamine, respectively, using the procedure developed by Bolm et al. (Fig. 2-3).17
The amino alcohols, except for ethanolamine, were themselves readily made by
NaBH4/I2-reduction of both enantiomers of the corresponding amino acids, during which
time no racemization occurs.26 The metal(II) complexes were made in good-excellent
yields by the reaction of slight molar excesses of the ligands either with cis/transPtCl2(SMe2)2 or trans-PdCl2(PhCN)2 in refluxing 1,2-dichloroethane or CH2Cl2 at r.t.
The complexes were yellow-orange, microcrystalline solids that were freely soluble in
polar organic solvents, such as CHCl3 and CH2Cl2, and insoluble in Et2O and hexanes.
All complexes were also sufficiently soluble in H2O to allow DNA-binding studies.
The molecular structure of S-1 is shown in Figure 2-4; it is isostructural with the known
precisely analogous palladium derivative.16 As expected, the metal adopts an
approximately square planar coordination geometry, and the pyridyloxazoline ligand is
roughly planar except for the iso-propyl substituent at the 4-position of the oxazoline ring
which projects prominently from one face of the complex and makes a torsion angle with
it of ca. 62 °. The ligand has a “bite angle” of 79.711(4) °, which is nearly identical to
that found for the palladium analogue, but unlike in that compound, whose M–oxazoline
bond (2.017(5) Å) is significantly shorter than its M–pyridine bond (2.048(6) Å), there is
no difference in the two M–N distances, which are both 2.015(11, 12) Å in S-1. However,
there is, as in the palladium analogue, a significant difference in the M–Cl distances: in
complexes of both metals, the M–Cl bond trans to the oxazoline ring is longer than that
trans to the pyridine ring, which consistently suggests that oxazoline is a stronger field
ligand than pyridine, and implies strong contribution from the resonance form that places
a formal negative charge on the N-atom of the free oxazoline.
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Figure 2-4: Partial ORTEP representation of the molecular structure of S-1, with Hatoms omitted for clarity. Thermal ellipsoids for Pt- and Cl-atoms are shown at
50 % probablility; all other atoms are refined isotropically (see Experimental
section). Selected bond distances (Å) and angles (°), with estimated standard
deviations in parentheses: Pt1–N1 2.015(11), Pt1–N11 2.015(12), Pt1–Cl11 2.2869(3),
Pt1–Cl12 2.298(4), N1–Pt1–N11 79.711(4), Pt1–N11–C10–C12 61.629(19).
The particular undecamer sequence chosen for the present studies (shown below) has
been used by Lippard and co-workers to obtain a solution NMR structure of a platinated
duplex and is known to adopt the typical B-form of DNA in the absence of platination.27
The putative metallation site is underscored.
Top strand - 5'-CTCTCGGTCTC-3'
Bottom strand – 3’-GAGAGCCAGAG-5’
After incubation of the ds DNA test sequence with complexes 1-6 and complete digestion
of the oligonucleotides, HPLC analyses were carried out. Nucleoside peaks were
identified by the coinjection of standards and integrated peak area ratios were calculated.
The ratios of nucleosides were calculated and analyzed as it independent of volume and
concentration of reaction, and is not influenced by volume of sample used for HPLC
analysis and eliminates errors associated with pipetting technique. Binding of cisplatin
analogues to a dsDNA sequence is consistent with a marked decrease in dG/dC and a
slight decrease in dA/dC because dG and dA are known to coordinate metal complexes.
This drastically shifts their retention times in RP-HPLC.28 The nucleoside peak area
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ratios for the control digests conformed to the stoichiometry of the nucleosides within the
DNA strands given their relative absorptivities.29 The dG/dA ratio can be used as a
measure of binding selectivity for dG over dA. Results are shown in Figure 4 for 1 eq. of
complex per duplex DNA. From the ratios of dG/dC it can be seen that the
pyridyloxazoline complexes tested are less reactive towards dG than cisplatin. From
comparison with the control experiment, the composition of nucleosides is reduced in dG
by ca. 40% upon exposure to cisplatin. Higher degrees of platination may be obtained by
reaction at elevated temperatures with an excess of platinum salt or through the use of
bis-DMF/NO3- compounds.27,28 The low thermal stability of our test sequence precluded
us from the use of the former and we avoided the latter as we wished not for complete
saturation, but to determine the differences in binding between enantiomeric complexes.
In all digests, dC/dT remains approximately constant implying that these bases are not
reactive towards the platinum complexes, as expected. Enantiomeric complexes showed
no discernable patterns in their DNA binding ability. In the case where R = iPr (R-1, S-1)
the S enantiomer appears less reactive towards dG, but in the case where R = Ph (R-2, S2) it is the R enantiomer which is less reactive. In the case of R = Bn (R-3, S-3), there is
little difference due to stereochemistry (Fig. 2-5). The unsubstituted ligand complex 6 (R
= H) appeared to be the least reactive of the platinum complexes; this was somewhat
surprising as it was thought the decreased steric constraints would allow for greater DNA
binding. It has been shown formerly that this compound has antineoplastic effects on
cancer cells in vitro.19 The lack of binding in our study implies that this compound may
have a different biological target and/or mode of action. Both palladium complexes tested
showed no significant deviations from the negative control; palladium complexes in a cis
geometry are known to have lower binding affinities towards DNA than cisdichloroplatinum compounds; however, the comparable trans-complexes often offer
cytostatic effects surpassing that of cisplatin.30
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Figure 2-5: Ratios of peak area for enzymatic digests of the undecamer duplex after
exposure to no Pt containing compound (0), cisplatin (cisPt), and compounds 1-6.
Error bars are +/- standard deviation.
In the single stranded digests, lack of secondary structure should make the
stereochemistry of the complexes less relevant. The complexes exhibited reactivity
different from what was observed in the case of the duplex. In the reaction with the
bottom strand (5’-GAGACCGAGAG-3’), where the only adjacent purines are dApdG, R1, S-1 and S-2 showed reactivity towards dG comparable to that of cisplatin (Fig. 2-6).
All complexes showed greater reactivity towards dA than cisplatin. Decreased selectivity
for dG is possibly due to the lack of an available NH proton. Digests of the top strand (5’CTCTCGGTCTC-3’) yielded very similar results to the duplex digestions where all
compounds bound to dG less efficiently than cisplatin.

67

6
5
4
dG/dC

3

dA/dC
dG/dA

2
1
0
0

cisPt

R-1

S-1

R-2

S-2

Figure 2-6: Ratio of peak areas for the enzymatic digests of the bottom strand
undecamer after exposure to no Pt containing compound (0), cisplatin (cisPt), and
compounds 1 and 2. Error bars are +/- standard deviation.
Thermal denaturation of platinated duplexes showed that cisplatin lowered the melting
temperature (Tm) of the duplex, which is consistent with the formation of 1,2-intrastrand
adducts (the stability of the duplex is compromised to the extent that a ∆Tm of -20 °C can
be observed),2,31 while the pyridyloxazoline complexes decreased the Tm only very
slightly (∆Tm = 1-3°C). This indicates that 1,2 adducts are likely not formed.
Denaturing polyacrylamide gel electrophoresis (PAGE) of the platinated ds and ss DNA
again confirmed the generally low reactivity of the compounds. However, DNA
platination is revealed by electrophoretic analysis of the reaction mixtures employing the
most reactive compound used in this study (R-1), (Fig. 2-7). The accumulation of positive
charge which occurs after platination of the sequence results in lower mobility of the
oligonucleotide within the gel matrix.
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Figure 2-7: Denaturing polyacrylamide gel electrophoresis (PAGE) (negative
exposure) of top strand (TS), bottom strand (BS) and double stranded (ds) DNA
subjected to 1 eq. of either R-1, cisplatin or no Pt. Lanes: 1: dsDNA, negative
control; 2: dsDNA + cisplatin; 3: dsDNA + R-1; 4: BS, negative control; 5: TS,
negative control; 6: BS + R-1; 7: TS + R-1; 8: BS + cisplatin; 9: TS + cisplatin.
A significant shifting of the bands in the lanes containing cisplatin was observed. The
lanes containing the pyridyloxazoline complex R-1 either showed one band identical to
the control (no platinum) or two bands, the top band (corresponding to a platinated ss
sequence) appearing very faintly.
It is possible that if left for longer periods of time the compounds tested may show
differences in binding between enantiomers as the diastereomeric adducts may be
resolved towards the thermodynamic product. It was however found that the ratios
determined at 36 and 48 h were not substantially different.

2.3 Conclusions
In conclusion, the pyridyloxazoline complexes of Pt and Pd tested in this study likely did
not form 1,2-adducts with DNA, but had a higher propensity towards the formation of
complexes with dA than cisplatin. It was also found that the nature and absolute
configuration of the substituent at C4 of the oxazoline ring had no systematic or simple
and predictable effect on reactivity. The previous work demonstrating the antineoplastic
effects of 6

19

may imply that monofunctional adducts formed are pharmacologically

relevant. In vivo or in vitro biological assays may, in turn, highlight whether the chirality
of these complexes is pertinent in regards to their efficacy as anticancer agents.
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2.4 Experimental
General
Pyridyloxazoline ligands and the metal precursors PdCl2(PhCN)2 and cis/transPtCl2(SMe2)2 were synthesised according to literature procedures and characterization
data matched those of the known compounds.20,21 Platinum compounds 1-3, 5, 6 were
synthesized by a general procedure as outlined for R-1; spectral data for enantiomeric
complexes were identical, as expected. Solution 1H NMR spectra were collected using a
Varian 400 spectrometer (400.09 MHz for 1H and 100.61 MHz for 13C) at r.t. in CDCl3
(unless otherwise noted) and referenced to residual 1H or

13

C in the deuterated solvent.

Coupling constants are given in Hz. Elemental analyses were conducted by Chemisar
Laboratories Inc., Guelph ON.

Denaturing polyacrylamide gels were cast and run

according to literature procedures.22 The resultant gels were documented by colour
digital photography over fluorescent TLC plates illuminated at 258 nm. For clarity, the
image presented has been rendered in grayscale, inverted and contrast/brightness adjusted
in Adobe Photoshop.
Optical rotations were recorded on an Atago Polax-2L polarimeter at a concentration of
1g/100 mL at 589 nm in CH2Cl2 solution.
Stock solutions of the complexes (40 µM) were prepared by dissolution in a minimum
amount of DMF (< 0.5 mL) followed by dilution with Milli-Q deionized water to 100 mL
and stored at r.t. in the dark for no longer than 2 weeks. DNA was purchased from the
University of Calgary DNA Services and used without further purification.
Syntheses
Dichloro-2-[(4R)-4-iso-propyl-4,5-dihydro-1,3-oxazol-2-yl]pyridineplatinum(II) (R-1)
The title complex was synthesized by the addition of cis/trans-PtCl2(SMe2)2 (0.23 g, 0.60
mmol) to 5 mL of 1,2-dichloroethane containing a slight excess of pyridyloxazoline
ligand (0.14 g, 0.72 mmol). The resultant yellow solution was heated to reflux for 4 h
over which time it darkened in colour. The solvent was removed in vacuo and the
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remaining oil triturated with Et2O (10 mL). Vacuum filtration gave 0.27 g (94%) of R-1
as an orange/yellow powder. Anal. calcd. for C11H14N2Cl2OPt: C, 28.96; H, 3.09; N,
6.14%. Found: C, 28.90; H, 3.10; N, 6.21%. 1H NMR δ: 9.51 (m, 1H, py), 8.17 (m, 1H,
py), 7.76 (m, 1H, py), 7.63 (m, 1H, py), 5.00 (m, 1H, CH2), 4.86 (m, 1H, CH), 4.71 (m,
1H, CH2), 2.99 (m, 1H, CH), 0.98 (d, 3H, CH3, 3J=7.1), 0.83 (d, 3H, CH3, 3J=6.9).
13

C{1H} NMR δ: 173.2, 149.7, 145.0, 139.4, 129.4, 126.6, 73.3, 68.2, 28.9, 18.9, 14.1.

HRMS (ESI) calcd. for (M + Na) C11H14N2Cl2ONaPt 477.0008; found: 477.0015. [α] = 65.0°.
Dichloro-2-[(4S)-4-iso-propyl-4,5-dihydro-1,3-oxazol-2-yl]pyridineplatinum(II) (S-1)
Yield: 94%. (ESI) calcd. for (M + Na) C11H14N2Cl2ONaPt 477.0008; found: 476.9996.
[α] = 70.0°. Orange plates suitable for X-ray diffraction analysis were provided by slow
diffusion of Et2O into a CH2Cl2 solution of the title complex.
Dichloro-2-[(4R)-4-benzyl-4,5-dihydro-1,3-oxazol-2-yl]pyridineplatinum(II) (R-2)
Yield: 72%. Anal. calcd. for C15H14N2Cl2OPt: C, 35.73; H, 2.80; N, 5.56%. Found: C,
36.02; H, 2.76; N, 5.54%.1H NMR δ: 9.63 (m, 1H, py), 8.15 (m, 1H, py), 7.67 (m, 1H,
py), 7.39 (m, 1H, py), 7.27 (m, 5H, Ar), 5.01 (m, 1H, CH2), 4.93 (m, 1H, CH), 4.85 (m,
1H, CH2), 3.66 (dd, 1H, CH2, 2J=13.9, 3J=10.7), 3.11 (dd, 1H, CH2, 2J=13.9, 3J = 5.8).
13

C{1H} NMR δ: 173.9, 150.1, 145.3, 139.7, 135.9, 130.2, 129.5, 129.2, 127.6, 126.8,

64.5, 39.8. HRMS (ESI) calcd. for (M + Na) C15H14N2Cl2ONaPt 525.0008; found:
525.0033.
Dichloro-2-[(4S)-4-benzyl-4,5-dihydro-1,3-oxazol-2-yl]pyridineplatinum(II) (S-2)
Yield: 68%. Anal. calcd. for C15H14N2Cl2OPt: C, 35.73; H, 2.80; N, 5.56%. Found: C,
36.03; H, 3.06; N, 5.52%. HRMS (ESI) calcd. for (M + Na) C15H14N2Cl2ONaPt
525.0008; found: 525.0033.
Dichloro-2-[(4R)-4-phenyl-4,5-dihydro-1,3-oxazol-2-yl]pyridineplatinum(II) (R-3)
Yield: 94%. Anal. calcd. for C14H12N2Cl2OPt: C, 34.30; H, 2.47; N, 5.71%. Found: C,
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34.53; H, 2.72; N, 5.52%. 1H NMR δ: 9.45 (m, 1H, py), 8.20 (m, 1H, py), 7.86 (m, 1H,
py), 7.62 (m, 1H, py), 7.38 (m, 5H, Ph), 5.88 (dd, 1H, CH2, 2J=10.2, 3J=4.9), 5.46 (dd,
1H, CH, 3J=4.9, 3J=3.8), 4.92 (dd, 1H, CH2, 2J=10.2, 3J=3.8). 13C{1H} NMR (CD2Cl2): δ:
174.3, 150.0, 149.6, 144.8, 139.5, 139.1, 130.3, 129.9, 129.1, 127.1, 126.8, 126.3, 81.1,
66.4. HRMS (ESI) calcd. for (M + Na) C14H12N2Cl2ONaPt 510.9851; found: 510.9845.
Dichloro-2-[(4S)-4-phenyl-4,5-dihydro-1,3-oxazol-2-yl]pyridineplatinum(II) (S-3)
Yield: 92%. Anal. calcd. for C14H12N2Cl2OPt: C, 34.30; H, 2.47; N, 5.71%. Found: C,
34.56; H, 2.75; N, 5.73%. HRMS (ESI) calcd. for (M + Na) C14H12N2ONaCl2Pt
510.9851; found: 510.9868.
Dichloro-2-[(4R)-4-iso-propyl-4,5-dihydro-1,3-oxazol-2-yl]pyridinepalladium(II) (R-4)
The title complex was synthesised as described in the literature. Characterization data
matched those of the known compound.17
Dichloro-2-[(4S)-4-iso-propyl-4,5-dihydro-1,3-oxazol-2-yl]pyridinepalladium(II) (S-4)
The title complex was made in the same way as R-4. Spectroscopic data matched those of
the enantiomeric compound.
Dichloro-2-[(4S)-4-sec-butyl-4,5-dihydro-1,3-oxazol-2-yl]pyridineplatinum(II) (5)
Yield: 84%. 1HNMR δ: 9.26 (d, 1H, py, 3J=5.5), 7.8 (dd, 1H, py, 3J=5.5, 3J=7.8), 7.76 (d,
1H, py, 3J=7.6), 7.56 (dd, 1H, py, 3J=7.8, 3J=7.6), 5.13 (m, 1H, CH2), 4.87 (m, 1H, CH),
4.78 (m, 1H, CH2), 2.75 (m, 1H, CH), 1.29 (m, 2H, CH2), 1.00 (t, 3H, CH3, 3J=7.4),
0.78 (d, 3H, CH3, 3J=6.8).

13

C{1H} NMR δ: 173.2, 149.8, 145.0, 139.3, 129.3, 126.5,

73.3, 66.9, 35.5, 26.5, 18.0, 11.9. HRMS (ESI) calcd. for (M + Na) C12H16N2ONaCl2Pt
491.0164; found: 491.0177.
Dichloro-2-[4,5-dihydro-1,3-oxazol-2-yl]pyridineplatinum(II) (6)
The title compound has been previously made by a different route.19 Following the
procedure for R-1, 6 was obtained in 72% yield. The limited solubility of this complex
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did not allow for the measurement of NMR spectral data. Anal. calcd. for C8H8N2Cl2OPt:
C, 23.20; H, 1.95; N, 6.76%. Found: C, 23.50; H, 1.89; N, 6.66%.
Crystallography
An orange plate was cut loose and then mounted on a glass fibre. Data were collected at
low temperature (-123 °C) on a Nonius Kappa-CCD area detector diffractometer with
COLLECT (Nonius B.V., 1997-2002). The unit cell parameters were calculated and
refined from the full data set. Crystal cell refinement and data reduction were carried out
using HKL2000 DENZO-SMN.23 The absorption correction was applied using HKL2000
DENZO-SMN (SCALEPACK). The crystal data and refinement parameters of S-1 are
listed in table 2-1.
Table 2-1-1: X-ray crystallographic structural parameters for compound S-1.
Crystal
Empirical formula
Formula mass
Colour, habit
Crystal dimensions (mm)
Crystal system
Space group
Z
a (Å)
b (Å)
c (Å)
α (°)
β (°)
γ (°)
Collection ranges
Temperature (K)
Volume (Å3)
Dcalcd (Mg m-3)
Radiation
Absorption coeff. (µ) (mm-1)
Absorption correction
F(000)
θ range for data collection (°)
Observed reflections
Independent reflections
Data/restraints/parameters
Goodness-of-fit on F2

S-1
C11H14Cl2N2Opt
456.23
Orange, plates
0.17 x 0.15 x 0.103
Monoclinic
P 21
4
6.7455(3)
20.2782(9)
9.5172(4)
90
93.10(2)
90
-4<=h<=4; -24<=k<=24; -11<=l<=11
150(2)
1299.93(10)
2.331
Mo Kα (λ = 0.71073 Å)
11.189
Semi-empirical from equivalents
856
2.94 to 25.03
11811
2550 (Rint = 0.0760)
2550/37/171
1.023
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Final R indices (l > 2σ(l))
R indices (all data)
Absolute structure parameter
Largest diff. peak and hole (e Å3)

R1 = 0.0321, wR2 = 0.0664
R1 = 0.0395, wR2 = 0.0693
-0.009(18)
0.889 and -0.702

The reflection data and systematic absences were consistent with a monoclinic space
group: P21). The SHELXTL/PC V6.14 for Windows NT (Sheldrick, G.M., 2001) suite of
programs was used to solve the structure by direct methods. Subsequent difference
Fourier syntheses allowed the remaining atoms to be located.

There were two

independent molecules in the asymmetric unit. For this crystal, twinning was also an
issue; it is discussed below. Only the heavy atoms (Pt, Cl) were refined anisotropically as
some of the lighter atoms became non-positive definite when they were allowed to refine
freely. The hydrogen atom positions were calculated geometrically and were included as
riding on their respective carbon atoms. The largest residue electron density peak (0.877
e/Å3) was associated with one of platinum atoms. Full-matrix least squares refinement
on F2 gave R1 = 3.21 for 2σ data and wR2 = 6.66 for all data (GooF = 1.021).
The structure was solved readily, but the initial refinement stalled at R = 12.9 %. Further,
the light atoms did not refine successfully with an anisotropic model. There were signs
of non-merohedral twinning in the E-statistics and the Fobs values were consistently
higher than the Fcalcs. WinGX

24

was used to “detwin” the data. ROTAX

25

found the

Twin Law, which turned out to be a 180° rotation about the direct lattice direction (1 0 0).
“Make HKLF5” was used to generate the detwinned file used in further refinement.
The structure refinement improved considerably with better values for R1, wR2, GooF,
standard uncertainties and residual electron density. The final R1 value came down to
3.21%. The final solution, however, could still not be refined completely anisotropically,
and the light atoms were left isotropic in the refinement. The constant for the Twin Law
refined to a value of 0.47309. All these points served to confirm the correct Twin Law
was chosen.
Nuclease Digest Studies
Duplex DNA was prepared by heating a 1:1 mixture of the complementary sequences in
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10 mM NaClO4 to 90 ºC and allowing the solution to come slowly to rt. The solution was
then cooled to 4ºC for 2h. Both single and double stranded DNA (2 µM) were reacted
with the complexes in a 1:1 molar ratio in 200 µL of 10 mM NaClO4 for 48 h in the dark.
The buffer was then adjusted to 50 mM Tris, 20 mM MgCl2, pH 7.5. Bovine serum
albumin (BSA) was added to a final concentration of 0.02 µg/mL and the DNA was
digested sequentially with bovine pancreas DNase I (Sigma, 36 U for 4 h), nuclease P1
(Sigma, 10 U for 18 h) and alkaline phosphatase (Promega, 20 U for 4 h). The samples
were then heated to 90 ˚C for 2 min to denature the enzymes and centrifuged for 10 min
at 10,000 g. The supernatant was analyzed at 254 nm by RP-HPLC on a Varian
Microsorb 100 Å C18 column using a flow rate of 1 mL min-1 and a solvent system of
100:0 0.1 M aqueous [Et3NH][OAc] (pH 6.5):MeCN from 0-5 min followed by a linear
ramp to 90:10 over a period of 20 min. Nucleoside peaks were identified by co-injection
of standards. The areas under the peaks were found by integration and analyzed in
relation to one another. These digests and the HPLC analyses thereof were carried out in
triplicate.
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Chapter 3

3

Peptide Nucleic Acid Pt(II) Conjugates: A Preliminary
Study of Antisense Effects in Xenopus laevis

The avid hybridization of peptide nucleic acid (PNA) to DNA and RNA, coupled with
the analogue’s stability towards enzymatic degradation, has led to its investigation as an
antigene/antisense agent. PNA targeted toward the 5’-UTR of an mRNA transcript can
effect efficient silencing; however, if targeted to an area within the coding region, the
PNA can be displaced by the moving ribosome and be an ineffective antisense agent.
Platinum-appended and standard PNAs antisense to an area within the open reading
frame of the gene noggin, were injected into Xenopus laevis embryos. Phenotypic
responses were observed and the preliminary results are reported herein.

3.1 Introduction
Antisense PNA (asPNA) exerts its effects differently from the most well established and
widely used oligodeoxynucleotide analogues, such as phosphorothioates, in that it acts
independently of RNaseH (please see chapter 1.3 for a more detailed discussion).
Mechanistically, with respect to translation, asPNA relies on steric blockage of the
mRNA transcript. This steric interference is most robust within the 5’-UTR, where
asPNA prevents ribosomal binding, effective knockdown of transcription can be readily
achieved. However, oftentimes when asPNAs targeting areas within the coding region are
used, little or no antisense effects are observed.1-3 When down-regulating a gene product
by asPNA, the target chosen must share little homology to other sequences within the
transcriptome. If selection of this target is limited to the 5’-UTR it can be difficult to find
a unique sequence. If the whole of the transcriptome was available for this purpose then
more sequences could be assessed. Since the discovery of RNAi, post-transcriptional
down-regulation of a gene by targeting the coding region is routinely possible although it
is often difficult to predict the efficiency/specificity. The use of PNA also offers clinical
advantages relating to serum stability, lower molecular weight and fewer off-target and
immunogenic effects.4
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The drug cis-diamminedichloroplatinum (II) (cisplatin) is a successful anti-cancer agent,
particularly in the treatment of testicular cancer where the disease can, in the vast
majority of cases, be cured.5 The mechanism of action is almost universally thought to be
brought about by the coordination of adjacent purines (preferentially G) to the metal
centre in an N7-Pt-N7 bonding arrangement.6 Platinum cross-links have been investigated
using transplatin modified PNA,7 and 2’-O-methylribonucleotides whereby the metal
centres are linked to the oligonucleotide analogue in a 1,3-intrastrand N7-Pt-N7 bonding
arrangement.8,9 A Pt chelating aminoethylglycine moiety has previously been
incorporated into a solid phase synthesis strategy with the aim of producing a library of
peptide based cisplatin analogues.10,11 Our aim is to incorporate this same platinum
chelating moiety into a PNA synthesis thereby combining the sequence specificity of
PNA and the irreversible, covalent platination of DNA and mRNA.
Xenopus laevis is an African frog which finds much use in developmental biology and
cell signaling studies. Eggs of this species are easily obtained, fertilized and cultivated,
and embryos are large enough to be injected with up to 20 nL of an aqueous solution.12 In
choosing a gene to knockdown, several criteria must be met: the gene must be expressed
early in development, show a clear phenotypic response upon knockdown (with literature
precedent), and it would also be desirable that an antibody is commercially available to
allow for Western analysis of protein levels. Noggin, a small signaling protein involved
in the cephalization cascade,13,14 fulfilled all of these criteria. The protein is thus named
due to the loss-of-function mutants displaying a headless phenotype. We therefore aimed
to inject Pt-containing and standard PNA complementary to an area within the open
reading frame of Xenopus noggin with the hypothesis that an increased antisense effect
would be brought about by the formation of Pt mediated cross-links.

3.2 Results and Discussion
Fmoc protection of β-alanine and aminoethylglycine proceeded smoothly and monomers
115 and 210 were incorporated into the solid phase supported synthesis of a PNA 15-mer
complementary to X. laevis noggin mRNA. Following removal of the Fmoc groups, the
oligomers were subjected to platinating conditions10 while on the solid support with baseprotective groups still present. As a control, a portion of the PNA was not platinated.
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After TFA cleavage from the resin and purification by RP-HPLC, the oligomers were
characterized by ESI-HRMS and injected into X. laevis embryos as unbuffered aqueous
solutions, figure 3-1. Once hybridized, the nearby GpG of the target may coordinate the
pendant metal centre. The target region is within the open reading frame of noggin, 376
bases downstream of the AUG start codon in an area predicted to have limited secondary
structure.

Figure 3-1: Solid-supported synthesis of a platinum-bearing PNA. Sequence identity
of the target with the putative platination site shown in bold.
In vitro characterization of binding was carried out with a DNA target for simplicity, cost
and, ease of handling. Unplatinated PNA-aminoethylglycine (PNA-AEG) demonstrated
an expectedly high melting temperature of 83˚C with its DNA complement as determined
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by temperature dependent UV-Vis spectroscopy, however, no cooperative transition
could be observed for PNA aminoethylglycinePtCl2 (PNA-AEGPtCl2) with its
complement up to 95˚C. These data are consistent with the presence of Pt-mediated
cross-linking to complementary DNA.
Microinjection of X. laevis embryos was carried out with PNA-AEG and PNA-AEGPtCl2
in three different concentrations of each along with an injection of cisplatin as a control.
Several rounds of injections were carried out; and when the embryos reached stage 40 the
then tadpoles were examined for any phenotypic response (Figure 3-2).

Figure 3-2: Microphotographs of nomal (left) otherwise abnormal (top right) and
headless (bottom right) phenotypes.
Data for phenotypic response, shown in table 3-1, indicate that there are no significant
phenotypic differences between tadpoles which encountered platinated versus
unplatinated oligomer in varying concentrations. High mortality rates can be attributed to
the quality of the embryos and also the prominence of unfertilized eggs (62% mortality
for uninjected embryos). To avoid this problem in the future, embryos will be injected
after the first cleavage (cellular division) so that all embryos injected are known to be
fertilized and likely viable. It can be seen that the injection of cisplatin resulted in 100%
mortality while other injections resulted in mortalities ranging from 80-86%. It is notable
that the PNA-AEG and PNA-AEGPtCl2 treated embryos demonstrated the headless
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phenotype, wherein it was completely absent from the control sample, figure 3-2.
Additionally, the abnormal phenotype was more abundant in the treated samples
compared to the control, and the amount of wild type body morphology was dramatically
knocked down.
Table 3-1: Phenotypic analysis of X. laevis embryos at stage 40 after microinjection
with PNA-AEG, PNA-AEGPtCl2 and cisplatin along with an uninjected control (wt
= wild type). Numbers are reported with the percent of total embryos given in
brackets. Total compound injected is denoted by low (1.15×10-13 mol), med (5.81×1013

mol) and high (11.62 ×10-13 mol).

asPNA

Total

Dead

Headless

Otherwise
abnormal

wt

PNA-AEG low

240

206(86.2)

3(1.3)

15(6.3)

16(6.2)

PNA-AEG med

217

182(83.9)

5(2.3)

12(5.5)

18(8.3)

PNA-AEG high

260

216(83.1)

5(1.9)

18(6.9)

21(8.1)

PNA-AEGPtCl2 low

249

210(84.3)

8(3.2)

15(6.0)

16(6.4)

PNA-AEGPtCl2 med

232

189(81.4)

3(1.3)

28(12.1)

12(5.2)

PNA-AEGPtCl2 high

268

215(80.2)

12(4.5)

26(9.7)

15(5.6)

Cisplatin med

105

105(100.0)

-

-

-

Control (no injection)

362

223(61.6)

0

8(2.2)

131.0(36.2)

There appears to be no pattern in the phenotypes or the mortality between the injection of
different PNAs in different amounts. Statistically, the platinated PNA showed no more
potent an antisense effect. There may be a slight antisense effect through steric blocking
of the mRNA without platination, in which case, a shorter PNA would be desired for
further studies. The appearance of wild type individuals can, in part, be explained by
failed injection as opposed to authentic lack of antisense action. It was also suspected that
our platinated oligomer was contaminated with unplatinated oligomer. PNA-AEG was
always observed to a small extent in mass spectra although this could simply have been
an artefact of the technique. Regardless, we were driven to find an alternate means of
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purification as existing methods were insufficient (this will be described in chapter 4).

3.3 Conclusions
These studies, although encouraging, are only preliminary and further characterization of
the system is needed to be carried out in vitro. RNA electrophoretic mobility shift assays
under both native and denaturing conditions could be used to determine if crosslinks have
formed to the Pt-PNA conjugate. Platinated adducts would be further characterized by
mass spectrometry. Western analysis of protein levels has yet to be carried out.
Microinjection of asPNAs avoids the issue of cell penetration/compartmentalization
found in cell culture studies; therefore, we would aim to utilize a eukaryotic cell-free
translation system to monitor protein production in vitro. The ultimate goal of this project
is to provide molecular tools – broadly useful, tunable antisense agents, for the study of
developmental biology in model organisms such as X. laevis and D. rerio.

3.4 Experimental
Peptide synthesis
PNAs were synthesized on a Rink amide resin using an Applied Biosystems 433A
peptide synthesizer and commercially available monomers (Applied Biosystems,
Warrington, UK.)

using standard Fmoc chemistry. Compounds 1

15

and 2

10

were

prepared according to literature procedures. PNA conjugates were purified by RP-HPLC
and

characterized

by

ESI-HRMS.

PNA-AEGPtCl2

HRMS(ESI)

Calcd.

for

C175H230Cl2N84O53Pt 4621.6943 Found 4621.4878. PNA-AEG HRMS(ESI) Calcd. for
C175H230N84O53 4356.7918 Found 4356.5552.
Thermal denaturation
Complementary DNA of the sequence 5’-GAC-TGA-GCA-AGA-AAC-TCA-GGA-G-3’
was purchased from The University Core DNA Services at The University of Calgary
and used without further purification. UV-Vis dependent thermal denaturation was
carried out in aqueous 100 mM NaCl, 10 mM Na2HPO4, 0.1 mM EDTA, pH 7.0 at a
strand concentration of 8µM. Denaturation was performed between 10 °C to 95 °C at a
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rate of 0.5 °Cmin-1. Melting temperature is given as an average of three runs within 1˚C
and estimated for cooperative transitions by the first derivative method.
Microinjections
Fertilization and microinjection of Xenopus laevis embryos were carried out according to
a published procedure.12 Embryos in 1X Marc’s modified ringer (MMR) were injected at
the one cell stage with 8 nL of solution. Embryos were injected with either 1.15×10-13,
5.81×10-13 or 11.62×10-13 mol of PNA-AEG, PNA-AEGPtCl2 or cisplatin. These
amounts correspond to a similar study in the literature.14After injection, embryos were
cultivated in 0.1X MMR until being assayed for phenotypic changes at stage 40.
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Chapter 4

4

Denaturing Polyacrylamide Gel Electrophoresis of
Peptide Nucleic Acids as a Purification and Analytical
Technique

A flexible and convenient protocol for the analysis and purification of peptide nucleic
acid oligomers and peptide nucleic acid-peptide chimeras by denaturing polyacrylamide
gel electrophoresis is described. Vertical slab gel electrophoresis, 26% in polyacrylamide
and 8 M urea at pH 3 was suitable for analysis of oligomers ranging in size from
tetramers (4-mers) to tetradodecamers (24-mers). Single–base resolution of oligomers
was achieved and separations are generally superior to those given by standard reversedphase HPLC techniques. The separation of a related series of PNA oligomers showed the
distance migrated was linearly dependent on the logarithm of the molecular weight. The
migration of oligomers through the gel is dependent the number of basic functional
groups present, such as amino groups, and the A and C content of the oligomer. Excerpts
from this chapter are taken from Dodd and Hudson Electrophoresis 2007, 28, 3884-3889.

4.1 Introduction
Peptide nucleic acid (PNA) is a polyamide-based oligonucleotide analogue possessing a
high affinity and sequence selectivity for complementary DNA and RNA as well as being
chemically robust and resistant to enzymatic degradation (for more on PNA and its
properties refer to chapter 1.3).1,2 These properties have led to its use as a hybridization
probe and investigation into its potential as an antisense or antigene agent.
The synthesis of PNA oligomers lends itself well to automation and is performed most
often by one of the two major approaches: the fluorenylmethyloxycarbonyl- (Fmoc)
route or tertiary-butyloxycarbonyl- (Boc) route using traditional solid-phase peptide
chemistry.3 After cleavage from the resin, purification of the oligomer is typically carried
out by reversed-phase high pressure liquid chromatography (HPLC) and the products are
subsequently characterized by mass spectrometry. As with other uncharged DNA
analogues, PNA has lowered solubility at neutral pH and shows a tendency to aggregate
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oftentimes making chromatographic separation more difficult than with the
corresponding DNA oligomers.3 Indeed, we have encountered problems with the
purification of certain sequences. The platinum bearing PNAs mentioned in the previous
chapter were particularly difficult in this regard. In lower yielding syntheses there is often
still enough of the ideal sequence present to allow its study, however, it is oftentimes
impossible to isolate in pure form by HPLC.
As an alternative to reversed-phase HPLC, Nielsen and Orgel have reported anionexchange chromatography at a pH of 10 as an efficient means of separation.4 This
technique was found to be sensitive to the G and T content of the PNA oligomer as these
bases become deprotonated at high pH. However, drawbacks of this system are the use of
specialized/expensive equipment and also the tendency of PNAs to rearrange and
depurinate under basic conditions.5
Polyacrylamide gel electrophoresis of PNA complexed with DNA or RNA is well
described in the literature wherein the electrophoretic mobility is imparted to the complex
by the natural anionic charge of the natural oligonucleotides.6 PNA has also been
polymerized into polyacrylamide gels for use in affinity electrophoresis of DNA
oligomers.7 Despite the utility and ubiquity of electrophoresis in nucleic acid chemistry,
there exists no protocol for the electrophoresis of PNAs themselves. Due to the typical
inclusion of a terminal lysine residue, PNA oligomers are cationic under acid conditions
and it was therefore reasoned that a protocol that was suitable for denaturing
electrophoresis of basic proteins may find success in the purification and analysis of PNA
oligomers. Additionally, given the basicity of the nucleobases, under acidic conditions
the charge of a PNA oligomer becomes dependent on the C and A content and skeletal
rearrangement is less common.5

4.2 Results and Discussion
General
It was found that the charge state of the oligomer was the dominant factor in determining
the rate of migration of the PNA however, size also plays an important role (vide infra).
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An increase in size will generally correspond to an increase in charge state (due to the
incorporation of A and C monomers). Unlike in DNA PAGE the concentration of
acrylamide and the degree of cross-linking need not be adjusted to accommodate
differently sized oligomers, it was found that the same system was convenient for
tetramers up to tetradodecamers and presumably beyond. Time and voltage become the
only experimentally determined variables necessary. The antagonism of size and charge
should not be construed as a drawback of the technique concerning the purification of
crude mixtures. The side products in a crude mixture will generally be of the same charge
state and are therefore separable based on molecular mass. PNAs used in this study are
noted below (Table 4-1).
Table 4-1: Sequence identity of PNAs used in the present work.
PNA

Sequencea N→C

Charge Stateb

1

H2N-T6-Lys-NH2

+2

2

H2N-Gly-GTAGATC(HMU)CT-Lys-NH2

+6

3

Ac-Gly-GCGCAAC-Lys-NH2

+6

4

Ac-Gly-GCGCAA(PhpC)-Lys-NH2

+5

5

Ac-Lys-T12Gly-NH2

+1

6

Ac-Lys-T13Gly-NH2

+1

7

Ac-Lys-T14Gly-NH2

+1

8

Ac-Lys-T15Gly-NH2

+1

9

H2N-Lys-T12Gly- NH2

+2

10

H2N-Lys-T13Gly- NH2

+2

11

H2N-Lys-T14Gly- NH2

+2

12

H2N-Lys-T15Gly- NH2

+2

a

HMU: hydroxymethyluracil; PhpC: phenylpyrrolocytosine. bCharge state is calculated

based on protonation of N-terminal amino groups, lysine sidechains, and adenine and
cytosine nucleobases.
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Sensitivity and resolution
PNA 1 (Table 4-1) was loaded on a 1.5 mm thickness gel in successive increments of
0.025 optical density units (ODU) from 0.025 - 0.2 ODU (0.23 – 1.84 µmol). After
electrophoresis the bands in the gel were visualized by UV shadowing over a fluorescent
TLC plate (Fig. 4-1). The lower detection limit of this technique was qualitatively
determined to be below 0.025 (ODU). Depending on the sequence up to 2 ODU can be
run without excessive streaking or band broadening making this technique amenable to
both analytical and preparatory work. Additionally, thicker gels (up to 2 mm) behave in
the same way and offer increased capacity for preparative scale purifications. The same
gel when subjected to rapid Coomassie blue staining gave a comparable detection limit
(Fig. 4-1), the dye was found to effectively bind to PNA at concentrations below the
detection limit for a typical protein.8 Although there exist many examples of staining
PNA duplexes in the literature,9 the staining of single stranded PNA has not been hitherto
reported.

Figure 4-1: Top: detection of PNA 1 by Coomassie blue. Bottom: detection of PNA1
by UV shadowing. Decreasing amount of PNA, from left to right: 6.99, 6.12, 5.24, 4.37,
3.50, 2.62, 1.75, 0.87 µg.
The resolution of the polyacrylamide gel as compared to HPLC can be seen in Figure 4-2.
This particular example illustrates that peaks observed in the HPLC trace could not be
resolved under optimized conditions, yet in the gel the major band can be easily separated
from the minor by-products.
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Figure 4-2: Comparison of polyacrylamide gel electrophoretogram and HPLC trace
of crude PNA 2.
Dependence of gel mobility on molecular weight
Single base resolution is observed between PNAs 9-12 as highlighted in Figure 4-3, these
oligomers differ by a mass of < 300 Da. When the inverse log of the molecular weight is
plotted against migration distance a linear relationship is observed between oligomers of
comparable sequence identity (Fig. 4-3). As is the case for PAGE of DNA, the absence
of charge differences gives an apparent linear relationship between the partition
coefficient and log molecular weight.10 Acetylation of the N-terminal amino group
greatly reduces the mobility of the PNA as this reduces the overall charge of the molecule
by one unit. From these data it is clear that loss or gain of a positive charge results in a
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remarkably large change in migration. Since acetylation (or lack thereof) is a common
source of impurities in PNA synthesis, the separation of these products is essential and
readily achieved by PAGE.

Figure 4-3: Left: Single base resolution of PNAs 9-12 (dicationic) from left to right.
Note: lane 2 contains both PNA 10 and 12. Right: Relationship between distance
travelled through the gel and oligomer molecular weight. Solid squares:
monocationic PNAs. Solid triangles: dicationic PNAs.
Dependence of gel mobility on PNA sequence
The environment of the gel matrix was found to be approximately at pH 3 by
electrophoresis of indicator dyes; this value is supported in the literature.7 Under these
acidic conditions, based on the reported pKa values of the nucleosides, three of the four
natural bases would be expected to bear a partial positive charge. In order to confirm the
contribution of charge to the oligomer from protonation of the nucleobases, the 4 natural
deoxynucleosides were run through the gel under identical conditions to the PNAs and
their mobility was found to be C>A>>G>T (Fig. 4-4). Therefore, the amount of charge
on an oligomer depends not only on pendant basic groups but also on the sequence and is
strongly dependent on A and C content while being insensitive to T and G content.
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Figure 4-4: Mobility of deoxynucleosides. From left to right: Methylene blue; 2’deoxyadenosine; 2’-deoxythymidine; 2’-deoxyguanosine; 2’-deoxycytidine.
Substitution of C with the fluorescent analogue phenylpyrrolocytosine (PhpC, 6-phenyl3H-pyrrolo[2,3-d]pyrimidin-2(7H)-one) slows the PNA beyond what could be explained
by the modest increase in molecular weight alone (Fig. 4-5). It is postulated that this
hetereocycle is not protonated at this pH under these conditions due decreased pKa
caused by the fusion of the aromatic pyrrole ring to cytosine. The ability to visualize the
fluorescently-labeled PNA while in the gel is quite useful for aiding identification and
separation from nonfluorescent by-products.
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Figure 4-5: Illumination at 260 nm (detection by UV shadowing, left) of PNAs 3 and
4 compared to fluorescence detection (illumination at 360 nm) of PNAs wherein only
4 is visible due to the presence of the fluorescent nucleobase replacement
phenylpyrrolocytosine (PhpC).
Extraction of PNA oligomers from the polyacrylamide matrix
Using the rapid freeze/thaw technique (see experimental section) recovery of the PNA
was above 80%. This is somewhat less than the near quantitative extraction of DNA from
polyacrylamide gels using a comparable technique and may be due to the lower overall
charge on PNA and the corresponding lower aqueous solubility of the PNA oligomers.
Sonication of the gel fragments was found to be requisite. In order to ensure the PNAs
were not degraded in the elution process the samples were lyophilized and run again on a
gel against the original sample, identical migration was observed (Fig. 4-6). The identity
of the PNA extracted from gels has also been confirmed by mass spectral analysis and
HPLC traces of the eluted fractions also confirmed the PNAs were not degraded.
Although the PNA recovered was contaminated with urea and salts, these are easily
removed by size exclusion chromatography.
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Figure 4-6: A crude mixture (left) run adjacent to a previously excised and
extracted band (right).
As a means of recovering PNA, electroelution was found to be less efficient (40%). In an
attempt to increase the recovery of PNA from the gel, chemical depolymerization of the
gel matrix using aqueous CuSO4/H2O2 was performed followed by reversed-phase solid
phase extraction of the supernatant.11 This aggressive approach yielded only
unidentifiable low molecular weight compounds implying degradation of the PNA.

4.3 Conclusions
In summary, a simple, accessible and inexpensive protocol for the analysis and
purification of PNA oligomers by denaturing polyacrylamide gel electrophoresis has been
developed as for PNA chemistry. The electrophoretic mobility was quite sensitive to the
A, C content and overall charge on the PNA oligomer and single-base resolution was
achieved. This technique operates under conditions that are more mild (pH 3) than
traditional reversed-phase HPLC (0.1 % trifluoroacetic acid in water, pH 1) and would be
equally amenable to other non-ionic nucleic acid analogues such as morpholinos12 or
methylphosphonates.13
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4.4 Experimental
Gel polymerization
All gels discussed are 26% polyacrylamide, 1.6% bisacrylamide. The polyacrylamide
gels were cast according to a modified literature procedure.14,15 In a typical experiment,
7.4 g urea (MP Biomedicals, Irvine, Ca., USA) were dissolved in 6.5 mL of 60% (w/v)
aqueous acrylamide and 1.1 mL 2.5% (w/v) aqueous N,N’-methylenebisacrylamide
(purchased as the solids from Biorad, Richmond, Ca., USA). Glacial acetic acid (925 µL,
Caledon Laboratories, Georgetown, On, Canada) and 50 µL concentrated aqueous
ammonia (BDH, Toronto, On, Canada) were added and the final volume adjusted to 15
mL with 18 MΩ deionized water (Waters Milli Q system). The solution was degassed by
application of vacuum and polymerization was initiated by the addition of 300 µL of 10%
(w/v) aqueous ammonium persulfate (APS, BDH) and 90 µL of N,N,N’,N’tetramethylethylenediamine (TEMED, Aldrich, Milwaukee, Wisconsin, USA). Plate
margins were taped or sealed with agarose and clamped and the solution poured between
plates measuring 8×10 cm with 0.15 cm spacers (Mini-Protean Vertical Slab Gel System,
Bio-Rad Laboratories, Hercules, CA). The running buffer used was 1 M acetic acid, 0.1
M glycine and the gels were pre-electrophoresed at a constant voltage of 10 V/cm
overnight at room temperature or until the distortion front was seen to pass entirely
through the gel. To prevent distortion during pre-electrophoresis the wells were overlaid
with a 10 % (w/v) polyethylene glycol (PEG - 8000, BDH, Toronto, On), 8 M urea, 1 M
acetic acid and 50 mM NH4OH solution according to a literature procedure.16 This
procedure was found to be scalable as a larger apparatus worked equivalently (Protean II
xi Vertical Slab Gel, Bio-Rad Laboratories, Hercules, CA).
Sample preparation
PNA oligomers were quantitated at 260 nm on a Cary 300 Bio UV-Vis
spectrophotometer using the nearest neighbour approximation.17 Specific volumes of
aqueous PNA samples of known concentration were lyophilized and subsequently
redissolved in 10 µL of 8 M urea acidified with 5 % acetic acid (v/v), heated to 90 ˚C for
1 minute, allowed to cool to room temperature and then loaded into the gel.
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Electrophoresis and visualization
Methylene blue (J. T. Baker Inc., Phillipsburg, NJ, USA) was used as a tracking dye; a 2
% aqueous solution was mixed in equal proportions to loading buffer and 1 µL was either
added to the PNA samples after heating or loaded directly into an adjacent lane so as not
to obscure rapidly migrating bands. Samples were run under a constant voltage of 20-30
V/cm. Generally, no PNA ran ahead of the methylene blue, and often the experiment was
run until the dye had passed completely through the length of the gel. After
electrophoresis the bands were visualized by placement of the gel upon a fluorescent
TLC plate and illuminated with a handheld UV lamp at 260 nm. Bands could also be
visualized by rapid Coomassie blue staining carried out according to a modified literature
procedure.8 The concentration of the fixing solution was adjusted to 40% isopropanol,
10% acetic acid and 50% H2O. All other steps were carried out as previously reported.
PNA recovery
To recover PNA from the polyacrylamide matrix, the appropriate bands were excised and
placed in 0.5-1.0 mL of deionized Milli Q water. The samples were frozen in either liquid
nitrogen or dry ice and thawed rapidly at 90 ˚C. After reaching 90 ˚C, the samples were
then sonicated at 60 ˚C for 1 h. Pulverizing the gel did not result in improved sample
recovery and therefore was deemed unnecessary. The extraction of PNA from the gel was
monitored by visualization of the excised gel fragment over a fluorescent TLC plate and
was stopped when there was no evidence of PNA remaining in the gel fragment. The
abovementioned procedure resulted in extraction of PNA to below visual detection limits.
The PNA samples were then passed through a Millex®-LG 0.2 µm syringe driven filter
(Millipore, USA) to remove any particulate matter. The samples were then desalted using
either Bio-Gel or Sephadex-based size exclusion chromatography and isolated by
lyophilization.
PNA synthesis and characterization
The PNA oligomers used in this study were synthesized according to a standard literature
procedure from the Fmoc-protected monomers supplied by ABI, Foster City, CA, USA.
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Alternatively, monomers synthesized by literature procedure were used,18 table 4-1.
Oligomers incorporating unnatural nucleobases (PNA 2 and 4) were prepared according
to literature procedures.19,20 Crude PNAs were purified by RP-HPLC performed using a
Waters 600 instrument using a Microsorb reversed-phase column (5 µm, 300 Å, C-18
bonded-phase from Varian Analytical Instruments, Walnut Creek, CA) using a linear
gradient of 0.1 % trifluoroacetic acid (TFA) in water: 0.1 % TFA in acetonitrile from
100:0 to 5:95 over 40 minutes, at 45 ºC. The oligomer identity was confirmed by ESITOF mass spectral analysis.
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Chapter 5

5

Reaction of 5-ethynyldeoxycytidine with 1,3-dipoles as
a route to heterocycle-appended, blue fluorescent base
analogues.

Fluorescently-labeled nucleobases are frequently used for the reporting of nucleic acid
structural phenomena. Post-synthetic modification is particularly attractive as groups that
are sensitive to solid-supported nucleic acid chemistries may be appended. Herein we
report the participation of 5-ethynyldeoxycytidine in the Huisgen 1,3-dipolar
cycloaddition with azides and nitrile oxides for the modular generation of useful
fluorophores. The reaction may proceed both with the monomer and, in the future, within
the context of an oligomer. Synthesis and photospectroscopic characterisation of
intrisically fluorescent triazole- and isoxazole-appended cytidines is reported.
Fluorescence was found to be highly dependent on solvent conditions and X-Ray
crystallographic data show the proton of the exocyclic amine of the nucleobase and the
triazole N engaged in a H-bond. Excerpts of this chapter are taken from Dodd, D.W.,
Swanick, K.N., Price, J.T; Brazeau, A.L.; Ferguson, M.J.; Jones, N.D; Hudson, R.H.E.
Org. Biomol. Chem. 2010, 8, 663-666.

5.1 Introduction
Modified nucleosides have been used to elucidate nucleic acid structural dynamics for
over half a century. In this pursuit, luminescent derivatives have enjoyed the most
success, and the literature is replete with reports of analogs that respond fluorometrically
to hybridization within the context of an oligomer (see chapter 1.1 for further detail).1-7
Fluorescent probes may be divided into two general classes: (1) those bearing a remotely
appended fluorophore, separated electronically and in space from the base-pairing face;
and (2) those in which the nucleobase is integral to the fluorophore. Members of the latter
class are more attractive because their fluorescent responses are more clearly indicative
of specific hybridization events. We aim to synthesize compounds that may be used as
base discriminating fluorophores, created pre- or post-synthetically. The following
paragraphs describe some existing techniques for the fluorescence labeling of nucleic
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acids.
Selection of methods for nucleic acid fluorescence labeling.
As the inherent fluorescence properties of nucleic acids are limited, for many years it has
been sought to label nucleic acids for fluorescence-based applications. These applications
are wide ranging; fluorescence microscopy, pertaining to chromosome analysis and
fluorescence in situ hybridization; gel staining, for better detection limits resulting from
lower background readings without the need of radiolabeling; and quantitative PCR,
measuring amplification of cDNA in real time, are just a few. Tagging of DNA with
affinity probes, biotin, and thiols for attachment to surfaces is also desirable. Below is a
very small segment of the array of chemistries available for these purposes (Fig. 5-1). For

Figure 5-1: A small selection of functionalities used for the labeling of nucleic
acids.
modification of phosphate groups modified phosphoramidites may be used. Pictured
above is an alkyne functionalized moiety for use in cycloaddition reactions. It has been
recently been used for templated ligation of oligonucleotides and lariat formation but can
also be used for the attachment of conventional fluorophores.8 One of the first base
modifications for labeling was described in the early 1970s by Leonard’s group. 4thiouracil can be reacted with a multitude of alkyl halides, the first of which was a
bromomethyl-derivatized coumarin9 yielding a fluorescent base analogue which is
unfortunately no longer base-pairing competent. Masked alkyl amino groups may be
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attached to bases. After protecting group removal the exposed amine may react with a
variety of active esters or alkyl halides.10 Disulfides can also be incorporated and are of
great importance for biosensors as they through their affinity to gold surfaces. They may
also undergo thiol exchange or be unmasked and reacted with Michael acceptors such as
maleimides or iodoacetamides. The maleimide functionality may also be used in a DielsAlder reaction with dienes.11
Azides have multiple uses as a reporter groups, they are absent from biological systems,
unreactive to most functionalities, and are readily synthesized (typically by SN2 or SNAr
mechanisms). They have been used as photoaffinity probes since the late 1960s12 and
more recently, in an adaptation of the classic Staudinger reduction,13 termed the
Staudinger ligation (Fig. 5-2).14 Although this reaction was originally designed for
protein labeling, it has also become quite popular with nucleic acid chemists and
therefore warrants discussion.15 Phoshines react with azides to form iminophosphoranes
which are readily hydrolyzed; however, in Bertozzi’s design, a proximal ester may act as
an electrophilic trap for the aza-ylid. Subsequent hydrolysis then gives a stable amide
bond and a non-toxic phosphine oxide.

Figure 5-2: The Staudinger ligation developed by Bertozzi for protein
labeling, since adopted for use with nucleic acids.
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Copper-catalyzed Huisgen cycloaddition of azides and alkynes (CuAAC).
The Cu(I)-catalyzed Huisgen cycloaddition of azides and alkynes, to give 1,4disubstituted 1,2,3-triazoles,16,17 has been exploited for rapid drug discovery,18 for
conjugation

of

modified

biological

macromolecules,19

for

derivatization

of

nanoparticles20 and (more relevent to our work) for the modification of nucleosides and
DNA.21,22 This cycloaddition is particularly well suited to nucleic acid chemistry for
several reasons. First of all, azides and alkynes are unreactive towards the functional
groups present in DNA, indeed to almost all functional groups present in living systems
(azides will react slowly with thiols).23 Azides and alkynes are small and do not perturb
the natural structure of nucleic acids to any great extent and the triazole generated is nontoxic
Ethynyl- and octadiynyl-modified uracil are the most commonly used substrates for this
“click” chemistry, with coumarin dyes, benzyl groups and biotin labels being attached at
the 5-position. Generally, the 5-postion of pyrimidines is a useful site for manipulation
due to its inherent reactivity and the propensity for substituents appended here to project
into the major groove while leaving the Watson-Crick face unhindered.1-7 The purine
analogs, 7-deazaadenosine and 7-deazaguanosine, have been used to similar ends as the
7-position can also be nicely accommodated in the major groove (Fig. 5-3).24-27
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Figure 5-3: Nucleoside(triphosphate)s for labeling of nucleic acids.
Azidonucleosides may not be used for phosphoramidite chemistry as they undergo a
Staudinger reduction in the presence of phosphorus (III) but may still be accommodated
using enzymatic techniques such as PCR or by being post-synthetically incorporated.28
Seela has reported the synthesis of a pyrrolodeoxycytidine bearing a pendant alkyne
which can undergo a cycloaddition with a non-fluorescent azidocoumarin to give a
fluorescent triazole (Fig. 5-4).25,29 Many such azides are commericially available that
fluoresce on reaction with an alkyne. These are desirable as there is little interference
(background fluorescence) from leftover starting materials; however, for us these belong
to the first category of base-discriminating fluorophores described: those bearing an
appended, traditional chromophore.
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Figure 5-4: Non-fluorescent starting materials to give a fluorescent
triazolylcoumarin.
Another popular position of attachement is the 2’-O of ribose. This is easily done by
reaction of the suitably protected nucleoside with propargyl bromide. Wagenknecht and
others have successfully applied this strategy for the generation of fluorescent
oligonucleotides.30 Although sometimes destabilizing towards duplex formation, large
chromophores attached at the 2’-postion are oftentimes useful reporter groups.30 Again,
however, this method does not satisfy our goals of creating minimally modified basediscriminating fluorophores.
Many more examples of click-modified nucleosides exist. But, however popular this
method is for uracil and purine analogs, the corresponding cytidine analogues are notable
by their absence. Prior to the present work, there had been no reports of the reactivity of
5-ethynylcytidine towards azides, nor have there been studies of the fluoresence of any
conjugated triazolylpyrimidines in the absence of an extraneous fluorophore. It has been
found that 8-ethynyldeoxyadenosine undergoes reaction with azides and the resultant
triazoles were highly fluorescent (as already described in chapter 1.1). Therefore, we
deemed fluorescent triazolyldeoxycytidines to be prime targets for potential use in the
various facets of nucleic acid chemistry.
“Metal-free” cycloadditions.
Post-synthetic labelling of DNA using the copper(I)-catalyzed azide-alkyne cycloaddition
(CuAAC) has been reduced to practice using alkyne-appended nucleobases, of which
some are commercially available.31 Disadvantageous to this procedure is, however, the

104

use of Cu(I) as catalyst, which must be ligand supported so as to not reductively damage
nucleic acids32 the half life of DNA in the CuAAC when no suitable ligand is present is
only a few minutes.33 Copper-free azide-alkyne cycloadditions can be promoted by using
strained alkynes, however, these alkynes are not accessed simply. and are unsuitable to
our puroposes as the strained alyknes34 for the most part would result in unconjugated
triazoles which would add little fluorescence benefit to the base (Fig. 5-2). Also, even
when conjugated systems do result, a mixture of regioisomers is obtained when no metal
catalysis occurs. These regioisomers would presumably result in different binding
affinities to a target strand when in the context of an oligomer and would also have
different photopysical properties (as highlighted by our work on triazolyadenosines, see
chapter 1.1).

Figure 5-5: Cyclooctynes prepared by the group of Bertozzi that may undergo
metal free cycloaddition (top) and the resultant regioisomers obtained though
their use (bottom).
There is a wealth of Huisgen 3+2 dipolar cycloadditions available to the synthetic
chemist and it is unreasonable to assume that only one may be amenable to solidsupported nucleic acid chemistries. Dehydrochlorination of hydroximoyl chlorides to
form one of the now most well known 1,3-dipoles, the nitrile oxide, was carried out as
early as 1894 by Werner and Buss.35 Huisgen studied the cycloaddition of nitrile oxides
with dipolarophiles (particularly alkenes) extensively and in the late 1950s and early
1960s and their reactivities allowed Huisgen to formally explain the concept of a dipolar
cycloaddition.36 Since that time, nitrile oxides have been used extensively in natural
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product synthesis where they are typically used to generate isoxazoles and isoxazolidines
as precursors to amino alcohols and α-hydroxycyclopentanones.37 Typically, nitrile
oxides are not isolable due to their propensity for dimerization so they are therefore
prepared in situ. The two most popular methods are shown below in figure 5-6.

Figure 5-6: Two general methods for the in situ generation of nitrile oxides.
Dehydrohalogenation of a hydroximoyl chloride (top) and dehydration of a
nitroalkane (bottom).
The first method to be discussed was initially described by Huisgen and Mack in
1961.38An oxime is first prepared from the condensation of hydroxylamine and an
aldehye, an electrophilic chlorine source is then introduced (shown here is Nchlorosuccinimide) to form the hydroximoyl chloride. These hydroximoyl chlorides can
either be isolated or subjected to base directly thus yielding the nitrile oxide. The second
method utilizes a nitroalkane in the presence of an excess of an arylisocyanate and was
developed around the same time as the first by Mukaiyama.39 Deprotonation of the
nitroalkane yields a nucleophile which may attack the isocyanate carbon. Decomposition
of the resulting intermediate gives the desired isonitrile and carbamate which promptly
releases CO2. Remaining aryl amine can then be consumed by excess isocyanate to give
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an unreactive urea.
In support of the idea that the cycloaddition of nitrile oxides and an alkyne-appended
base is amenable to solid-supported chemistries, it has been shown that the conjugation of
a solid-supported, propargyl-derivatized DNA and various aryl nitrile oxides proceeds
quantitatively and regioselectively through the formation of a 3,5-disubstituted
isoxazole.40,41 The proposed reaction is shown in comparison to the CuAAC in figure 5-7.
Because the resultant isoxazole is aromatic, the reaction is stereospecific, and due to the
lack of attention paid to the linkage is nucleic acid chemistry we also decided to pursue
this family of nucleoside derivatives for further use as base-discriminating fluorophores.

Figure 5-7: The CuAAC (left) as contrasted with the nitrile
oxide/alkyne cycloaddition which may proceed without the need of
catalysis.

5.2 Results and Discussion
The synthesis 5-ethynyl-2’-deoxycytidine is shown in figure 5-7. This would come to be
the common starting material for both cycloaddition reactions. Starting from the HCl salt
of 2’-deoxycytidine, the 2’- and 5’-hydroxyl groups were quantitatively acetylated for
ease of purification in later steps. The protected nucleoside was then iodinated using
I2/HIO3

in

biphasic

AcOH/H2O/CCl4

in

good

yield.42,43 The

product

was

chromatographed at this stage as any impurities were found to drastically reduce yields in
the next step. Sonogashira coupling of the iodonucleoside with trimethylsilylacetylene in
deoxygenated THF at room temperature using CuI and Pd(PPh3)4 (0.1 mol %) as
catalysts, and subsequent deprotection with K2CO3 in methanol yielded 5ethynyldeoxycytidine in 75% overall yield from deoxycytidine (Fig. 5-8).

107

Figure 5-8: Synthesis of 5-ethynyldeoxycytidine to be used as a dipolarophile
in Huisgen cycloadditions.
Triazolyldeoxycytidines: syntheses and photoluminescence.
5-ethynylcytidine was stirred with 4 different aryl azides in the presence of Cu(I)
(generated in situ from CuSO4 and sodium ascorbate) in 1:1 THF:H2O solution. The
resulting triazole-containing compounds 1–4 (Fig. 5-9) were characterised by 1H and
13

C{1H} NMR spectroscopies and HRMS. X-ray diffraction data were collected for 1 and

2 (see experimental).
Derivatives 1 and 3 were targeted for their likely visible fluorescence and also for
onward electrochemical polymerization and attachment to surfaces. A fluorenylsubstituted nucleoside (not shown) was similarly targeted for fluorene’s inherent
fluorescence; however, repeated in situ oxidation of the intended compound at the doubly
benzylic position to give 4 under the synthetic conditions led us instead to develop a
rational synthesis of the fluorenonyl derivative from the corresponding azide.
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Figure 5-9: Triazolylnucleosides employed in the present work.
All of the deoxycytidine analogues were fluorescent in the blue (375–385nm). Quantum
yields were determined by the relative method44-46 using anthracene and quinine sufate as
standards and ranged from low to moderate, the highest being that of 4 for which ΦF =
0.089 in EtOH (Table 5-1). This figure is almost twice that of the commercially available
and ubiquitous methylpyrrolocytosine, which has had continued success in DNA
structural elucidation for many years.47-50
Table 5-1: Fluorescence quantum yields and excitation and emission maxima of
compounds 1-4 in various polar solvents.
Φ (H2O)

Φ (EtOH)

Φ (DMF)

λEx (EtOH)

λEm (EtOH)

1

0.002

0.011

0.005

330

375

2

0.003

0.013

0.004

330

380

3

0.006

0.066

0.047

320

380

4

0.006

0.089

0.060

320

385

Unusual, mutually consistent solvatochromatic effects were observed for all compounds.
On changing the solvent composition from H2O to EtOH in ca. 10 vol% increments,
dramatic variations in emission intensity resulted (Fig. 5-10). Related non-linear
solvatochromism has been observed for fluorenone-containing compounds and has been
explained by the presence of multiple excited states that are differentially stabilized by
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Figure 5-10: Variation in r.t. emission intensity of compounds 3 (♦)
and 4 (■) at their respective maxima relative to emission intensity in
neat H2O as a function of solvent composition.

the solvation shell.51 The compounds had single broad emission bands at r.t. (Fig. 5-11),
but at low temperature showed three distinct, closely-separated emission maxima. These
indicated multiple excitation states that could in principle be the source of the observed
solvatochromism, although more resarch would be required to establish this
unequivocally. Only very small shifts in excitation and emission maxima (< 5nm) were
observed on varying the solvent composition. The response of a fluorescent nucleobase to
changes in solvent is a good predictor of its performance as a base-pairing discriminator
because match and mismatch combinations result in differential solvation of the excited
state.1 It is interesting that the triazolylnucleosides synthesised herein react similarly to
solvent perturbations regardless of the aryl substituent, which implies that the triazole and
the base are an integral part of the fluorophore. Many other solvents were investigated
(EtOAc, CH2Cl2, MeOH, MeCN, 1,4-dioxane and cyclopentanone) and, to our surprise, it

110

Figure 5-12: Fluorescence excitation and emission sprecta for
compound 3 at r.t. in H2O.

Figure 5-11: Fluorescence emission maxima for compound 3 in various
solvents at room temperature plotted against solvent polarity as guaged
by Et(30) values.
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was found that solvent polarity (guaged by ET(30) values) was not correlated with
emission intensity (Fig. 5-12).
X-ray diffraction revealed that the three aromatic rings are coplanar in the solid state:
torsion angles around the ring junctions are < 10 (Fig. 5-13). A proton of the exocyclic
amine of the nucleobase and N3 of the triazole ring are separated by ca. 2 Å, which
implies stabilization of coplanarity by an intramolecular H-bond

Figure 5-13: ORTEP representations of the molecular structure of
compounds 1 (left) and 2 (right) with ellipsoids at 30% probability
showing the dihedral angles about ring junctions and and interatomic
distance suggesting a hydrogen-bonding arrangement.
Gas-phase DFT calculations were carried out by Alison Brazeau and were used to
elucidate the effect of this H-bond on the HOMO-LUMO gap in 1, which should be
sensitive to the coplanarity of the rings, and also to determine the MOs responsible for
the observed fluorescence. Mapping these MOs revealed that the nucleobase itself is
indeed an integral part of the fluorophore. In all compounds 1–4, the HOMO is derived
predominantly from the triazole and nucleobase heterocyles, and in all but one case (4),
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there is also a small but significant contribution to the LUMO from the base. This implies
that these analogues may exhibit greater sensitivity to hybridization events than
conventional fluorophore-appended nucleosides.
Nitrile oxide/alkyne cycloaddition of 5-ethynylcytidine
With the help of Jacqueline Schulman, at the time an undergraduate student in the
Hudson laboratory, pyrenylisoxazolylribocytidine 5 was synthesized by reaction of
pyrene nitrile oxide (generated in situ from the corresponding oxime using NaOCl or
chloramine-T) and 2’-3’-5’-O-triacetyl-5-ethynylcytidine at room temperature in THF.
Yield for the cyclization reaction was below 10%; however, slow addition of NaOCl
overnight with a syringe pump allowed for increased yields (35%) that are yet to be fully
optimized. Subsequent removal of the protecting groups yielded the ribonucleoside for
photophysical characterization (Fig. 5-14).

Figure 5-14: Synthesis of pyrene derivatized isoxazolylribocytidine 5.
This work is still preliminary but fluorescence data obtained for 5 show promise. The
pyrenyl substituted compound showed a high quantum yield of 0.28 in ethanol. This is
demonstrated in figure 5-15. Plotting emission against abrorption can allow for the
comparison of newly synthesized compounds to fluorescence standards (see experimental
section for greater discussion). Fluorescence was significantly quenched (up to 20 fold)
in water/ethanol mixtures, as shown in figure 5-16. It appears that in more polar
environments excimer emission may be being observed as is indicated by the broad
nature of the emission spectrum in 5:1 H2O:EtOH. This solvatochromism is a good
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Figure 5-15: Plot of integrated emission versus absorption to
determine the quantum yield of 5 (see experimental).

Figure 5-16: Solvatochromism of compound 5 in H2O/EtOH
mixtures. Drastic reduction in emission occurs upon increase in
solvent polarity.
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indication that the analogue may report on binding events when in the context of an
oligomer. More interesting still is the potential application for experiments based on
FRET as the photophysical properties of pyrene are well established in this regard.
Excimer formation by pyrene has been exploited for hybridization assays53-55 and we
intend to place these analogues proximately in order to gauge hybridization events and
attempt to define mismatch sequences.

5.3 Conclusions
In conclusion, a family of fluorescent nucleoside analogues has been made, and their
potential for use in DNA structural analysis has been evaluated through study of their
photophysical properties. Compounds 3 and 4 are more intensely fluorescent than many
probes currently being applied in practical biological assays and are unusually sensitive
to the nature of the solvent. Crystal structures reveal the presence of an intramolecular Hbond which enhances the coplanarity of the heterocycles. These X-ray diffraction data are
the first for any triazolyl-nucleosides despite the great attention paid to the class
represented in the literature. Their incorporation into oligomeric nucleic acids will follow
shortly. Further work will involve synthesis of the phosphoramidite of 5-ethynyl-2’deoxycytidine to be incorporated into DNA and its reactivity towards nitrile oxides and
azides explored within the context of an oligomer.

5.4 Experimental
General Considerations:
All chemicals were obtained from commercial sources and were used without further
purification. Solvents were dried by passing through columns of activated alumina. Flash
column chromatography (FCC) was performed on Merck Kieselgel 60, 230-400 mesh
and thin layer chromatography (TLC) was performed on Merck Kieselgel F-60 plates.
Chemical shifts are reported in parts per million (δ), were measured from
tetramethylsilane (0 ppm) and are referenced to the residual proton in the deuterated
solvent: CDCl3 (7.26 ppm), DMSO-d6 (2.48 ppm), D2O (4.75 ppm) for 1H NMR and
CDCl3 (77.0 ppm), DMSO-d6 (39.5 ppm) for 13C NMR. Multiplicities are described as s
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(singlet), d (doublet), t (triplet), q (quartet), m (multiplet) and br s (broad singlet).
Coupling constants (J) are reported in Hertz (Hz). Exchangeable protons were identified
by their disappearance when the sample was shaken against D2O. High resolution mass
spectra (HRMS) were obtained using electrospray ionization time of flight methods (ESITOF). Solution 1H NMR spectra were collected using a Varian 400 spectrometer (400.09
MHz for 1H and 100.61 MHz for 13C) at r.t. unless otherwise noted.
Synthesis of 3’, 5’-diacetyl-2’-deoxycytidine
2’-Deoxycytidine HCl salt (0.95 g, 3.6 mmol) was dissolved in AcOH (10 mL) and
stirred at 35°C until dissolution at which time the reaction was allowed to come to rt. A
mixture of CHCl3 (8 mL) and AcCl (3 mL) was added and the reaction continued to be
stirred overnight after which time the colourless solution was concentrated to ca. 4.0 mL
and placed under high vacuum. Subsequently, the residue was dissolved in MeOH (50
mL) and evaporated to yield a white foam which was left under high vacuum overnight
and was of sufficient purity to be carried forward to the next step. Crude yield: 1.22 g
(quant.). Spectroscopic data matched that of the literature compound.56 1H NMR (DMSOd6) δ: 2.03 (s, 3H), 2.06 (s, 3H), 2.42 (dd, 2H, 2J = 2.4, 3J = 6.4), 4.22 (m, 1H), 5.18 (m,
1H), 6.08 (t, 1H, 3J = 6.8), 6.13 (d, 2H, 3J = 8.0), 7.95 (d, 2H, 3J = 7.6), 8.51 (s, 1H,
NH), 9.56 (s, 1H, NH).
Synthesis of 5-iodo-3’, 5’-diacetyl-2’-deoxycytidine
To a stirred solution of 3’,5’-diacetyl-2’-deoxycytidine (3.42 g, 11.0 mmol) in H2O (17.0
mL) was added I2 (1.65 g, 6.50 mmol), HIO3 (0.48 g, 2.73 mmol), CCl4 (17 mL) and
AcOH (25 mL). The resultant mixture was heated to 40°C and stirred vigourously for 24
h. Solvent was removed in vacuo to yield an orange solid. Crude product was purified by
FCC (EtOAc:Acetone 1:1 – 1:2) to yield 4.14 g (86%) of an off-white foam. Spectral
data conformed to literature precedent.43 1H NMR (DMSO-d6) δ: 2.06 (s, 3H), 2.09 (s,
3H), 3.65 (m, 1H), 4.20 (m, 2H), 4.25 (m, 2H), 5.17 (m, 1H), 6.10 (t, 1H, 3J = 4.0), 7.24
(br s, 1H,), 8.01 (s, 1H), 8.16 (br s, 1H,).
Synthesis of 5-trimethylsilylethynyl-3’,5’-diacetyl-2’-deoxycytidine
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Solid 5-iodo-3’,5’-diacetyl-2’-deoxycytidine (1.20 g, 2.75 mmol), and Pd(Ph3)4 were
dissolved in dry deoxygenated THF (8mL) under N2 to which were added solid CuI (0.23
g, 1.21 mmol), trimethylsilylethyne (1.07 mL, 8.25 mmol) and Et3N (1.15 mL,
8.25mmol). The solution was stirred in the dark for 24 h at rt. After removal of solvent in
vacuo the product was purified by FCC (EtOAc:Acetone 2:1 – 1:1) to yield 997 mg
(89%) of an off-white solid. 1H NMR (CDCl3) δ: 0.15 (s, 9H), 2.00 (s, 3H), 2.04 (s, 3H),
2.32 (m, 2H), 4.22 (overlapping, m, 3H), 5.13 (m, 1H), 6.31 (t, 1H, 3J = 7.0), 6.75 (br s,
1H), 7.86 (br s, 1H), 7.91 (s, 1H).

13

C NMR (DMSO-d6) δ: -0.5, 8.4, 20.3, 45.6, 63.2,

73.6, 81.3, 85.3, 90.0, 96.1, 99.6, 144.6, 152.9, 163.5, 169.6, 169.7. HRMS (ESI): Calcd.
for C18H25N3O6Si 407.1513 Found 407.1520.
Synthesis of 5-ethynyl-2’-deoxycytidine
To a stirred mixture of K2CO3 (0.65 g, 4.72 mmol) and MeOH (15 mL)4 was added 5trimethylethynyl-3’,5’-diacetyl-2’-deoxycytidine (0.55 g, 1.34 mmol). The mixture was
stirred at 0°C for 2 h then filtered through Celite. The Celite plug was washed with
MeOH (3 × 3 mL) and the filtrate was concentrated and purified by flash column
chromatography (MeOH:EtOAc 20:80 Rf=0.2) to yield 306 mg (91%) of an off white
foam. 1H NMR (D2O) δ: 2.21 (m, 1H), 2.38 (m, 1H), 3.46 (s, 1H), 3.69 (dd, 1H, 2J = 3.6,
3J = 12.4), 3.78 (dd, 1H, 2J = 5.2, 3J = 12.4), 3.97 (m, 1H), 4.33 (m, 1H), 6.13 (t, 1H, 3J
= 4.0), 8.14 (s, 1H).
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C NMR (DMSO-d6) δ: 40.4, 61.3, 70.5, 81.3, 82.9, 89.1, 94.7,

110.3, 142.4, 155.1, 158.9. HRMS (ESI): Calcd. for C11H13N3O4 251.0906 Found
251.0911.
General Procedure for the Huisgen cycloaddition
To a 1:1 THF/H2O stirred solution of CuSO4 (0.1 eq) and sodium ascorbate (0.2 eq) was
added 5-ethynyl-2’-deoxycytidine (1 eq) and an organic azide (1.1 eq) at 0 °C. After
these additions the solution was brought to rt and stirred until total consumption of 5ethynyldeoxycytine as determined by TLC analysis. After evaporation of solvent, the
residue was dissolved in THF, adsorbed onto silica gel, and purified by FCC.
Synthesis of 2’-deoxy-5-(1-(phenyl)-1H-1,2,3-triazol-4-yl)cytidine
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The title compound was synthesised by following the general procedure. Thus, to a
stirred 1:1 THF/H2O solution (5 mL) was added 5-ethynyl 2’-deoxycytidine (250 mg,
0.99 mmol), azidobenzene (129 mg, 1.09 mmol), CuSO4 5 H2O (22.4 mg, 0.09 mmol)
and sodium ascorbate (39 mg, 0.18 mmol) yielding 335 mg (74%) of a light yellow
powder after FCC. This material was recrystallized from 1:1 MeOH/H2O to yield tan
coloured needles suitable for X-ray diffraction studies. 1H NMR (DMSO-d6) δ: 2.10 (m,
1H), 2.22 (m, 1H), 3.60 (m, 1H), 3.67 (m, 1H), 3.81 (m, 1H), 4.25 (m, 1H), 5.18 (dd, 1H,
J = 4.78, 4.96), 5.24 (d, 1H, 3J = 4.27), 6.18 (t, 1H, 3J = 6.32), 7.52 (t, 1H, 3J = 7.35),
7.63 (overlapping, dd, 3J = 8.03, 7.35), 7.67 (overlapping, br s, 1H), 7.83 (br s, 1H,),
7.91(d, 2H, J = 8.03), 8.48 (s, 1H), 8.85 (s, 1H).
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C NMR (DMSO-d6) δ: 40.8, 48.7,

60.8, 69.7, 85.5, 87.4, 119.4, 120.5, 129.1, 129.9, 136.4, 140.4, 153.8, 162.6. HRMS
(ESI): Calcd. for C17H18N6O4 [+Na+] 393.1277 Found 393.1287.
Synthesis of 2’-deoxy-5-(1-(thiophen-3-yl)-1H-1,2,3-triazol-4-yl)cytidine
Solid CuSO4 · 5 H2O (35 mg, 0.14 mmol) and sodium ascorbate (84 mg, 0.43 mmol) was
added to 5-ethynyl-2’-deoxycytidine (214 mg, 0.85 mmol) dissolved in THF:H2O (1:1, 5
mL). Liquid 3-azidothiophene (165 mg, 1.70 mmol) was added to the mixture which was
stirred for 24 h at 35°C after which time the solvent was removed. Purification by flash
column chromatography (TLC MeOH:DCM 1:1 Rf=0.8) gave the product as an off-white
solid. Yield: 140 mg (43%). 1H NMR (DMSO-d6) δ: 2.11 (m, 1H), 2.20 (m, 1H), 3.64 (d,
2H, 3J = 16.0), 3.82 (m, 1H), 4.26 (m, 1H), 5.19 (m, 1H), 5.25 (m, 1H), 6.18 (s, 1H),
7.59 (br s, 1H), 7.64 (s, 1H), 7.81 (br s, 1H), 7.84 (s, 1H), 8.06 (s, 1H), 8.46 (s, 1H), 8.77
(s, 1H). 13C NMR (DMSO-d6) δ: 48.6, 60.8, 69.7, 85.4, 87.3, 96.2, 115.5, 119.8, 120.8,
119.8, 120.8, 128.6, 135.1, 140.3, 142.1, 153.8, 162.5. HRMS (ESI): Calcd. for
C17H16N6O4 [+H+] 377.1041 Found 377.1032.
2’-Deoxy-5-(1-(2,2’-bithiophen-3-yl)-1H-1,2,3-triazol-4-yl)cytidine
Solid CuSO4 5 H2O (58.2 mg, 0.23 mmol), sodium ascorbate (142 mg, 0.72 mmol), 5ethynyl-2’-deoxycytidine (360 mg, 1.43 mmol), and 4-azido-2,2’-bithiophene (594 mg,
2.87 mmol) were combined and stirred at r.t. for 48 h in a solution of THF:H2O (1:1, 10
mL). The solvent was removed and the crude product was purified by flash column
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chromatography to give the title compound as a light brown solid. Yield: 100 mg (15%).
1

H NMR (DMSO-d6) δ: 2.09 (m, 1H), 2.22 (m, 1H), 3.60 (d, 1H, 3J = 12.5), 3.68 (d, 1H,

3J = 11.8), 3.83 (dt, 1H, 3J = 3.6, 7.0), 4.26 (m, 1H), 5.18 (s, 1H), 5.26 (s, 1H), 6.18 (t,
1H, 3J = 6.3), 7.15 (dd, 1H, 3J = 3.4, 5.1), 7.47 (dd, 1H, 3J = 3.6, 4J = 1.0), 7.63 (dd, 1H,
3J = 5.1, 4J = 1.0), 7.84 (d, 1H, 4J = 1.5), 8.00 (d, 1H, 4J = 1.4), 8.45 (s, 1H), 8.83 (s,
1H). 13C NMR (DMSO-d6) δ: 40.8, 60.8, 69.7, 85.4, 87.4, 96.2, 114.0, 116.9, 119.8,
125.2, 126.7, 128.6, 135.0, 135.2, 138.2, 140.4, 142.1, 153.9, 162.4. HRMS (ESI): Calcd.
for C19H18N6O4S2 [+Na+] 481.0732 Found 481.0729.
Synthesis of 2’-deoxy-5-(1-(9H-fluoren-9-on-2-yl)-1H-1,2,3-triazol-4-yl)cytidine
Solid CuSO4 · 5H2O (39.6 mg, 0.16 mmol), sodium ascorbate (63.4 mg, 0.32 mmol), 5ethynyl-2’-deoxycytidine (400 mg, 1.59 mmol), and 2-azido-9H-fluorenone (387 mg,
1.75 mmol) (prepared from 2-aminofluorenone via a literature procedure)57 were
combined and stirred at r.t. for 48 h in a solution of THF:H2O (1:1, 10 mL). 1H NMR
(600MHz, DMSO-d6) δ: 2.11 (m, 1 H), 2.23 (m, 1 H), 3.63 (m, 1 H), 3.67 (m, 1 H), 3.84
(m, 1 H), 4.27 (m, 1 H), 5.14 (t, 1 H, 3J = 5.0), 5.26 (d, 1 H, 3 J = 4.1), 6.21 (t, 1 H, 3 J=
6.4), 7.46 (t, 1 H, 3J = 7.6), 7.54 (br s, 1 H), 7.70 (m, 2 H), 7.77 (br s, 1 H), 7.93 (d, 1 H,
3 J = 7.0), 8.09 (d, 1 H, 3 J = 8.2), 8.13 (s, 1 H), 8.21 (d, 1 H, 3 J = 8.2), 8.45 (s, 1 H),
9.04 (s, 1 H). 13C NMR (DMSO-d6) δ: 41.1, 61.4, 70.4, 85.8, 87.8, 116.2, 117.7, 120.2,
122.2, 124.8, 125.7, 127.0, 130.4, 134.0, 135.2, 136.3, 137.5, 140.9, 144.2, 145.1, 162.9,
192.3. HRMS (ESI): Calcd. for C24H22N6O4 [+Na+] 495.1393 Found 495.1392.
X-Ray Crystallographic Data
Selected crystal data for 1·2H2O, C15H20N6O6S, M = 412.23, orthorhombic, P212121, a =
4.8637(6) Å, b = 12.1128(18) Å, c = 30.967(5) Å, α = β = γ = 90°, U = 1814.2(5) Å3, Z =
4, T = 150(2) K, Dc = 1.510 Mg/m3, µ = 0.227 mm-1, F(000) = 864, GoF = 1.086, R1 and
wR2 were 0.0752 and 0.1196, respectively, for 279 parameters and 6165 reflections [I >
2σ(I)]. Crystal data have been deposited with the CCDC under reference number 751468.
Photophysical Data, Quantum Yields
Method
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Photoluminescence quantum yields (Φ) were found by the relative method44-46 using
anthracene (ΦF=0.32) and quinine sulphate in 0.1M H2SO4 (Φ=0.55) as a reference
standard. The quantum yield of the unknown Φ(x) can be calculated by the following
equation:
Φ(x)= Φ(ST) (AST/AX) (FX/FST) (η2X/η2ST)
Where Φ(ST) is the quantum yield of the standard, A is the absorbance at the excitation
wavelength, F is the integrated area in the emission curve, the subscripts X and ST refer
to unknown and standard and η is the refractive index of the solvent. When measuring a
series of diluted solutions with various absorbance readings the following equation may
be used:
Φ(x)= Φ(ST) (GradX/GradST) (η2X/η2ST)
Where Grad is the gradient from the plot of integrated area in the emission curve versus
absorbance at the excitation wavelength. Prior to measuring the quantum yield of the
unknown samples, the validity of the methodology was confirmed by measuring these
characterized compounds: anthracene (ΦF=0.29, in ethanol),58 dichloroanthracene
(ΦF=0.58, in ethanol)8 and deuterated anthracene (ΦF=0.32, in cyclohexane),59 and gave
the following values 0.27, 0.58, 0.34 that are in very good agreement with the literature
values.
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Chapter 6

6

Hydrogelation abilities of nucleobase-modified cytidines
possessing substituted triazoles

Nucleoside-derived hydrogelators have been sought for their potential biomedical
applications, such as are found in tissue engineering and drug delivery. By judiciously
adding a degree of hydrophobicity certain analogues are able to form micelles, bi-layers
and gels in water. Research in this area has yet to lay down solid ground rules for the
rational design of novel nucleoside gelators making further studies necessary.

The

synthesis and examination of a series of aryl-substituted 5-triazolylcytidines yielded an
analogue

that

gelates

water.

5-(1-(2,2’-bithiophen-3-yl)-1H-1,2,3-triazol-4-yl)-2’-

deoxycytidine was found to form gels in water down to 0.3 wt%. The ribocytidine
analogue failed to form gel in aqueous solution; but was able to form a hydrogel in the
presence of guanosine. Images obtained by SEM show the different architectures of the
gel; varying from cribriform, to fibrous, to lamellar. The present gelating compound
studied may have potential as a component of a controlled-release drug delivery system.
Excerpts of this chapter have been taken from Dodd, D.W.; Hudson, R.H.E. Artificial
DNA, 2010, 1, 90-95.

6.1 Introduction
Polymeric hydrogels have been used as medical implants and show promise as drug
delivery systems. Due to their high water content, the gels are typically biocompatible
and can be designed to respond to certain external parameters such as, pH, electric field
and temperature.1 While polymeric hydrogels based on polyacrylates and peptides remain
the most prevalent, interest in small-molecule gelators has continued to grow.2-4 In the
case of low molecular weight gelators, interactions which hold together the framework
and trap water within interstitial spaces are necessarily non-covalent. This generally
makes the gel more prone to dissociation which is not necessarily deleterious for
applications in biomedical engineering. Scissile, non-covalent gelling interactions are
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even desirable for the application of controlled drug release as the scaffold may break
down easily and diffuse after outliving its primary function. Furthermore, the
pharmacophore can be incorporated into the gelator itself, forgoing the need to capture a
drug within the gel.5
Necessary to their biological functions, nucleobases form interactions in perpendicular
directions. Hydrogen bonding in the plane of the heterocycle coupled with perpendicular
π-π stacking hold together higher-order nucleic acid structures found in nature and also
make nucleobases a suitable scaffold for the development of hydrogelators. Indeed,
modified nucleosides have been found to gelate water and this, taken together with the
possibility of nucleoside analogues being pharmacologically relevant as anti-tumour
and/or anti-viral drugs, makes them attractive targets. For many years it has been known
that certain guanosine derivatives form hydrogels at high concentration in a K+ dependent
manner.6 From this starting point, a number of nucleoside-lipid conjugates have been
investigated and found to gel water with varying success.7 Attachment of hydrophobic
moieties via the sugar are common; however, a rarer strategy employed by Kim and coworkers aimed at derivatizing the nucleobase at the 5-position of deoxy- and
ribouridine.8,9 Huisgen cycloaddition of an alkyne functionalized nucleobase and an azide
provides a modular means of accessing a variety of analogues and, reasoning that aryl
moieties would increase the potential for stacking interactions, they synthesized a series
of alkylbenzyltriazole-appended uridines. Some of the nucleosides were found to form
stable gels down to the low concentration of 0.2 wt%, with the deoxy-series being more
effective than the corresponding ribonucleosides. Nielsen and coworkers have previously
reported the synthesis of 5-triazolylydeoxycytidines, however, the study lacks
characterization data and the resultant compounds were not investigated for gelation
properties.10 As a postlude to our work with triazolylcytidines as potential basediscriminating fluorophores,11 and the recognition of the paucity of examples of cytidinebased hydrogelators,7,12 we have investigated the gelation properties of 1H-substituted-5triazolyl(deoxy)cytidines (Fig. 6-1).
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Figure 6-1: Kim’s alkylbenzyltriazole-appended uridine compared to the same
triazoly(deoxy)-cytidine.

6.2 Results and Discussion
The nucleoside derivatives were accessed via the sugar-protected 5-ethynylcytidine as a
key intermediate. The ethynyl nucleoside was obtained in good yield by Sonogashira
coupling between trimethylsilylacetylene and the acetylated iodo-nucleoside, followed by
desilylation with TBAF. Huisgen cycloaddition of the ethynyl nucleoside with a variety
of alkyl- and arylazides afforded sugar-protected conjugates which gave the final
compounds after methanolysis to remove the acetate groups. The synthetic approach
used to access compound 4b is shown in figure 6-2.
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Figure 6-2: Synthesis of bithiophenyl-triazolylcytidine 4b using Sonogashira
coupling and the Huisgen cycloaddition
The ribonucleoside analogues shown in figure 6-3 were synthesized by this route in good
yields, while the deoxy-series were synthesized by a previously reported procedure.11

Figure 6-3: 5-Triazolycytidines prepared and examined for the present work.
Examination of their properties revealed that compound 1 unfortunately did not form a
gel with water as the corresponding uridine analogue did.

Since this structural

modification did not translate from deoxyuridine to deoxycytidine, compounds with
different hydrophobic substituents were investigated. Compounds with slightly smaller
hydrophobic groups such as 2 (thiophene) and 3 (phenyl) tended toward forming
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crystalline solids. Although both solid-state structures (2 from ref. 11, 3 see chapter 5)
showed inclusion of a large number of solvent molecules (water or methanol), no guiding
structural principles were discerned. It was posited that the main driving force for crystal
formation was H-bonding due to the extent of H-bonding displayed in the solid state.
Thus, in an attempt to offset the amount of H-bonding relative to hydrophobic
interactions, we prepared compounds 4-6 with larger hydrophobic substituents. Happily,
we found that the bithiophenyl compound 4a formed a gel during an attempted
recrystallization from water. Guided by this observation we prepared compounds with
structurally similar aryl moieties varying the nature of the ring, size, and
rigidity/conformation such as biphenyl (5a,b) and fluorenonyl (6),11 but none of these
compounds possessed the ability to form hydrogels. As we continued to synthesize aryl
derivatives, it was becoming increasingly evident that the resultant compounds were
predominantly crystalline and 4a was the only compound which gelled water per se.
Dissolution of 4a in water under heating followed by allowing the solution to come to rt
resulted in an opaque gel down to a minimum gelling concentration (MGC) of 0.3 wt. %,
persisting in that state for 1-2 h at ambient temperature. More robust, albeit more opaque,
gel (persisting for ca. 24 h) formed from solutions of higher concentration (> 3 wt %).
After these findings, the ribo-analogue 4b was pursued.
In contrast to 4a, the ribo-analogue 4b would not form gel at any concentration, the upper
limit being determined by solubility. However, in the case of a solution containing 4b and
its base pairing partner guanosine in a 1:1 ratio, gelation occurred down to a MGC of 0.5
wt % compound 4b. The introduction of guanosine into a solution of 4a had no
significant effect on the MGC (gels formed down to 0.4 wt%) and it is important to note
that guanosine alone does not form a hydrogel at the concentration tested.
Scanning electron microscopy of desiccated hydrogels (xerogels) and the non-gelating 4b
revealed interesting supramolecular architectures. In the case of 4b, where gelation did
not occur, some fibrous areas along with amorphous regions are visible; however, the
sample was predominantly crystalline (Fig. 6-4). Images from gel formed from the
mixture of 4b with guanosine are in stark contrast to those of 4b alone. No crystalline
structures remain visible and a porous, cribrifom or sponge-like material dominates.
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Lamellar modes of aggregation are observed for 4a. Ribbons on the order of 1-5 µM in
width and < 1 µM in depth are clearly observed running in an organized, parallel
arrangement for lengths of greater than 50 µM.

Figure 6-4: Scanning electron micrographs of xerogels or powder of 4b (A, B), 4a
derived from a 1 wt% gel (C) and 4b at 1 wt% with one molar equivalent of
guanosine (D).
In their analysis of intermolecular bonding of the uridine-based hydrogelators, Kim and
co-workers implied the importance of both hydrogen bonding involving the nucleobases
and the hydroxyl groups of the (deoxy)ribose. A balance must also be struck in the
hydrophobicity/hydrophilicity of the compound to favor hydrogelation over complete
solubilization or crystallization. While solid-state structures were not reported for the
uridine compounds, ab initio calculations13 have revealed that the energetically preferred
conformation was as depicted in figure 6-1, wherein the C-H of the triazole ring is cis to
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the C4=O of the nucleobase in a nearly coplanar arrangement. The N3 of the triazole is
greater than 3Å from the 5’-OH group making the likelihood of H-bonding between them
improbable in an aqueous environment. A solid state structure has been reported for a
cytidine bearing a triazole substituent at C5 wherein the conformation about the triazolenucleobase bond is reversed due to the existence of an intramolecular N⋅⋅⋅H bond.11 The
resultant trajectory of the benzyl substituent is consequently different between the two
nucleosides and such subtle structural differences likely contribute to their ability to
hydrogelate.
Cytidine derivatives with smaller hydrophobic substituents tended to crystallize readily.
From the observation of the network of H-bonding in the solid state structures of 2 and 3,
it was decided to increase the hydrophobicity of the compounds by increasing the number
of aryl groups. At this point, it was found that the bithiophenyl-triazolyldeoxycytidine
formed a hydrogel. To investigate the tolerance to structural modification and possibly
discover other gelators as well as potentially reveal some underlying structural principles
for hydrogelating competent analogues, two other derivatives were targeted.

The

biphenyl derivative 5 possesses unfused aromatic groups, but unlike the triazolethiophene system which is nearly coplanar (in the solid state), many studies indicate that
the biphenyl system exhibits significant twist (ca. 40 °).14 Since this modification led to
compounds (5a,b) that did not form hydrogels, compound 6 in which the phenyl rings are
bridged by a carbonyl group and thus fused in coplanar arrangement was prepared in
order to better mimic the bithiophene moiety. This compound also failed to hydrogelate
and serves to highlight the capricious nature of this type of supramolecular chemistry.
The previously reported uridine hydrogelators showed that deoxynucleosides
outperformed the ribonucleosides for reasons unknown. The effect of an added hydroxyl
group was more drastic in our case with our ribonucleoside 4b not displaying any
gelation properties and simply precipitating out as a fine, microcrystalline suspension.
Whether the extra hydroxyl group interferes by disadvantageously H-bonding and/or
affecting the sugar conformation is not known.
SEM images of a xerogel formed from 4a show an organized framework of lamellae
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running in parallel. Similar to structures obtained by single crystal X-ray diffraction, one
must be cautious when interpreting these data as drying of the sample has been known to
occasionally introduce artifacts.15 We suspect that the tendency for 4b to crystallize
interferes with its ability to form a gel. Fibrous networks can be seen (Fig. 3A,B),
however, crystals predominate. The introduction of guanosine to a solution of 4b results
in gelation. This could be due to guanosine interfering with crystallization or by
becoming involved in the molecular assembly responsible for gelation itself. The gel
formed in this case is very different from that of 4a and appears much less organized on
the micron scale. It is of interest to note that no significant change was observed in 4a’s
gelation ability on the introduction of guanosine.
Uridine, in interaction with itself, can form slip base pairs as can cytidine; however,
hemi-protonated cytosine, as found in the i-motif may form 3 H-bonds, the effect of pH
was therefore investigated and acidification was found to hamper the gelation ability of
4a. A 0.5 wt% gel of compound 4a was gradually acidified with microlitre titres of 0.1 M
HCl. At pH 5.0 the gel became unstable to inversion and at pH 4.2 nothing but a fine
precipitate remained. Presumably, this behaviour is derived from the protonation of the
N3 of cytosine and may allow for development of a pH responsive drug delivery system.
There are inherent benefits of the photophysical and electrochemical properties of the
incorporated bithiophene. 4a is known to be fluorescent and fluorometrically responsive
to its environment.11 This could easily allow for visualization of gel decomposition.
Electrochemical reactivity offers the potential for electropolymerisation of 4a in the gel
state and this work is currently under study.

6.3 Conclusions
In conclusion, we have synthesized a variety of nucleoside analogues in a modular
fashion from 5-ethynyl(deoxy)cytidine and various azides. This class of molecules
contained 4a which was able to gelate water down to a MGC of 0.3% and may have
application in controlled drug release.
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6.4 Experimental
General Considerations
Chemicals were obtained from commercial sources unless otherwise noted and used
without further purification. Flash column chromatography (FCC) was performed on
Silicycle Siliaflash 60, 230-400 mesh and thin layer chromatography (TLC) was
performed on Merck Kieselgel F-60 plates. Chemical shifts are reported in parts per
million (δ), were measured from tetramethylsilane (0 ppm) and are referenced to the
residual proton in the deuterated solvent: CDCl3 (7.26 ppm), DMSO-d6 (2.48 ppm), D2O
(4.75 ppm) for 1H NMR and CDCl3 (77.0 ppm), DMSOd6 (39.5 ppm) for

13

C NMR.

Multiplicities are described as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet),
br s (broad singlet) and ov (overlapping). Coupling constants (J) are reported in Hertz
(Hz). Exchangeable protons were identified by their disappearance when the sample was
shaken against D2O. High resolution mass spectra (HRMS) were obtained using
electrospray ionization time of flight methods (ESI-TOF). Solution 1H NMR spectra were
collected using a Varian 400 spectrometer (400.09 MHz for 1H and 100.61 MHz for 13C)
at rt.
Scanning Electron Microscopy
Hydrogels were frozen in liquid nitrogen and lyophilized prior to imaging. Coarse
powder samples were adhered to the surface and sputtered with a Au/Pd alloy using a
Hummer VI apparatus to a thickness of 12-15 nm prior to imaging on a Hitachi S-3400 N
scope.
Gelation test
The compound was heated in water at the appropriate concentration until dissolution.
After allowing the solution to come to room temperature the gelation ability was
determined by the “stable-to-the-inversion-of-the-container” method.16

Synthesis
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5-Trimethylsilylethynyl-2’,3’,5’,-tri-O-acetyl-cytidine
To dry deoxygenated THF (20 mL) was added 2’,3’,5’,-tri-O-acetyl-5-iodocytidine (3.00
g, 6.06 mmol), Pd(PPh3)4 (705 mg, 0.61 mmol) and CuI (349 mg, 1.89 mmol) under an
atmosphere

of

N2.

On

dissolution,

Et3N

(2.53

mL,

18.2

mmol),

and

trimethylsilylacetylene (1.09 mL, 18.2 mmol) were added and the solution was stirred
under N2 for 24 h or until deemed complete by TLC. After solvent removal in vacuo the
product was purified by FCC eluting with a gradient of MeOH in CH2Cl2 (0:1 to 1:9).
Evaporation of the appropriate fractions yielded 2.04 g (85%) of an off white powder. 1H
NMR (CDCl3) δ: 0.21 (s, 9H), 2.05 (s, 3H), 2.10 (s, 3H), 2.19 (s, 3H), 4.36 (ov m, 2H),
4.39 (ov m, 1H), 5.29 (dd, 1H, J = 5.2 and 5.3), 5.36 (dd, 1H, J = 3.5 and 5.3), 5.84 (br s,
1H), 6.09 (d, 1H, J = 3.52), 7.89 (s, 1H), 8.38 (br s, 1H).

13

C NMR δ: -0.2, 8.6, 46.1,

20.4, 20.9, 62.2, 69.0, 73.9, 79.1, 88.4, 92.2, 95.2, 101.8, 143.3, 153.7, 164.4, 169.3,
169.5, 170.0. HRMS (ESI): Calcd. for C20H27N3O8Si [+H+] 466.1645 Found 466.1579.
5-ethynyl-2’,3’,5’,-tri-O-acetyl-cytidine
Solid 5-trimethylsilylethynyl-2’,3’,5’,-tri-O-acetyl-cytidine (1.00 g, 2.15 mmol) was
dissolved in THF at 0˚C and 2 equivalents of TBAF were delivered as a 1.0 M solution in
THF (430 µL, 4.30 mmol). After the solution was allowed to come to rt stirring was
continued for 1 h at which time the reaction was complete as judged by TLC. Solvent
was removed to reveal yellow oil which, after FCC (MeOH:CH2Cl2, 0:1 to 1:9), gave 804
mg (95%) of a white powder. 1H NMR (CDCl3) δ: 2.07 (s, 3H), 2.11 (s, 3H), 2.19 (s,
3H), 3.35 (s, 1H), 4.37 (ov m, 2H), 4.38 ( ov m, 1H), 5.29 (dd, 1H, J = 5.3 and 5.9), 5.37
(dd, 1H, J = 3.5 and 5.3), 5.80 (br s, 1H), 6.10 (d, 1H, J = 3.5), 7.13 (br s, 1H), 7.96 (s,
1H).

13

C NMR δ: 20.4, 20.5, 20.8, 62.3, 69.2, 73.9, 74.9, 79.3, 84.0, 88.5, 90.5, 144.3,

153.7, 164.4, 169.4, 169.5, 170.2. HRMS (EI): Calcd. for C17H19N3O8 393.1172 Found
393.1177.
2’,3’,5’,-tri-O-acetyl-5-(1-(2,2’-bithiophen-3-yl)-1H-1,2,3-triazol-4-yl)cytidine
To a stirred 1:1 THF/H2O solution (10 mL) was added 5-ethynyl-2’,3’,5’,-tri-Oacetylcytidine (250 mg, 0.64 mmol), 4-azido-2,2’-bithiophene11 (145 mg, 0.70 mmol),
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CuSO4 · 5 H2O (22.4 mg, 0.09 mmol) and sodium ascorbate (39 mg, 0.18 mmol). Stirring
was continued for 8 h at rt. Solvent was then removed and 353 mg (92%) of a tan
coloured powder was obtained after FCC. 1H NMR (CDCl3) δ: 2.08 (s, 6H), 2.10 (s, 3H),
4.32 (dd, 1H, J = 12.1 and 2.4), 4.38 (m, 1H), 4.61 (dd, 1H, J = 12.1 and 7.0), 5.33 (dd,
1H, J = 5.5 and 5.3), 5.47 (dd, 1H, J = 5.3 and 4.8), 6.20 (d, 1H, J = 4.8), 7.00 (dd, 1H, J
= 5.1 and 3.7), 7.19 (d, 1H, J = 3.7), 7.24 (d, 1H, J = 5.1), 7.45 (br s, 1H), 7.54 (ov s,
1H), 7.55 (ov s, 1H), 7.99 (s, 1H), 8.27 (br s, 1H), 8.52 (s, 1H).

13

C NMR (CDCl3) δ:

20.4, 20.9, 30.8, 63.3, 70.1, 73.6, 76.7, 77.3, 79.8, 88.4, 98.1, 112.5, 116.3, 118.0, 124.6,
125.5, 128.0, 135.2, 135.8, 138.6, 139.0, 142.3, 154.2, 162.8, 169.6, 171.0. HRMS (ESI):
Calcd. for C25H24N6O8S2 [+H+] 601.1175 Found 601.1180.
5-(p-methylbenzyl)-1H-1,2,3-triazol-4-yl)-2’-deoxycytidine 1
Prepared via literature procedure11 in 78% yield: 1H NMR (DMSO-d6) δ: 2.07 (m, 1H),
2.16 (m, 1H), 3.15 (s, 3H), 3.59 (dd, 1H, J = 3.4 and 11.9), 3.67 (dd, 1H, J = 3.4 and
11.9), 3.78 (dd, 1H, J = 3.4 and 7.0), 4.24 (m, 1H), 6.14 (app t, 1H, J = 6.2), 7.17 (d, 1H,
J = 8.4), 7.24 (d, 1H, J = 8.4), 7.80 (br s, 1H), 7.92 (br s, 1H), 8.39 (s, 1H), 8.48 (s, 1H).
HRMS (ESI): Calcd. for C19H22N6O4 [+Na+] 421.1595 Found 421.1589.
5-(1-(2,2’-bithiophen-3-yl)-1H-1,2,3-triazol-4-yl)cytidine 4b
To a slurry of K2CO3 in MeOH (280 mg, 2.0 mmol in 15 mL) was added 2’,3’,5’,-tri-Oacetyl-5-(1-(2,2’-bithiophen-3-yl)-1H-1,2,3-triazol-4-yl)cytidine (300 mg, 0.50 mmol)
and the mixture was stirred for 30 min or until reaction completion as determined by
TLC. After filtration over Celite the filtrate was evaporated and the residue adsorbed onto
silica gel and purified by FCC (< 15 cm silica, isocratic CH2Cl2:MeOH, 8:2) yielding 223
mg (94%) of a tan coloured powder. 1H NMR (DMSO-d6) δ: 3.49 (m, 1H), 3.65 (m, 1H),
3.96 (m, 1H), 4.16 (dd, 1H, J = 2.15 and 5.28), 5.05 (dd, 1H, J = 5.28 and 6.84), 5.81 (d,
1H, J = 6.84), 5.52 (br s, 3H), 7.16 (dd, 1H J = 3.5 and 5.9), 7.46 (d, 1H, J = 3.5), 7.53
(br s, 1H), 7.62 (d, 1H, J = 5.9), 7.81 (ov br s, 1H), 7.83 (s, 1H), 7.98 (s, 1H), 8.43 (s,
1H), 8.42 (s, 1H).
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C NMR (DMSO-d6) δ: 40.8, 60.8, 69.7, 85.4, 87.4, 96.2, 114.0,

116.9, 119.8, 125.2, 126.7, 128.6, 135.0, 135.2, 138.2, 140.4, 142.1, 153.9, 162.4 HRMS
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(ESI): Calcd. for C19H18N6O5S2 475.0831 Found 475.0855.
5-(1-(biphenyl-4-yl)-1H-1,2,3-triazol-4-yl)-2’-deoxycytidine 5a
Prepared via literature procedure11 in 89% yield. 1H NMR (DMSO-d6) δ: 2.10 (m, 1H),
2.20 (m, 1H), 3.63 (m, 2H), 3.81 (m, 1H), 4.29 (m, 1H), 6.18 (app t, 1H, J = 6.8), 7.41 (t,
1H, J = 7.3), 7.50 (dd, 2H, J = 7.0 and 7.3), 7.64 (br s, 1H), 7.74 (d, 2H, J = 7.5), 7.85 (ov
br s, 1H), 7.93 (d, 2H, J = 7.9), 8.01 (d, 2H, J = 7.9), 8.49 (s, 1H), 8.91 (s, 1H). 13C{1H}
NMR (DMSO-d6) δ: 40.8, 60.8, 69.7, 85.4, 87.4, 96.3, 119.3, 120.8, 126.79, 120.9,
129.1, 135.6, 138.7, 140.4, 140.7, 142.7, 153.9, 162.4. LRMS (ESI): Calcd. for
C23H22N6O4 [+H+] 447.5 Found 447.2., Calcd. for C23H22N6O4 [+Na+] 469.4 Found
469.2.
5-(1-(biphenyl-4-yl)-1H-1,2,3-triazol-4-yl)cytidine 5b
Prepared via literature procedure11 in 83% yield. 1H NMR (DMSO-d6) δ: 3.52 (m, 1H),
3.68 (m, 1H), 3.99 (m, 1H), 4.21 (dd, 1H, J = 2.1 and 5.3), 5.05 (dd, 1H, J = 5.3 and 6.7),
5.91 (d, 1H, J = 6.7), 7.41 (t, 1H, J = 7.3), 7.50 (dd, 2H, J = 7.1. and 7.4), 7.68 (br s, 1H),
7.73 (d, 2H, J = 7.1), 7.89 (ov br s, 1H), 8.01 (d, 2H, J = 7.8), 8.2 (d, 2H, J = 7.8), 8.58
(s, 1H), 9.01 (s, 1H). HRMS (ESI): Calcd. for C23H22N6O5 [+H+] 463.1724 Found
463.1791.
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Chapter 7

7

Hoogsteen recognition by pyrrolocytosines in DNA and
PNA

Fluorophores acting as base surrogates that respond fluorometrically to nucleic acid
structural events have found uses across the biological sciences. However, the problem of
the design and synthesis of these molecules remains a chemical one. Based on the known
scaffold of pyrrolocytosine, two different fluorescent base analogues were exploited for
two different applications in the present work. Firstly, modified PNAs containing
phenylpyrrolocytosine bases designed to engage guanine with an additional hydrogen
bond were tested in cell culture. Elevated melting temperatures, localization to cellular
compartments, and allele-selective inhibition of expression of mutant huntingtin protein
were observed. Second, driven by the historical usage of tryptophan in the fluorescence
study of proteins and the commercial availability of indole derivatives, we appended a
suitably-substituted indole ring system to the known pyrrolocytidine scaffold. This
resulted in the base analogue (indole-3-acetamide)pyrrolocytosine which was
incorporated into oligodeoxynucleotides and displayed fluorometric response to
hybridization. Incorporation of this monomer was, however, in low yield and the
modification was found to be mildly destabilizing to duplex formation. Some results from
this chapter appear in Hu, J.; Dodd, D.W.; Hudson, R.H.E.; Corey, D.R. Bioorg. Med.
Chem. Lett. 2009, 19, 6181-6184.

7.1 Introduction to the pyrrolocytosine scaffold
Pyrrolocytosine
The heteroannulation of 5-alkynyluridine, resulting in furanouridine was described more
than a quarter of a century ago. It is of limited use as its Watson-Crick base-pairing face
is not complementary to any natural nucleobase; however, substitution of the furan
oxygen for nitrogen yields the base-pairing competent pyrrolocyctosine (pC) (Fig. 7-1).
The story of pyrrolocytosine (pC) begins in 1987 with a paper from Inoue and coworkers1 where they synthesized both the 6-unsubstituted and methyl-subsituted (R=H,
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Me. Fig 7-1) monomers and incorporated them into dodecadeoxyribonucleotides via the
phosphotriester approach; they found that the modified bases were able to base-pair with
G and did not affect duplex stability appreciably. Almost 10 years later Gamper and coworkers prepared the cyanoethylphosphoramidite of the unsubstituted (R = H) pC but
found that degradation occurred during the oxidation step in the automated synthesis.
They were however able to incorporate a furanouridine monomer without observing
unwanted degradation during the oxidation step.2

Figure 7-1: Hydrogen bond acceptor (A) and donor (D) sites for furanouridine
(top left) and pyrrolocytosine (bottom left) showing (in)compatibility for
hybridization with guanine.
Gamper did find though that during the deprotection and cleavage of the
oligodeoxynucleotide from the resin with concentrated aqueous ammonia conversion of
furanouridine to pyrrolocytosine resulted. Pyrrolocytosine is one of the rarer isosteric
pyrimidine analogues and has been used as an emissive C analogue in mismatch
detection,3 and also in the study of RNA secondary structure.4 6-Methylpyrrolocytosine is
the most commonly used derivative and is only modestly emissive as the monomer and is
quenched successively on incorporation into single-stranded and double-stranded
oligonucleotides.5 Able to base-pair effectively with guanine, it can be stabilizing or
destabilizing to the duplex depending on the identity of the substituent at the 6-position of
the pyrrole and the sequence context. 6-Methylpyrroloctosine, first synthesized in 1987,1
remained unexploited as a BDF until its rediscovery in 2001.5 It was also not made in
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phosphoramidite form until 2004.6 Since that time, it has been increasingly investigated
due to its quenching upon hybridization and more recent commercial availability despite
its low fluorescence efficiency (ΦF = 0.05). Although initially synthesized by an alternate
route, it is now commonly synthesized from uridine via Sonogashira coupling chemistry
after iodination at C5 as shown in figure 7-2.6

Figure 7-2: Synthetic route to pyrrolocytosine by Sonogashira
chemistry followed by a 5-endo-dig cyclization and O→N atom
exchange in aqueous ammonia.
Although the 6-methyl-substituted pyrrolocytosine has found success as a basediscriminating fluorophore, by variation of R group identity, greater emission and
increased fluorescence response can be achieved. Substituting for a phenyl group yields a
compound that is much more emissive than methylpyrrolocytosine and has a higher
degree of quenching upon hybridization (85% versus 50% although this varies with
sequence context). The overall greater luminescence of 6-phenylpyrrolocytosine can be
demonstrated by the visual discrimination of mismatches which was not possible at
comparable concentrations of the conventional luminophore (Fig. 7-3).3 The greater
emission intensity and increased responsiveness may translate to lower detection limits in
SNP analysis.
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Figure 7-3: SNP analysis using a 6-phenylpyrrolocytosine containing
oligonucleotide. From left to right, single-stranded, G match sequence, A mismatch.
Note: quenching occurs only on hybridization to the perfectly matched sequence.
Even though the A-mismatch exists as a duplex at the analysis temperature, no
quenching is observed.3
Phenylpyrrolocytosine has been incorporated into DNA and RNA for use as a probe for
HIV-1 reverse transcriptase RNase H activity. This application would be highly useful in
drug-screening assays as HIV reverse transcriptase is a desirable target for small
molecules. Upon cleavage of the heteroduplex up to 14-fold emission increases were
observed and the modified base acted as a superior substrate to the standard FRET-base
technology previously used.7
Mechanistically similar to the “G-clamp” (outlined in chapter 1.1), [bis-o(aminoethoxy)phenyl]pyrrolocytosine (boPhpC) was designed to interact with the
Hoogsteen face of guanine (Fig. 7-4).

Figure 7-4: The proposed interaction of [bis-o-(aminoethoxy)phenyl]pyrrolocytosine to guan(os)ine with an additional hydrogen bond to the
Hoogsteen face.8

141

This base has been incorporated into PNA and was shown to increase the thermal
stability of duplexes with natural nucleic acid oligomers by ca. 10°C although this does
vary with sequence context.8 The compound, like the “G-clamp”, has a very high
quantum yield (Φ = 0.32 for boPhpC in H2O); however, unlike the “G-clamp” boPhpC is
highly responsive to microenvironmental conditions. Upon hybridization to a match
sequence the emission intensity is decreased by greater than 50%. The high quantum
yield, responsiveness and stabilizing properties of this base replacement give it potential
for antisense/antigene applications and as a reporter group.
Although boPhpC showed remarkable binding properties the Hudson group sought to
further optimize binding. In the previous work, they found that one substitution with an
aminoethoxy arm at the ortho position of the phenyl ring showed very similar thermal
stability to the bis-substituted compound with its complement sequence. This was
investigated to find if accumulated positive charge (from the cationic aminoethoxy
substituents) on the PNA oligomer increased binding to the DNA target by electrostatic
means. As electrostatics were not deemed vital to binding the question arose of whether
the linker was of appropriate length and also whether perhaps a meta-substituted
compound would show increased binding due to a greater lack of steric interference and
electrostatic interference with the O6 of the opposite guanine. Compounds shown in
figure 7-5 were therefore synthesized, incorporated into PNA and their binding efficiency
tested against DNA and RNA targets.9
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Figure 7-5: Varying substitutions of the phenyl ring of PhpC.8,9
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The guanidinium substituted pC, mono-meta-guanidinum-pC (mmguaPhpC), showed the
strongest binding to both RNA and DNA targets putatively because of the formation of 2
hydrogen bonds to the Hoogsteen face of guanine. It was also shown that metasubstituted compounds were stronger binders and that the first choice of linker length was
appropriate as the propyl linker had slightly less affinity towards its complement. These
compounds also reported fluorometrically on binding and are good candidates for future
structural elucidation or antigene/antisense applications. The Hudson Laboratory
therefore sought out a collaborative project with Dr. David Corey’s Laboratory in order
to test the efficacy of the modified base boPhpC in regards to modifying gene expression.
In particular, the binding properties of the modified oligomers seemed well suited
towards treatment of Huntington’s disease, an area of expertise in the Corey Laboratory.

7.2 Introduction to Huntington’s Disease
Pathophysiology of Huntington’s Disease
Huntington’s disease (or Huntington’s chorea) (HD) is an autosomal dominant
neurodegenerative disorder that affects 4-10 out of 100,000 people of European descent.
Records of what are thought to be Huntington’s disease date back as far as 1374 and it
was Paracelcus in the early 1500s that coined the term chorea due to the dance-like
involuntary movements of the sufferers. In the 16th and 17th centuries the cause of the
disease was, like many other diseases, thought to be possession by the devil.10 It has been
postulated that one or more of the excecuted Salem “witches” in 1690s Massachusetts
suffered from the disease, although this is likely conjecture it is a fitting explanation;
progression of the disease is marked by (sometimes violent) mood swings and
uncontrolled, jerking movement. George Huntington, a physician working in Long
Island, wrote the classical description of the disease’s symptomology in 1872.11
Huntington recognized that the diseased organ was the nervous system, but beyond
that… Well, these are the treatments he suggested below.
“The treatment of chorea now most generally adopted is by purgatives, tonics, counterirritants, and anti-spasmodics. The first indication is, if possible, to remove the exciting

143

cause and it will probably be different in each individual case. Bleeding used to be
employed, and it is said with good results, but it is rarely used at present, except in cases
when there is much pain in the head, or along the spine, when it may be taken moderately
by cups or leeches.” – Huntington, G. 1872 from “On Chorea” ref. 11.
Then, as now, there was no cure. Drugs for the disease such as setraline, fluoxatine, and
tetrabenazine are wholly insufficient and treat only the symptoms.12-14 The disease
usually manifests itself at the age of 35-40 yrs and progresses rapidly. Cognitive and
psychiatric disturbances, coupled with crippling motor dysfunction lead to patients that
eventually lose the ability to walk, talk and even sleep. Always fatal, the patient will
often fall to general infection, heart disease or aspiration pneumonia brought about by the
inability to swallow.15
Milton Wexler, who started Hereditary Disease Foundation with the help of Woody
Guthrie’s widow, knew that his two daughters had a 50:50 chance of suffering the same
fate as his wife Lenore who succumbed to HD at age 53. One of Milton Wexler’s
daughters, Nancy, would be instrumental in identifying the genetic basis of HD (a first
for any disease) thereby increasing our knowledge of the disease and the potential for a
cure. To identify the gene responsible for the disease, genetic samples from a highly
affected community in Venezuela were subjected to restriction fragment length
polymorphism (RFLP) and linkage analyses.16 These analyses showed a genetic marker
linked to the disease on the fourth chromosome and, 10 yrs later, a truly massive
collaborative project found the gene responsible for HD and the nature of the mutation
responsible for the disease state.17 The mutation is a CAG trinucleotide repeat expansion
in an intragenic region towards the N-terminus of the resultant protein and increasing
severity in cases of HD is correlated to an increase of these repeats. The disease is
therefore termed a polyglutamine or poly-Q disorder as the mutation results in an
elongated stretch of glutamine residues. The gene product of this sequence is a 348 KDa
protein called huntingtin (htt), it acts in many capacities in the cell and many of its
functions, although intensely researched, remain unknown. The gene is expressed
ubiquitously; however, the highest levels are found within the central nervous system
where HD causes the most destruction. Huntingtin has been shown to have potential
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interaction with up to 50 other proteins (mostly towards the N-terminus) and the degree
of interaction, in many cases, depends on the length of the CAG repetitive sequence.
Different isoforms of htt interact with proteins that are involved in apoptosis, clathrinmediated endocytosis, vesicle transport, cell signaling, transcriptional regulation and
morphogenesis. These interactions have previously been reviewed.18,19 The gene is
important in early embryonic development; Htt knock-out is lethal in mice before
gastrulation and is necessary for nervous system development.20 Mutant htt is neurotoxic
mostly thought to be due to aggregation of the poly-Q tracts leading to plaque formation;
however, the wild-type protein is also important for neuronal health and may be
neuroprotective against the mutant allele. This offers a difficult challenge: to target and
block the action of the mutant protein while maintaining function of the wild-type. For
reasons outlined in chapter 1.3 the antisense approach is ideal for this. Research groups
have selectively targeted SNPs within the mutant mRNA sequence using siRNAs with
varying degrees of success.21-24 The problem with this strategy is that the SNPs are not
universal and no one treatment could be used to success in all patients. What all HD
patients do have in common is an elongated CAG repeat region. This repeat has been
targeted with antisense nucleotides in the past and is also partly the subject of this
chapter.25-29
Antisense therapies for HD
Mutant Htt transcripts have been targeted with various ASOs. PNA, ENA, LNA,
2’FANA, and PS-DNAs have all been tested in cellulo against patient derived cells.28 The
intitial studies concentrated on using PNAs where it was found that when targeted to the
CAG repeat very small oligomers were able to decrease mutant htt expression while
maintaining most of the wild-type (wt) protein in the cell. PNAs were conjugated to a
stretch of 8 lysine residues of D-stereochemistry in order to improve solubility and
increase cellular uptake while remaining resistant to peptidases. Effects were seen when
using oligomers as small as 7mers and little difference was observed between using
oligomers 13 and 21 bases long.25 Up until quite recently the original successes have
been hard to improve upon using a wide range of different ASOs. The highest
knockdown and selectivity observed to date has been achieved using RNAi. Although
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perfectly matched siRNAs showed very poor selectivity for the mutant allele, central
mismatches within the guide stand allow the ASO to operate through a more miRNA like
mechanism. In this case, the transcripts are not cleaved but are blocked by the association
of AGO2 (and potentially other proteins) and very high selectivity is achieved (> 30
fold).29
Based on the perceived value of the steric blockade mechanism and on the findings of the
intial report25 we aimed to introduce boPhpC containing oligomers into PNAs to target
the intronic CAG repeat of Htt. It is known that boPhpC increases the stability of
PNA/nucleic acid hybrids8 and we therefore hypothesized that higher thermal stability of
the heteroduplexes would result in more potent antisense drugs.

7.3 PNA mediated allele selective inhibition of mutant
huntingtin expression. Results and discussion.
Single base substitutions
A series of PNA-peptide conjugates were synthesized with 1 modified base in varying
positions in order to determine the optimum placement of boPhpC within the oligomer.
Sequences are shown in table 7-1 and contain one C-terminal lysine (K) and 8 N-terminal
lysines for enhanced uptake by cells. The thermal stability of DNA/PNA-peptide
conjugate duplexes was determined by temperature dependent UV-Visible spectroscopy
against 13mer and 19mer DNA targets (Table 7-1).
Table 7-1: PNA-peptide conjugates containing one modified boPhpC base (denoted
X) synthesized in the present work. Melting temperatures (TM) and their
comparison to unmodified PNA-1 (∆ TM) are given.
PNA

DNA length

TM (°C)

∆ TM (°C)

PNA 1 K-GCT-GCT-GCT-GCT-G-K8D

13mer

69.5

-

PNA 2 K-GXT-GCT-GCT-GCT-G-K8D

13mer

74.5

+5.0

PNA 3 K-GCT-GCT-GXT-GCT-G-K8D

13mer

74.0

+4.5
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PNA 4 K-GCT-GXT-GCT-GCT-G-K8D

13mer

74.3

+4.8

PNA 1 K-GCT-GCT-GCT-GCT-G-K8D

19mer

79.6

-

PNA 2 K-GXT-GCT-GCT-GCT-G-K8D

19mer

84.4

+4.8

PNA 3 K-GCT-GCT-GXT-GCT-G-K8D

19mer

83.8

+4.2

PNA 4 K-GCT-GXT-GCT-GCT-G-K8D

19mer

84.0

+4.4

PNA 1, which had already been examined by Corey’s group, gave a melting temperature
of 69.5 ˚C against a 13mer complementary sequence. Incorporation of one boPhpC
results in roughly a 5˚C stabilization. Although the differences between PNAs 2-4 are
minimal, added stability seems to correlate with the proximity of the modification to the
N-terminus of the PNA as in PNA 2 the modification is closest to the N-terminus and in 3
it is the furthest. Against a 19mer DNA target we see an increase in TM in all PNAs of
ca. 10˚C. This is likely due to the interaction of the cationic lysine residues with the
anionic backbone of DNA. It is therefore important to obtain data on thermal stability
using DNAs or RNAs that are of sufficient length to accommodate this peptide tail.
Conjugates 1-4 were tested against HD patient derived fibroblasts in cell culture and
mutant and wt Htt protein levels were gauged after 4 days of incubation by western

Figure 7-6: Western analysis of protein levels in fibroblasts after exposure to PNAs 2
and 3 showing selective inhibition of the mutant protein (top bands) over wt (lower
bands).
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analysis (see experimental for details). The results are shown in figure 7-6.
Modified PNA conjugates 2-4 were all shown to selectively inhibit the translation of the
Htt mutant transcript over wt. However, one must be cautious when interpreting data
from western blots as they are only semi-quantitative. No significant differences were
observed between 2-4 and therefore no real conclusions about where optimal placement
of the modification might be could be drawn. Moreover, other experiments carried out by
Dr. Jiaxin Hu found that, in comparison to PNA 1, PNAs 2-4 were less selective and of
similar overall potency. It was also observed that a 7mer repeat sequence with one
modification (PNA 5, Fig. 7-7) offered little selectivity.

Figure 7-7: Western analysis demonstrating that 7mer conjugate PNA 5
targeted to Htt shows little selectivity towards the mutant allele.
From these data it can be said that 13mers or 7mers containing 1 boPhpC modification
offer no advantage over unmodified PNAs as far as inhibition of mutant Htt is concerned.
However, they do offer one advantage that will be discussed shortly. We then
endeavoured to test oligomers with multiple modifications to further increase the thermal
stability of the duplexes and perhaps gain insight into the relationship between binding
affinity and selectivity.
Multiple base substitutions
Peptide-PNA conjugates (6-8) containing multiple base substitutions were synthesized
and sent to Dr. Corey’s laboratory for testing by Dr. Jiaxin Hu. TM values were
determined against a complementary RNA sequence and the resultant data are shown in
table 7-2.
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Table 7-2: TM data for PNA/RNA duplexes and IC50 values for inhibition of mutant
and wild-type Htt expression in fibroblasts. All sequences contain 1 N-terminal and
8 C-terminal D-lysine residues. X = boPhpC.
PNA Conjugate

TM( ∆ TM )°C

IC50/mut (µM)

IC50/wt (µM)

PNA 1 GCTGCTGCTGCTG

82.9

0.047 ± 0.2

>2

PNA 2 GXTGCTGCTGCTG

84.5 (1.6)

0.54 ± 0.05

1.68 ± 0.7

PNA 3 GCTGCTGXTGCTG

85.4 (3.5)

0.71 ± 0.07

1.86 ± 0.1

PNA 6 GXTGCTGXTGCTG

83.9 (1)

0.58 ± 0.05

1.3 ± 0.1

PNA 7 GXTGXTGXTGCTG

> 87 (>4)

0.97 ± 0.02

>4

PNA 8 GXTGXTGXTGXTG

> 87 (>4)

2.6 ± 0.7

>4

Against an RNA complement the boPhpC modification was stabilizing towards duplex
formation albeit to a lesser extent than with DNA. All PNAs were selective to the mutant
protein as seen by comparison of IC50 vaules for mutant versus wild-type protein;
however, the selectivity and potency decreases with the number of substitutions made.
PNA 8 has an IC50 of 2.6 µM for the mutant allele and greater than 4 µM for the wildtype. At these concentrations the oligomers begin to display toxic effects.
Fluorescence microscopy
Dr. Hu was able to gain some benefit from the fluorescence boPhpC. Through confocal
microscopy, it was possible to visualize the oligomer in cellulo up to nine days after
transfection. The oligomers were found to have a punctuate distribution and colocalized
with the endosomal marker transferrin. There are many previous reports of tracking the
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location of PNAs within cells and they are found to be concentrated endosomally.30-32 In
these studies PNAs were tagged with extraneous fluorophores which may affect cellular
distribution. There are examples in the literature where such tags can direct the
trafficking of oligomers in cells. Barton has found that a ruthenium-octaarginine
conjugate is directing towards the nucleus33 and fluorescent dyes have been found to alter
the distribution of cell penetrating peptides.34 This is believed to be the first example of
‘label-free’ fluorescence imaging of an ASO in cells. The only flaw to this technique lays
in the responsiveness of the fluorophore to its environment. It is not known
if/when/where the fluorophore is being quenched and we can therefore say little about
concentration.

7.4 PNA mediated allele selective inhibition of mutant
huntingtin expression. Conclusions.
In conclusion, boPhpC containing PNAs were shown to knockdown the expression of
mutant Htt. It is not clear why increased binding of the oligomers to target RNA could
result in lower selectivity and potency but factors may include non-specific binding,
aggregate formation or endosomal sequestration. Regardless, the modification of duplex
stability by the addition of these monomers makes them a useful addition to the chemical
toolbox for future work. The real importance of this to the field is that the fluorescence of
the monomer can be exploited for imaging purposes with concomitant gene silencing.
Such dual purpose oligomers may find a great deal of use across the biological sciences
in the near future.

7.4 PNA mediated allele selective inhibition of mutant
huntingtin expression. Experimental.
Synthesis of PNA-peptide conjugates.
PNA-peptide conjugates were synthesized on a Rink amide resin using an Applied
Biosystems 433A peptide synthesizer and standard FMOC chemistry.8 Commercially
available PNA monomers (Applied Biosystems, Warrington, UK) and Fmoc-D-
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Lys(Boc)-OH (Novabiochem, Hohenbruun, Germany) were used with the exception of
the boPhpC monomer which was synthesized by Dr. Filip Wojciechowski according to
literature precedent.8 Oligomers were purified by RP-HPLC and characterized by ESIHRMS as previously described.35,36
Cell culture and transfection
Cell culture and transfection was carried out as described.27 In brief, patient-derived
fibroblast cell lines GM04281 were obtained from the Coriell Institute (Camden, NJ) and
contained 17 intronic CAG repeats for the wild-type Htt allele and 69 for the mutant.
Fibroblasts were kept in the absence of antibiotics at 37˚C with an atmosphere of 5% CO2
in MEM (sigma) supplemented with 5% heat inactivated FBS and 0.5% MEM nonessential amino acids. Cells were plated at 60,000 cells per plate once reaching
confluence in supplemented MEM 2 days prior to transfection. PNA-peptide solutions
were heated at 65˚C for 5 min and diluted to the desired concentration with OptiMEM
and pipette into wells. After a period of 24 h the media was replaced with supplemented
MEM. Cells were harvested 4 days after initial transfection for protein analysis.
SDS-PAGE and western blotting
SDS-PAGE and western blotting were carried out as described.27 In brief, cells were
harvested with trypsin EDTA solution (invitrogen) and lysed and protein concentration
was determined by the bicinchoninic acid assay (BCA). SDS-PAGE was carried out with
a stacking gel comprised of 4% acrylamide/bisacrylamide (34.7:1) 450 mM Tris-acetate
pH 8 and a separating gel comprised of 5% acrylamide/bisacrylamide (34.7:1) 150 mM
Tris-acetate pH 6.8 using XT Tricine (Bio-Rad) as running buffer. The gels were run at
100 V for 4 h and were water cooled to prevent overheating. The expression of actin was
monitored to ensure equal protein loading. The proteins were then transferred to a
membrane (Hybond-C) and blocked. Primary antibodies were anti-htt from Chemicon
and anti-actin from Sigma. Horseradish peroxidase (HRP) derivatized anti-rabbit
antibody conjugate was used for visualization in conjunction with SuperSignal West Pic
Chemiluminescent Substrate and were quantified using ImageJ software in relation to the
negative control (mismatch PNA K-GCC-ACT-ACT-GAT-A-D-K8).
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7.5 Indole-3-acetamide substituted deoxypyrrolocytidine.
Introduction
Having explored some uses of the pyrrolocytosine scaffold in the context of PNA we then
aimed towards making similar substitutions for use in oligodeoxynucleotides (ODNs).
Substitutions influence the fluorescence and binding properties when in the context of an
oligomer. Tryptophan is used in fluorescence studies of proteins because of its intrinsic
fluorescence. Tryptophan undergoes solvatochromic emission, is quenched by nearby
protonated amino acids, and can therefore be used to measure conformational states of
proteins. It was reasoned that pC substituted with a derivative of indole could also have
interesting properties and be used as an environmentally sensitive nucleobase. Also,
following from our previous work, we sought to modify the base so that a secondary Hbonding interaction could occur at the Hoogsteen face of an opposing guanine in order to
further

stabilize

the

duplex.

Therefore

the

base

analogue,

(indole-3-

acetamide)pyrrolocytosine (IAMpC) was synthesized and is shown in figure 7-8.
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Figure 7-8: Structural comparison of cytosine, PhpC and the indole
derivatized IAMpC with proposed Hoogsteen interactions with
guanine shown.
The strategy for the synthesis of ODNs containing IAMpC involved a post-synthetic
conversion of ODNs containing incorporated phosphoramidite 5 (Fig. 7-9) the synthesis
of which was carried out by Dr. Filip Wojciechowski and will not be discussed here.
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A test of whether the Boc group could be removed under standard DNA protocols
(NH4OH or NH3/MeOH) was performed by Dr. Filip Wojciechowski and both the
removal of the Boc group and amminolysis of the ethyl ester group was achieved.

Figure 7-9: Convertible phosphoramidite of IAMpC (left) and IAMpC
(right) used for fluorescence studies of the monomer.
The absorption and fluorescence spectra of IAMpC were measured in aqueous buffer and
showed an absorption band centred at 375 nm and an emission maximum at 505 nm. This
emission wavelength of IAMpC (505 nm) is the beginning of the green region (490-570
nm), and is significantly shifted from previously studied pCs. The compound also has a
desirable large Stokes shift (130 nm) (Table 7-3). Study of the photophysical properties
of IAMpC revealed that it has a very high fluorescence quantum yield in organic
solvents. Remarkably the fluorescence quantum yield approached zero in aqueous buffer
or water (Table 7-3). The effect of the medium on the fluorescence was also examined
by studying acetone:water mixtures. As the polarity of the medium increases, the
fluorescence emission noticeably decreases.
Such a dramatic decrease in emission on solvent polarity increase is a unique property of
the (indole-3-acetamide)-substituted pyrrolocytosine among all the pC analogues that we
have studied to date. Other pC analogues have demonstratedmore modest fluorometric
response (30-50%) to changes in the solvent environment. This decrease in the
fluorescence quantum yield has the potential for IAMpC to fluorometrically report on the
state of hybridization or report on protein/ligand binding or 8-oxoguanosine detection.
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Table 7-3: Fluorescence data for IAMpC in various solvents
Solvent

Exc, λmax(nm)

Em, λmax(nm)

ФF

1,4-dioxane

388

454

0.27

acetone

387

455

0.57

ethanol

388

472

0.48

water

375

505

~0.004

7.6 Indole-3-acetamide substituted deoxypyrrolocytidine.
Results and discussion
With the phosphoramidite of IAMpC in hand, it was set out to investigate the
hybridization properties and fluorescence response of IAMpC when in the context of an
oligomer. The synthesis of oligodeoxynucleotides (ODNs) containing IAMpC was
carried out, a selection of which are shown in table 7-4.
Table 7-4: Sequences synthesized for the present work.
ODN-1

5’-TCT-CXC-TCT-C-3’

ODN-2

5’-GCG-AAT-XTA-A-3’

ODN-3

5’-TCT-GXC-TCT-C-3’

ODN-4

5’-TCT-GCC-TCT-C-3’

ODN-5

5’-GAG-AGG-CAG-A-3’

Coupling yields of the IAMpC monomer were good to excellent; however, after cleavage
from the resin using concentrated aqueous ammonia overnight at 55˚C HPLC analysis
revealed the presence of two peaks. A representative HPLC trace of this is shown in
figure 7-10.
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7-10: HPLC trace of crude ODN-3 after cleavage from the
support using NH4OH overnight at 55˚C.
The two distinct peaks were collected and subjected to mass spectral analysis. The faster
eluting peak is the desired ODN-3 in high purity (see figure 7-11) while the slower
eluting peak is the desired oligomer plus a mass of 100.1 Da. This figure corresponds to
the extra mass of the N-Boc protective group. Firstly, the oligomer was subjected to
longer exposures to concentrated ammonia at a slightly elevated temperature of 60˚C
with no success. It appeared that the ratio of protected to unprotected remains almost
unchanged. More aggressive approaches such as 40% methylamine were attempted also
to no success and appeared to degrade the oligomer over time before removal of the Boc
was complete. This problem must be solved for further development of this work, it is
possible that the protecting group is not required during DNA synthesis and this should
be attempted.
In the case of ODN-3, the desired oligomer was purified in sufficient quantity for further
study. Thermal denaturation profiles of IAMpC-containing ODN-3 and unmodified
ODN-4 with their complement ODN-5 are shown in figure 7-11.
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7-11: Melting curves for IAMpC containing ODN-3 (dashed line)
and ODN-4 (solid line) with ODN-5 showing decreased thermal
stability of the modified duplex.
The TM of ODN-3/ODN-5 duplex was determined to be 36.5˚C while that of ODN4/ODN-5 was 41.0˚C. The IAMpC modification therefore destabilizes the duplex by
4.5˚C. This could due to the linker being of inappropriate length. It is also true that an
ammonium group (such that is present in boPhpC) is a better hydrogen bond donor than
the carboxamide present in IAMpC for Hoogsteen recognition. These data were
confirmed by fluorescence dependent thermal denaturation as shown in figure 7-12.
From the fluorescence data collected we can see that IAMpC is quenched by
approximately 30 % on binding to its complementary sequence. Although not optimal,
the sequence is yet to be tested against mismatch sequences and this modified base may
still find use as a BDF. All necessary complementary ODN sequences have been
synthesized and purified; however, the IAMpC containing ODNs are lacking due to the
problems of Boc group removal that were discussed earlier.
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7-12: Thermal denaturation monitored by fluorescence emission
confirming a melting temperature of 35˚C and showing fluorescence
quenching on binding to a match sequence.

7.7 Indole-3-acetamide substituted deoxypyrrolocytidine.
Conclusions.
In conclusion, a new indole-containing pyrrolocytosine analogue has been incorporated
into DNA and responds fluorometrically to the presence of a target sequence. IAMpC
was found to be mildly destabilizing towards duplex formation. It is postulated that the
nature of the extending ‘arm’ is at fault, previous pC analogues that operate by
Hoogsteen recognition have been cationic and 5 atoms in length or longer. IAMpC’s
‘arm’ is 4 atoms in length and electronically neutral. Compounding problems with Boc
removal may, in the future, warrant a new synthetic design.
To provide a conclusion for the preceeding chapters, the design and syntheses of
fluorescent, in some cases duplex-stabilizing, cytosine analogues was carried out.
Successful incorporation of selected analogues into PNA and DNA scaffolds yielded
oligomers that could be used for both sequence interrogation and alteration of gene
expression. Platinum complexes were synthesized and evaluated for their suitability as
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antineoplastic agents. Platinum was also used in an attempt to increase the hybridization
strength of PNA to an RNA target. The work contained herein may be expanded in
several directions. One of these is the development of on-resin approaches to generate
usefully modified oligomers through the use of dipolar cycloadditions. Others would
include the testing of the suitability of these monomers for enzymatic incorporation and
further photophysical characterization of oligomers used in knockdown experiments.

7.7 Indole-3-acetamide substituted deoxypyrrolocytidine.
Experimental.
DNA synthesis and purification
DNA was synthesized at 0.2 µmol scale on an ABI 392 DNA synthesizer using
commercially available reagents obtained from ChemGenes (Wilmington, MA) with
either 5-ethylthiotetrazole or 4,5-dicyanoimidazole (0.25 M) as activator using the cycles
and conditions supplied by the manufacturer. For unmodified bases, coupling times were
extended to 180 seconds. IAMpC phosphoramidite was coupled manually at 10-fold
excess in 200 µL MeCN with 100 µL of 0.25 M 5-ethylthiotetrazole with a coupling time
of 10 min. The efficiency of this method was first investigated using the commercially
available C monomer. Oligomers were cleaved from the resin using concentrated aqueous
ammonia at 55C overnight, isolated by lyophilisation and first purified ‘DMT on’ by RPHPLC on a C-18 300 Å column using 100 mM NEt3•HOAc, pH 6.5 and MeCN as eluent.
Lyophilized ‘DMT on’ was treated with 80% acetic acid, lyophilized again and subjected
to the same HPLC conditions. ODNs were characterized by HRMS. ODN-3 - HRMS
calcd. 3125.0034 found 3125.7002.
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Thermal denaturation experiments
ODN concentration was calculated using the nearest neighbour method37 for unmodified
sequences. The absorption coefficient of IAMpC at 260 nm was calculated to be 15450
M-1cm-1 by the gradient of a plot of absorbance versus concentration. UV-Vis dependent
thermal denaturation was carried out in aqueous 100 mM NaCl, 10 mM Na2HPO4, 0.1
mM EDTA, pH 7.0 at a strand concentration of 8µM. Denaturation was performed
between 10 °C to 95 °C at a rate of 0.5 °Cmin-1. Melting temperature is given as an
average of three runs within 1˚C and estimated for cooperative transitions by the first
derivative method.
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